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ABSTRACT 
Dupuytren’s disease is defined in Green’s Operative Hand Surgery as  a condition of the hand 
characterised by the development of new tissue in the form of nodules and cords. Hand 
function can be significantly impaired and whilst the mainstay of treatment is surgery, 
recurrence has been reported in approximately 40-50% of patients. Myofibroblasts are 
central to the pathogenesis of Dupuytren’s disease although what regulates the 
myofibroblast phenotype during Dupuytren’s disease remains unclear. 
This thesis set out to test the hypothesis that the myofibroblast phenotype in Dupuytren’s 
disease is regulated by dermal fibroblasts and inflammatory mediators, specifically 
advanced glycation end products (AGEs) and TNF-α. 
I aimed to (1) systematically characterise the distribution of myofibroblasts (α-smooth 
muscle actin positive cells (α-SMA)) throughout excised Dupuytren’s tissue in relation to 
clinical disease activity (fixed flexion deformity and recurrence); (2) establish an in vitro 
contraction model to examine Dupuytren’s myofibroblasts and (3) use this model to 
examine how myofibroblast phenotype may be regulated by dermal fibroblasts and 
inflammatory mediators. 
I examined 103 Dupuytren’s cords and correlated the histological findings with the patient’s 
clinical flexion contracture and disease severity. Histological nodules, defined as a focal 
condensation of SMA positive cells, were seen in two-thirds of excised digital cord 
samples. These nodules were found in the vicinity of the proximal interphalangeal joints of 
the fingers. Nodules were more frequently observed in digits with less severe contractures 
and more active disease, whereas non-nodular cords were significantly associated with 
advanced digital contracture, reflecting end stage disease. Based on our current 
understanding of how myofibroblasts thrive on tension and contract against resistance, a 
mechanism for digital contraction has been proposed: nodules containing highly contractile 
myofibroblasts are present in active Dupuytren’s disease where digital flexion and extension 
of the interphalangeal joints is still possible and these nodules involute in end-stage disease, 
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where severe contractures limit digital movement.  
In order to further study Dupuytren’s myofibroblasts, I also compared cell contraction in 
stress-released collagen gels with that in restrained gels using a culture force monitor 
(CFM). With the latter I was able to reliably measure cell-generated forces within restrained 
collagen gels. By using genetically matched sets of cells from patients, I also correlated cell 
contractility with α-SMA expression. Unlike control skin cells that initially contract and then 
plateau, Dupuytren’s myofibroblasts show continually increasing contractile force. 
Furthermore, increased contractility of Dupuytren’s myofibroblasts was reflected by higher 
α-SMA protein content and alignment of the α-SMA to stress fibres. Interestingly mRNA 
levels of α-SMA were similar in all matched cells, reflecting post-translational regulation of 
protein levels in myofibroblasts. 
Based on the observation that recurrence is significantly reduced following 
dermofasciectomy, I also tested whether dermal fibroblasts down-regulate the contractile 
Dupuytren’s myofibroblast. I co-cultured Dupuytren’s myofibroblasts and dermal fibroblasts 
and found that contractility of Dupuytren’s cells is not influenced by dermal cells. Therefore, 
reduced recurrence rate following dermofasciectomy may be due to other factors, such as 
more complete excision of affected tissue combined with reduced tension following 
application of full thickness skin grafts.  Finally, recent studies have suggested that 
inflammatory mediators and AGE-RAGE interaction play a role in the development of the 
myofibroblast phenotype. I therefore used the CFM to examine the effect of AGEs and TNF-
α on myofibroblast contractility. No difference in contractility of dermal fibroblasts was 
observed with AGEs, although a two-fold increase was seen with TNF-α. 
Overall, I have characterised the distribution of myofibroblasts in Dupuytren’s tissue and 
these data have led to interesting insights into disease pathogenesis.  I have also established 
a reliable in vitro model for assessing Dupuytren’s myofibroblast phenotype and used this to 
demonstrate that whilst dermal fibroblasts do not downregulate myofibroblast activity, pro-
inflammatory mediators may play a key role in modulating myofibroblast phenotype in this 
disease. 
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1.1  Dupuytren’s disease 
Dupuytren’s disease is a condition of the hand characterized by thickening and contraction 
of the fascia of the palm and fingers. It is a fibroproliferative disorder t hat results in 
progressive deformities through physical shortening of the diseased fascia. It may lead to 
significant digital contractures (Fig 1.1) and impairment of hand function to the extent that 
patients with severe flexion contractures may require amputation. 
 
 
 
 
 
 
 
                
Figure 1.1.  Dupuytren’s contracture affecting the little and ring fingers. 
This condition bears the name of Baron Guillaume Dupuytren, the chief surgeon at the Hotel 
Dieu in Paris (1831), who described the treatment of this condition in front of an audience 
and then without anaesthetic performed a simple release of the fascia  (reviewed in Elliot, 
1999). 
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1.2  Epidemiology 
Epidemiological studies have consistently shown that Dupuytren’s disease affects 4-6% of all 
Caucasians, although it is commoner in individuals of Northern European extraction 
(reviewed in Ross, 1999). A Scottish study showed more than 25% of males and 17% of 
females over the age of 65 years have signs of Dupuytren’s disease (Ling, 1963). An 
extensive population study in Iceland of 2165 randomly selected individuals reported 
Dupuytren’s disease in 7.2% between the age of 45 and 49 and up to 39.5% between age of 
70 and 74 (Gudmundsson et al., 2000). All patients in this study were examined by the same 
medical practitioner. Dupuytren’s disease is commoner in men than women, with 
approximately 5.9:1 male-to-female ratio aged 45 -55 years (Hindocha et al., 2009). The 
difference in prevalence seen with gender has been shown to be age dependent. Men tend 
to present in their fifth decade whereas women present a decade later. By the eighth and 
ninth decades of life the ratio of men to women being affected by Dupuytren’s disease is 
nearer 1.5:1 (Mikkelsen et al., 1999). Dupuytren’s disease has also been reported in 
children, although is rare (Urban et al., 1996). 
Dupuytren’s disease is less common in individuals from non-caucasian backgrounds. A 10-
year retrospective study of 9,938 patients from the Department of Veterans Affairs 
computer system (USA) was conducted to determine the racial distribution of this disorder. 
The estimated prevalence was reported as 734 per 100,000 in Caucasians, 130 per 100,000 
in Afro-Carribeans, 237 per 100,000 in Hispanics, 144 per 100,000 in native Americans, and 
67 per 100,000 in Asians. Although Dupuytren’s disease is rarely seen in people from African 
or Asian descent, it is interesting that Indian patients living in the UK are now developing the 
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disease (Srivastava et al., 1989). A high prevalence of Dupuytren’s disease is also seen in 
Japan. However, 90% of these cases are reported to have no contracture, suggesting that 
the disease may show a different phenotype in Japan (Egawa, 1985).  
Finally, large epidemiological studies have suggested that patients with Dupuytren’s 
contracture followed up over 15 years show increased mortality from malignancy 
(Gudmundsson et al., 2000; Mikkelsen et al., 1999; Wilbrand et al., 2000). Although this 
observation was maintained when adjusted for age, smoking and occupation, other 
significant risk factors also need to be considered and further more detailed analysis is 
required. 
1.3  Aetiology  
The cause of Dupuytren’s disease remains uncertain and has been linked to different 
aetiologies. These include alcohol, smoking, occupation and trauma, epilepsy, diabetes and 
rheumatoid arthritis.  Different theories have been proposed to account for each of their 
roles in the pathogenesis of Dupuytren’s disease although some remain controversial 
(Hindocha et al., 2009; Yi et al., 1999).  
1.3.1  Genetics 
Dupuytren’s disease is often familial. A detailed study conducted in Edinburgh examined 
fifty patients with Dupuytren’s disease and reported 16% familial incidence as documented 
from the patient’s history. However, in the same study the incidence rose to 68% when up 
to third degree relatives were examined (Ling, 1963). Despite this genetic link, the 
inheritance pattern remains unclear. Autosomal dominance with variable penetrance has 
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been proposed as a likely mode of inheritance, although to date no single gene has been 
identified and many sporadic cases have also been reported (Burge, 1999; Hu et al., 2005).  
Dupuytren’s disease may be a complex oligogenic condition and discordance of Dupuytren’s 
disease in pairs of monozygotic twins, whereby only one partner of each was reported to 
have Dupuytren’s disease, has also implied a role for environmental factors (Lyall, 1993). It 
is possible that an inherited susceptibility may influence tissue sensitivity to the effects of 
environmental exposures. This may explain why Dupuytren’s disease should start at a 
particular age or even at different times in two hands. 
Many studies have used DNA microarray technology to compare gene expression profiles 
using both explants and cells isolated from Dupuytren’s fascia and control carpal ligament, 
in an attempt to identify susceptible genes and identify novel therapeutic targets (Lee et al., 
2006; Pan et al., 2003; Satish et al., 2008). Results have varied and have included genes 
previously shown to be involved in Dupuytren’s disease such as fibronectin, tenascin-C, all 
three transforming growth factor (TGF)-β isoforms and type III, IV and VI collagens. Not 
surprisingly, many genes expressed are involved in extracellular matrix (ECM) organisation 
and more recent studies found genes for a disintegrin and metalloproteinase domain 
(ADAM-12), Periostin, proteoglycan-4 also to be upregulated (Lee et al., 2006; Pan et al., 
2003; Satish et al., 2008). Novel gene candidates reported to be highly expressed in 
Dupuytren’s nodular tissue include MafB (musculoaponeurotic fibrosarcoma oncogene 
homolog B) (Lee et al., 2006), aldehyde dehydrogenase 1 family member (ALDH1A1), and 
Iroquois homeobox protein 6 (IRX6) (Shih et al., 2009a; Shih et al., 2009b).  This latest study 
examined differential gene expression in Dupuytren’s fascia, non-diseased transverse 
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palmar fascia, palmar skin overlying nodule, palmar fat and compared to control carpal 
ligament tissue. They found increased ADAM12, ALDH1A1, and IRX6 expression levels in 
Dupuytren’s disease fat compared to control tissue (Shih et al., 2009a). In all these studies a 
consistent pattern of candidate genes has not been reported and therapeutic strategies 
based on the genes identified have yet to be developed.  
Furthermore, no association has been shown between naturally occurring gene 
polymorphisms and Dupuytren’s disease. Specifically a lack association with TGF-β1, TGF-β2 
and TGFβ receptors has been documented in Dupuytren’s disease (Bayat et al., 2002a; Bayat 
et al., 2002b; Bayat et al., 2003). However, these findings do not necessarily exclude direct 
or indirect involvement of other relevant gene polymorphisms in the pathogenesis of 
Dupuytren’s disease. 
1.4  Palmar fascia anatomy 
The hand has a precise ordered three-dimensional system of subcutaneous fascial fibres 
(fibrous tissue) that makes up the palmar and digital fascia. This fascia lies between the skin 
and deeper structures of the hand. It is essentially a framework that forms the soft tissue 
skeleton of the hand. It also supports the palmar skin and protects the hand against shear 
and compressive forces. The normal fascia consists of both longitudinal and transverse 
components (Fig. 1.2). As fascial fibres traverse the palm towards the digits, they condense 
to form “bands” or ligaments. These palmar fascial fibres  become involved in those 
individuals that develop Dupuytren’s disease to form cords. 
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Figure 1.2. Normal anatomical structures and palmar fascia of the left hand. Illustration adapted 
from Gray’s Anatomy (37th Edition).  
LEFT HAND 
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In contrast to the palmar fascia, the digital fascia is a more complex structure. It is tubular 
and envelopes the flexors and extensor tendons with a fine meshwork of transverse, 
oblique and horizontal fibres. Various constituents of this fascia condense to form bands 
(Fig. 1.3) and which can become involved in the disease process. 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.  Normal anatomical structures of the distal palmar fascia and digital fascia of the 
hand. The main anatomical structural elements of the normal bands and ligaments are labelled for a 
single digit in the hand. Normal bands and ligaments (blue) are shown in relation to neurovascular 
bundles (black), flexor tendons (black arrows), and interphalangeal joints (red arrows) (adapted from 
McFarlane, Journal of Plastic & Reconstructive Surgery, 1974).  
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1.5  Clinical presentation 
In Dupuytren’s disease, changes in palmar skin and the formation of palmar nodules have 
classically been described as the first signs of Dupuytren’s disease. Subsequent cord 
formation leads to gradual contraction and digital deformity. Dupuytren’s lesions occur 
along precise fascial fibres that have a predominantly longitudinal orientation along lines of 
tension in the hand. Therefore, certain components of the palmar fascia, such as the 
transverse fibres (Fig. 1.2), are never involved, except in the first web space. This difference 
may be due to the fact that mechanical stress may be involved in the aetiology of 
Dupuytren’s disease:  the thumb, unlike the fingers, applies stress in both the longitudinal 
and transverse axes (McGrouther, 2005). 
1.5.1  Dermatopathology 
Skin changes can be the earliest manifestation of Dupuytren’s disease and skin pits caused 
by deep full thickness skin retraction into the subcutaneous tissue by the diseased fibres 
which insert into the dermis may be observed (McGrouther, 1982) (Fig. 1.4). Fibrotic 
replacement of the subcutaneous fat in the deeper layer of the fat has also been described 
(reviewed in Rayan, 1999) and as a result of these changes, the thickened palmar skin 
becomes tethered and loses its normal mobility. Based on these observations, Heuston 
initially suggested that Dupuytren’s disease pathogenesis may to some extent be influenced 
by the overlying skin (Hueston, 1985; Hueston, 1963; Maccallum and Hueston, 1962). 
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Figure 1.4. Dupuytren’s contracture with a clinical nodule and a palmar skin pit. Dupuytren’s 
disease affecting the little finger with a clinical nodule (dotted arrow) and a more proximally based 
skin pit (black arrow) is seen in the palm. 
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1.5.2  Nodule 
The palmar nodule has been described as one of the earliest signs of Dupuytren’s disease 
(Maccallum and Hueston, 1962). A clinical nodule is defined as a palpable subcutaneous 
lump (McGrouther in Green’s operative hand surgery, 2005) and anatomical descriptions 
suggest nodules originate amongst the longitudinal fibres extending in to the dermis and 
within the superficial components of the palmar and digital fascia (McGrouther, 1982). 
Whilst clinical nodules may result from cell proliferation and extracellular matrix synthesis 
pushing upward on the skin, bunching up of the skin caused by contraction of the underlying 
fascia may also appear as a clinical nodule {McGrouther, 1982 #86; McGrouther, 2005)(Fig. 
1.5).   
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Figure 1.5. Clinical nodules.  (A) Palpable clinical nodule in the palm with no digital contracture. (B) 
Same nodule seen magnified with a scale bar.  (C) Dupuytren’s contracture presenting with a clinical 
nodule (back arrow) and cord. The nodule is co-located with the proximal interphalangeal joint (PIPJ) 
and the prominent tendon-like cord can be seen extending proximally into the palm.  (D) 
Dupuytren’s contracture with a clinical nodule seen here as bunching of the palmar skin (black 
arrow). 
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1.5.3  Cord  
Luck viewed the nodule as a “powerhouse” that matures as the disease progresses to form 
cord (Luck, 1959). However, whilst this may in part account for cord formation, it has also 
been suggested that normal bands in the hand hypertrophy and thicken in response to 
increased tension. These bands are precursors to pathological cords that become prominent 
and clinically acquire the consistency and appearance of tendon (Fig. 1.6) (McFarlane, 1974; 
McGrouther, 2005). Cords develop gradually and maturation may take place in the presence 
or absence of clinical nodules.  
 
Figure 1.6.  Dupuytren’s cord. (A) Lateral view of Dupuytren’s contracture affecting the left 
little finger and the prominent cord is highlighted with a dotted black line.  (B) Antero-
posterior view of the same hand (note the black arrow at the wrist denotes routine pre-
operative marking for purposes of identification). 
 
The various types of palmar and digital cords, the normal bands from which they arise, and 
the clinical significance of the diseased cords are summarised in Table 1.1.  
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Table 1.1  Summary of pathological cords in Dupuytren’s disease, their anatomical origins 
and clinical implications (adapted from R.B. Shaw, PRS, 2006)  
Diseased cord Origin (band) Clinical implication 
Pretendinous cord Pretendinous band MCPJ contracture 
Vertical cord Vertical fibres/ septa Triggering 
Spiral cord Pretendinous band, Spiral 
bands, Lateral digital sheet, 
Grayson’s ligament and 
Retrovascular band 
MCPJ, PIPJ contractures and 
displacement of 
neurovascular bundle 
Natatory cord Natatory ligament Decreased digital abduction 
Central cord Pretendinous cord PIPJ contracture 
Retrovascular cord Retrovascular band PIPJ, DIPJ contractures 
Lateral cord Lateral digital sheet PIPJ, DIPJ contractures and 
displaces neurovascular 
bundle 
Abductor cord Abductor digiti minimi 
tendon 
PIPJ contracture 
Thumb proximal 
commissural cord 
Proximal commissural 
ligament 
1st web contracture 
Thumb distal commissural 
cord 
Distal commissural ligament 1st web contracture 
Thumb pretendinous cord Pretendinous band MCPJ contracture 
MCPJ (metacarpophalangeal joint); PIPJ (proximal interphalangeal joint); DIPJ (distal interphalangeal joint)  
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1.5.4  Disease progression and diathesis 
The course and progression of Dupuytren’s disease is unpredictable as disease may remain 
confined to the palm and not progress to cause digital flexion deformity. It is in cases which 
progress to digital contractures that surgical intervention may be considered. Palmar 
involvement usually precedes disease extension into the digits, but the disease may begin or 
remain confined to the digit.  
Dupuytren’s disease often occurs bilaterally. The ring finger is most commonly affected, 
followed closely by the small finger. The thumb, middle finger and the index finger (ie. radial 
side of the hand) are less frequently involved as compared with the ulnar two digits (Rayan, 
1999). 
Some patients have a stronger predisposition to getting the disease and are said to have a 
strong “diathesis” (Hueston, 1963). The initial description of Dupuytren’s disease diathesis 
by Heuston has been modified and recognised diathesis factors now include a positive 
family history (1st degee relatives), bilateral disease, ectopic lesions (thickened knuckle pads 
or Garrod’s pads), male gender and age at onset of younger than 50 years (Hindocha et al., 
2006). Radial sided disease has also been suggested as an additional factor (Abe et al., 
2004c). 
1.5.5  Ectopic Dupuytren’s disease  
Although Dupuytren’s disease refers to involvement of the palmar surface of the hand, a 
proportion of patients have extra palmar disease. This includes Garrod’s pads (or thickened 
knuckle pads over the proximal interphalangeal joint (PIPJ)), which have been reported in 
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approximately 50% of patients. Proportionally, the index finger is more frequently affected 
by Garrod’s pads and it is almost twice as common in patients with bilateral compared to 
unilateral disease (Caroli et al., 1991). Whilst a spectrum of knuckle changes have been 
described varying from loss of PIPJ skin wrinkles to knuckle pads (Rayan, 1999), it has also 
been reported that the cell type and extracellular matrix of Garrod’s pads and Dupuytren’s 
nodules were identical when examined at an ultrastructural level (Caroli et al., 1991).  
A smaller proportion of patients also present with distant ectopic disease. These include 
plantar fibromatosis (Lederhose disease, 6-31%) that involves the soles of the feet, and 
often does not lead to contractures (Classen and Hurst, 1992). Patients may also present 
with contraction of the penile fascia (Peyronie’s disease, 2-8%), resulting in penile deformity 
and erectile dysfunction (Gholami and Lue, 2002). Ectopic disease, in particular Garrod’s 
pads is associated with more aggressive disease pattern in the hand (Abe et al., 2004b; 
Hindocha et al., 2006) 
1.6  Histology of Dupuytren’s tissue 
Studies of Dupuytren’s disease progressed using histology to examine tissue excised from 
patients.  This revealed the presence of what have been described as histopathological 
nodules.  Luck first described the histological nodule as a focus of fibroblasts which 
resembles a fibroma or as a focal fibroplasia (Luck, 1959). Histological textbook descriptions 
now define a histopatholoigcal nodule as collection of cells in a whorled pattern (Reviewed 
by McGrouther in Green’s Operative Hand Surgery, 2005).   
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Both Luck (Luck, 1959) and Chiu and McFarlane (Chiu and McFarlane, 1978) described 
clinical nodules at various locations in the palm and digits of the hand.   Luck viewed the 
initial and essential lesion in Dupuytren’s contracture as the focus of proliferating  
fibroblasts. He states “that while grossly, a focus may exist as a solitary lesion in the palmar 
fascia, multiple foci are the rule. In most instances, the fibroblastic focus creates a palapable 
nodule”.  Chiu and McFarlane (Chiu and McFarlane, 1978) also describe many areas of 
cellular activity in diseased Dupuytren’s tissue.  In line with Luck’s findings, this study 
reported histological nodules to vary significantly in size from tiny foci of cells to larger well 
defined nodules. However, Chiu stated that “some *nodules+ were large enough to be 
palpated clinically, but most were microscopic in size”. Therefore, it seems that clinical 
nodules do not always necessarily correlate with histological nodules.  Hence when using 
the term ‘nodule’ it is important to distinguish between the two different types. Throughout 
this thesis I use the term ‘clinical nodule’ to describe a palpable subcutaneous lump and the 
term ‘nodule’ to describe a histological nodule defined as a collection of cells in a whorled 
pattern (McGrouther in Green’s Operative Hand Surgery, 2005).  
Following Luck’s histological description of Dupuytren’s nodules other studies have also 
examined Dupuytren’s tissue using light microscopy. Gabbiani and Majno also noted the 
presence of histological nodules and observed that in these highly cellular areas , cells often 
had two characteristic features, namely intracellular fibrils and cross banded nuclei 
(Gabbiani and Majno, 1972). Samples of skin and underlying cord obtained at 
dermofasciectomy from 20 patients have also been examined by light microscopy. Varying 
amounts of hypercellular and collagenous tissue were reported. Hypercellular foci 
demonstrated very variable cellularity. In these areas swollen and rounded cell nuclei were 
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noted compared to largely acellular regions which were characterised by very long 
elongated thin nuclei (McCann et al., 1993). This study also showed that Dupuytren’s tissue 
extended into the dermis and in three cases reached the epidermis. 
Numerous studies have attempted to classify different stages of Dupuytren’s disease based 
on histology using light microscopy.  These studies have most often interpreted their 
findings within a histological framework defined by Luck: proliferation, involution and the 
residual phase (Luck, 1959).   Luck described the proliferative phase to comprise a focal 
fibroplasia where cells are arranged in no purposeful arrangement in a histological nodule.  
As nodules involute fibroblasts align themselves predominantly in a longitudinal direction 
along stress lines passing through the nodule. In the final residual phase the nodule 
disappears, leaving fibrous cord which is almost acellular and tendon-like.  This is reflected 
in the three histological stages of Dupuytren’s disease proposed by Rombouts and 
Ballaguer: (1) a proliferative stage with high cellularity and the presence of mitotic figures, 
(2) a fibrocellular stage characterised by high cellularity but no mitotic figures and the 
presence of reticulin network, and finally (3) a fibrous stage with few cells separated by 
broad bundles of collagen fibres (Balaguer et al., 2009; Rombouts et al., 1989).  Chiu’s 
classification also broadly fits this theme: nodules in early disease have been described as 
composed of proliferating perivascular spindle-shaped cells with no increased collagen 
deposition. These become more closely packed in active disease with little intervening 
collagen, and in advanced disease less numerous elongated cells are described separated by 
broad parallel bands of collagen (Chiu and McFarlane, 1978).   Histological texts also suggest 
that microscopic findings depend on the age of the nodule starting with cellular 
proliferation of plump, immature appearing spindle-shaped fibroblasts, some mitotic 
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activity and minimal collagen deposition. Nodules that have been present for a long time are 
less cellular and contain markedly increased amounts of dense birefringent collagen.  Here 
fibroblasts are smaller and more slender. Cords between nodules are composed of dense 
fibrocollagnous tissue which resembles tendons (Weiss and Goldblum, 2008).    
Histological staging determined by light microscopy studies has also been correlated with 
recurrence of following fasciectomy. These studies demonstrate that highly cellular and 
proliferative Dupuytren’s tissue seen in primary disease correlates with higher disease 
recurrence rate (71%) when compared to the recurrence rate of less cellular fibrous tissue 
samples (18%) (Rombouts et al., 1989).  Similar findings were confirmed in a larger series of 
139 Dupuytren’s samples, although histological staging was found to be independent of 
Dupuytren’s diathesis (Balaguer et al., 2009). 
Electron microscopy techniques have also been used to further examine Dupuytren’s tissue 
to try and better determine the cell type that comprises each stage of disease.  
Myofibroblasts are modified fibroblasts with smooth muscle-like features that were first 
observed in granulation tissue of healing wounds by electron microscopy (Gabbiani et al., 
1971). This led to the suggestion of a contractile role for these cells in wound healing. 
Subsequently, myofibroblasts were observed in Dupuytren’s nodules; cells composing 
histological nodules were described to have three ultrastructural features: a fibrillar system 
similar to smooth muscle cells, nuclear deformations as found on contracted cells, and cell -
to-cell and cell-to-stroma attachments (Gabbiani and Majno, 1972).  Similarly, in a study of 
21 Dupuytren’s tissue samples, myofibroblasts were observed in clinical nodules, whereas 
proximal cord tissue was found to have longitudinally aligned collagen fibres with elongated 
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mature fibroblasts (Badalamente et al., 1983).  Finally, in a study that examined the 
ultrastructural relationship of skin to nodule and cord, myofibroblasts were not seen at the 
skin/cord interface, although they were reported in specimens from skin/nodule interface 
(Rudolph and Vande Berg, 1991; VandeBerg et al., 1982). 
The presence of myofibroblasts in Dupuytren’s tissue has been assessed at different disease 
stages by electron microscopy.   Dupuytren’s fascia from 38 patient samples was examined 
and the findings correlated with the duration of disease activity in each case.   Early disease 
was defined as a nodule in the palm without contracture. The authors reported that “early” 
nodules were composed of proliferated perivascular fibroblasts. “Active” disease was 
defined as palmar nodules with contracture for less than 3 years and in these samples the 
predominant cell seen in nodules was the myofibroblast.  Diffuse thickening of the palmar 
fascia with joint contracture for more than 3 years was defined as “advanced” disease and 
although myofibroblasts and fibroblasts were also reported in these samples, they were 
present in much reduced numbers (Chiu and McFarlane, 1978).  However, a study that 
examined 43 patient samples by electron microscopy found that proliferative stage nodules 
were chiefly composed of myofibroblasts with a small number of immature fibroblasts. The 
involutional stage consisted of nodules and some fibrous tissue extending from them and 
scar-like tissue was reported in the residual stage with few fibrocytes sparsely poplated 
amongst the collagenous matrix (Iwasaki et al., 1984).  Similarly, proliferative phase nodules 
have been reported to be composed of myofibroblasts with a few fibroblasts whereas 
involutional nodules were described as being essentially composed of myofibroblasts. 
Nodules in the residual phase were described as hypocellular with slender cells aligned with 
thick bands of collagen giving them a tendon-like appearance (Schurch et al., 1990). Finally, 
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a study that examined 24 Dupuytren’s patient samples by electron microscopy reported 
that clinical recurrence is not related to patient age at onset, duration, or severity of 
disease. Instead, recurrence was related to the presence of myofibroblasts in nodules 
(Gelberman et al., 1980; Rudolph and Vande Berg, 1991). 
Immunohistochemical studies of histopathological nodules revealed more about the 
distribution of myofibroblasts in Dupuytren’s tissue.  Myofibroblasts have been shown to 
characteristically express α-smooth muscle actin (α-SMA) which is the actin isoform typical 
of vascular smooth muscle cells (Skalli et al., 1986).  Unlike in granulation tissue where the 
expression of α-SMA is transient, increasing over time  during wound closure and gradually 
disappearing during scar formation (Darby et al., 1990), -SMA expression in Dupuytren’s 
disease appears to be more sustained, with large numbers of -SMA rich cells observed in 
diseased tissue.  α-SMA expression was initially described to exhibit positive staining in 
Dupuytren’s nodule tissue by immunofluorescence (Benzonana et al., 1988). In a key study, 
it was demonstrated by immunofluorescence that some of the cells from Dupuytren’s 
nodules and hypertrophic scars express α-SMA in addition to vimentin, whereas cells from 
normally healing granulation tissue, eschars and normally healed scars  only expressed 
vimentin. Furthermore, using gel electrophoresis β and γ actin was demonstrated in dermis 
and normal scar, whereas hypertrophic scars and palmar fibromatosis also contained α-SMA 
(Skalli et al., 1989). Subsequently, skin and cord samples from 20 patients undergoing 
dermofasciectomy were stained for α-SMA with the skin/ cord tissue orientation 
maintained. They reported diffusely distributed α-SMA positive cells in the dermis of eight 
samples. This study also noted foci of hypercellular Dupuytren’s tissue staining positive for 
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α-SMA and the pattern of staining observed was variable, from very intensely stained foci to 
weakly stained and dispersed patches (McCann et al., 1993).  
In another study, immunohistochemical analysis of excised Dupuytren’s cord samples from 
8 patients has shown hypercellular zones within nodules comprised up to 40% α-SMA 
positive cells, compared to 20% in less cellular regions of the same specimen (Hindman et 
al., 2003). Considerable variation in cellularity was reported between patient samples. Other 
studies have quantified the number of α-SMA positive cells within Dupuytren’s nodules. 
Using immunofluoresent staining studies have found that between 1-26% of cells isolated 
from clinical nodules and 1-9% of control flexor retincaulum cells stained positive for α-SMA 
(Tomasek and Rayan, 1995). Similarly in a more recent study 9.7% of cells derived from a 
clinical nodule, 2.7% from cord tissue and 1.3% from control flexor retinaculum cells stained 
positive for α-SMA (Bisson et al., 2003).  Finally, high levels of α-SMA protein have also been 
shown to be expressed in nodule-derived cells compared to cord cells and control dermal 
fibroblasts by western blotting (Dave, 2001 #35}.  
The expression of -SMA in Dupuytren’s disease therefore appears to be more sustained 
than in the wound.  These data suggest that aberrant regulation of -SMA expression is 
occurring in Dupuytren’s myofibroblasts compared to wound myofibroblasts.   A better 
understanding of what drives -SMA expression may be gained from studies examining the 
promoter of α-SMA and the environmental factors within Dupuytren’s disease that 
contribute to the sustained expression of this protein.   Some studies report lower numbers 
of myofibroblasts in late stage Dupuytren’s disease (Chiu and McFarlane, 1978; Iwasaki et 
al., 1984; Schurch et al., 1990), suggesting that -SMA expression may be induced early in 
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disease but down regulated later in disease.   Serial biopsies from the same patients or an 
animal model of Dupuytren’s disease would be helpful in understanding the kinetics of α-
SMA expression through different stages of disease but neither of these options are 
available. 
1.61  Other histological observations 
Dupuytren’s nodules have also been examined by electron microscopy for vascular changes. 
Within histological nodules and around the periphery of these nodules it has been shown 
that the majority of microvessels were occluded due to bulging of the endothelial cells into 
the lumen. These microvessels were surrounded by extensive layers of basal laminae and 
the histological nodules were described as essentially avascular (Kischer and Speer, 1984). 
Several investigators have also identified inflammatory cells in Dupuytren’s tissue. In 
particular, macrophages have been shown in cellular nodules clustered specifically around 
new blood vessels and a correlation between the numbers of macrophages and the 
presence of myofibroblasts has been reported (Andrew et al., 1991). Increased mast cells in 
excised Dupuytren’s’s tissue compared to control carpal ligament has also been reported 
(Schubert et al., 2006). Further studies have examined biopsies taken from the interface 
between palmar skin and excised Dupuytren’s tissue for inflammatory cells using light and 
electron microscopy. Large numbers of macrophages were reported in samples taken from 
the palmar skin/clinical nodule interface compared to palmar skin/cord (VandeBerg et al., 
1982). Increased numbers of Langerhans cells and CD45 positive cells have also been 
reported in histological nodules and at the dermo-epidermal junction in the overlying 
palmar skin (Qureshi et al., 2001). These studies have all examined Dupuytren’s tissue 
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excised from patients with contractures and hence tissue samples will inevitably reflect 
active or advanced Dupuytren’s disease. Nodules of both proliferative and involutional 
stages have been reported to contain small foci of perivascular haemorrhage with 
macrophages, some lymphocytes and mast cells (Iwasaki et al., 1984). 
1.7  Treatment 
Many different treatment types, both operative and non-operative have been trialled in the 
management of Dupuytren’s disease. Currently surgery is the mainstay of treatment for 
patients with significant digital contractures resulting from Dupuytren’s disease. However, 
increasingly in selected cases, minimally invasive techniques such as collagenase injections are 
being trialled.  
1.7.1  Surgical treatment 
Surgery is indicated in patients with functional disability or progressive digital contracture 
with PIPJ and MCPJ contractures of 30 degrees or more. Over time a number of different 
operative techniques have been used and can be broadly classified as fasciotomy, 
fasciectomy and dermofasciectomy (McGrouther, 2005).  
Fasciotomy is simple division of the cord and was described by Baron Guillaume Dupuytren 
and Sir Astley Cooper (Fig. 1.7) (Elliot, 1999). It can be performed as an open or 
percutaneous procedure (needle fasciotomy). It is principally used to treat isolated 
pretendinous cords in the palm and is useful in selected cases, for example elderly patients 
with significant co-morbidity. 
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Fasciotomy can be carried out at multiple levels and it has also been indicated for initial 
correction of joint contracture as part of a staged procedure (Bryan and Ghorbal, 1988).  
 
Figure 1.7. Open fasciotomy to correct digital contracture.  (A) Primary Dupuytren’s contracture.  
(B) Fasciotomy release carried out at the level of the metacarpophalangeal joint (MCPJ) and note 
residual contracture at the proximal interphalangeal joint (PIPJ).  (C)  Segmental fasciectomy at the 
PIPJ with, (D) correction of the PIPJ flexion deformity and subsequent closure with a z-plasty. 
 
Limited fasciectomy is the most common procedure and involves surgical excision of the 
affected fascia (Fig. 1.8) (Hueston, 1961). Fasciectomy involves varying degrees of resection 
of Dupuytren’s tissue. Whilst limited fasciectomy removes macroscopically diseased fascia 
within the surgical field, a segmental fasciecotomy involves excision of up to 1cm of 
diseased fascia and achieves a similar result to fasciotomy (Andrew and Kay, 1991; 
Moermans, 1991). 
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Figure 1.8. Limited fasciectomy to correct digital contracture.  (A) Primary Dupuytren’s contracture. 
(B) Dupuytren’s diseased fascia (highlighted with the black arrow) is excised through a longitudinal 
incision.  Flexor tendons and subcutaneous fat can be soon at the base of the operating field.  (C)  
Wound closure with z-plasty with incision over distal palmar crease left open. (D) Outcome 3 weeks 
following fasciectomy, with no residual flexion contracture. 
 
 
Radical fasciectomy entails extensive removal of the palmar and digital fascia in an attempt 
to remove all longitudinal fibres to the digits. However, complications from this procedure 
are more common without reduced disease recurrence rates (McIndoe and Beare, 1958). 
Dermofasciectomy is surgical excision of the diseased fascia combined with replacement of 
the overlying palmar skin with full thickness non-palmar skin grafts (McGrouther, 2005) (Fig. 
1.9). Typically dermofasciectomy is used in cases of recurrence or very aggressive primary 
disease, where there is significant skin involvement. Based on the observation that 
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Dupuytren’s disease does not recur beneath skin grafts, a “firebreak” dermofasciectomy has 
also been advocated with strategic placement of full thickness skin grafts at a flexion crease 
that would act as firebreak in areas of potential flare-up of recurrent disease (Hueston, 
1984). 
A
D
B
C
 
Figure 1.9. Dermofasciectomy to correct digital contracture resulting from recurrent disease.  (A) 
Recurrent Dupuytren’s contracture,  (B) Outline for skin excision  (C) Post excision of palmar skin and 
contracted fascia  (D) Outcome at 1 year following resurfacing of cutaneous defect with non-palmar 
full-thickness skin graft from the groin skin, showing no recurrence of Dupuytren’s contracture 
 
Unfortunately, surgery may also be associated with complications, including inadvertent 
injury to the tendon (0.2%), digital nerve (1.7-7.8%) or artery (1.9-9.7%) with the potential 
loss of a digit. Other potential complications include infection (1-10.6%), reduced grip 
strength, complex regional pain syndrome, delayed wound-healing (very common) and 
recurrence of contracture (Bulstrode et al., 2005; Dias and Braybrooke, 2006; Foucher et al., 
2003; Honner et al., 1971; Loos et al., 2007; Sennwald, 1990).  
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1.7.2  Minimally invasive procedures, surgical adjuncts and non-operative 
treatment 
Enzymatic fasciotomy using collagenase injections augmented by mechanical stress and 
splinting has been trialled in a few studies (Badalamente and Hurst, 2007; Hurst et al., 2009; 
McCarthy, 1992; Starkweather et al., 1996; Watt et al., 2010). A recent phase III randomized 
placebo-controlled trial in the USA showed that collagenase (clostridium histolyticum) 
treatment significantly improved outcomes (Hurst et al., 2009). In total 308 patients with 
joint contractures of 20 degrees or more were enrolled (mean MCPJ (55°) and PIPJ (45°)). 
Primary MCPJ or PIPJ cord contractures were randomly assigned to receive up to three 
injections of collagenase or placebo at 30-day intervals. Significantly more digits (64%) 
treated with collagenase than cords injected with placebo (6.8%) were reduced to within 
less than 5 degrees of full extension. However, 77% of MCPJ and only 40% of PIPJ treated 
contractures treated with collagenase met this end point at 30 days.  Serious complications 
included two tendon ruptures in digits with PIPJ contractures and one case of complex 
regional pain syndrome was reported. Other than superficial bruising and swelling, there 
were no significant changes in flexion or grip strength, no systemic allergic reactions and no 
nerve injuries were observed. Based on this study, it appears that enzymatic fasciotomy has 
a role in treating early contractures, although treatment outcomes for MCPJ contractures 
appear to be better than for PIPJ contractures.  
Early splinting is also often used, either in isolation or more commonly, as an adjunct to 
enzymatic fasciotomy and surgery. However, for splints to be effective in isolation without 
surgery, they need to be worn continuously and this in itself is an unacceptable impairment 
(Abbott et al., 1987). A recent systematic review of post-operative splinting in Dupuytren’s 
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disease suggested that splints are widely used and supported mainly by clinical reasoning 
and anecdotal evidence. The difficulty the reviewers found was that the multiple studies did 
not control for variables, including the use of different types of splints, duration of 
treatment and patient compliance (Larson and Jerosch-Herold, 2008).  
Slow continuous elongation of Dupuytren’s contracture by an external fixator has been 
shown to result in remodelling of the contractile fascia and gradual extension of the digit. 
However, following discontinuation of traction digital contracture rapidly recurred (Citron 
and Messina, 1998; Messina and Messina, 1993). Based on these observations, the Digit 
Widget ™ has been proposed to provide a period of continuous elongation followed by 
definitive treatment by limited fasciectomy (Hand Biomechanics Lab, USA). Proponents 
claim that in more advanced cases, gradual release of the joint contractures leads to 
improved functional outcomes. However, this has yet to be verified. 
Local radiotherapy for Dupuytren’s disease has been used with some success in patients 
with early disease and limited contractures (Betz et al., 2010; Keilholz et al., 1996; 
Seegenschmiedt et al., 2001). However, a study with median 7 year follow-up suggested no 
benefit from radiotherapy (Weinzierl et al., 1993). Although data are now available at 13 
years follow up, there remains the potential for slow wound healing in patients treated with 
radiotherapy who might subsequently undergo surgery and the optimal radiotherapy dose 
remains uncertain (Betz et al., 2010). Furthermore, there are potential issues with treating a 
benign disorder with radiotherapy.  
A prospective randomised controlled trial using intra-operative topical treatment with 5-
fluorouracil was performed in an attempt to control fibroblast proliferation in Dupuytren’s 
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disease (Bulstrode et al., 2004). This was based on data from the same group that suggested 
an anti-proliferative effect of 5-fluorouracil in cultured Dupuytren’s fibroblasts (Jemec et al., 
2000). However, in the clinical trial, there was no significant difference in recurrent 
contracture at 18 months between control and 5-fluorouracil treated digits.   
Steroids have also been used with variable success in Dupuytren’s disease (Ketchum and 
Donahue, 2000). None of the 75 hands treated in this study had MCPJ contractures of more 
than a 15° and none had PIPJ contractures at the outset of treatment with triamcinolone 
injections. Although temporary resolution of the nodules was observed following 
intralesional triamcinolone injection, improvement of the joint contracture was not seen. 
Furthermore, increased tendon rupture was also reported with frequent steroid injections 
(Ketchum and Donahue, 2000). It has been proposed that the therapeutic benefit of steroids 
in early disease is due to their anti-inflammatory role (Meek et al., 1999; Meek et al., 2002). 
Finally, other non-operative therapies have been trialled for Dupuytren’s disease, albeit with 
limited success. Treatment with oral vitamin E (Richards, 1952), allopurinol (Hurst and 
Badalamente, 1999; Murrell, 1991), ultrasound therapy (Stiles, 1966) and dimethyl 
sulphoxide (DMSO) (Hurst and Badalamente, 1999) have all been used and have 
demonstrated no clinical effect. 
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1.8  Recurrence following surgery 
Recurrence rates following surgery for Dupuytren’s contracture can vary significantly, 
depending on the type of procedure. True recurrence or recurrent contracture are defined 
as the appearance of a new lesion (Dupuytren’s tissue) or resulting fixed flexion deformity 
due to Dupuytren’s disease tissue (and not scar tissue), in a previously operated field. In 
contrast, disease extension refers to new lesions outside the previously operated area but 
within the same hand. 
Following open or percutaneous fasciotomy, recurrence rates have been reported between 
40-70% as soon as 2 years following surgery (Bryan and Ghorbal, 1988; Foucher et al., 2003; 
Rodrigo et al., 1976; van Rijssen and Werker, 2006). The recent phase III trial of 308 patients 
treated with collagenase has only reported on 30 day outcomes (Hurst et al., 2009). Results 
from the earlier phase of this trial suggests that the recurrence rates were approximately 
8% in patients with MCPJ contractures and 57% with PIPJ contractures at 2 years follow-up 
(Badalamente and Hurst, 2007). Increased recurrence following fasciotomy for PIPJ 
contractures compared to MCPJ contractures has also been reported in other studies (Bryan 
and Ghorbal, 1988; Foucher et al., 2003).   
Recurrence rates following fasciectomy are approximately 40-50% at 5 years (Foucher et al., 
1992; Hueston, 1961; Tonkin et al., 1984). However, recurrence rates have been reported as 
high as 71% at 10 years (Norotte et al., 1988) and 100% at 20 years follow-up (McGrouther, 
2005).  
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In comparison, recurrence following dermofasciectomy is quoted at 1-8% between 2-12 
years follow-up (Brotherston et al., 1994; Hall et al., 1997; Tonkin et al., 1984). One study 
reported that in 46 patients following dermofasciectomy, no recurrence and no recurrent 
contracture greater than 15 degrees was found after 6-12 years follow-up (Brotherston et 
al., 1994). Heuston through his observation that Dupuytren’s contracture did not recur 
beneath skin grafts, advocated their strategic placement at a flexion crease would act as 
‘firebreak’ between areas of potential flare-up of recurrent disease (Hueston, 1984). A 
recent study of 79 patients with PIPJ contracture randomised patients to either a firebreak 
skin graft or fasciectomy. At 36 months follow-up no difference was observed in recurrence 
rate following either firebreak dermosfasciectomy or fasciectomy (Ullah et al., 2009). 
Recurrence of Dupuytren’s contracture has been correlated with various factors, including 
increased expression levels of several matrix metalloproteinases (MMPs) and a disintegrin 
and metalloproteinase with thrombospondin motifs (ADAMTSs) (Johnston et al., 2008), 
histological staging (Balaguer et al., 2009; Rombouts et al., 1989) and Dupuytren’s diathesis 
(Hindocha et al., 2006). Histological findings suggest that highly cellular and proliferative 
Dupuytren’s tissue seen in primary disease correlates with higher disease recurrence rate 
(71%) when compared to the recurrence rate of less cellular fibrous tissue samples (18%) 
(Rombouts et al., 1989). Although similar findings were confirmed in a larger series of 139 
Dupuytren’s samples, histological staging was found to be independent of Dupuytren’s 
diathesis (Balaguer et al., 2009). In a study that examined 24 Dupuytren’s patient samples 
by electron microscopy reported that clinical recurrence is not related to patient age at 
onset, duration, or severity of disease. Instead, recurrence was related to the presence of 
myofibroblasts in the nodules (Gelberman et al., 1980; Rudolph and Vande Berg, 1991). The 
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authors demonstrated that myofibroblast presence may help to predict recurrence of 
disease and based on this suggested that palmar skin should be excised when adherent to 
disease nodules. 
Dupuytren’s diathesis is also considered important in predicting recurrent disease following 
surgery. The presence of all diathesis factors is associated with a higher risk of recurrent 
Dupuytren’s disease (71%) compared with a baseline risk of 23% in patients with 
Dupuytren’s disease but none of the diathesis factors (Hindocha et al., 2006). This was 
shown in a study conducted on 322 patients in Northwest England, where patients with 
Dupuytren’s disease were assessed for diathesis based on clinical history and examination. 
Odds ratios of developing recurrent disease were calculated using logistic regression. 
Interestingly, in the largest series of 73 fasciectomy cases in Japan, the reported recurrence 
was only 14% at 4 years follow-up and the significant diathesis factors only included radial 
side disease, ectopic lesions and an early onset of disease (Abe et al., 2004a). The authors 
suggested that low recurrence rates reflected the relatively shorter follow-up period, 
although a less aggressive Dupuytren’s disease phenotype amongst Japanese people should 
also be considered.  
1.9  Myofibroblasts 
The cells that primarily contribute to the pathogenesis of Dupuytren’s disease are 
myofibroblasts.  Myofibroblasts were first defined by Gabbiani as cells showing three 
ultrastructural features: a fibrillar system similar to smooth muscle cel ls, nuclear 
deformations (the severest recognisable by light microscopy as cross banded nuclei) and 
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cell-to-cell and cell-to-stroma attahments (Gabbiani et al., 1971).  Myofibroblasts can be 
distinguished from fibroblasts by the presence of bundles of intracellular contractile 
microfilaments, extensive cell-to-matrix attachment sites (fibronexi) and intercellular 
adherens and gap junctions (Eyden, 2005; Schurch et al., 2006).  
The presence of myofibroblasts represents a key event during normal wound healing and 
tissue repair. These highly contractile cells are normally seen in the gravid uterus and 
transiently during wound healing.  Typically, myofibroblasts disappear as the scar matures 
or when tissue remodelling is complete. However, myofibroblasts can also be detrimental 
for tissue function when they persist and become excessive. Examples of this are seen in 
hypertrophic scars (Ehrlich et al., 1994), keloid scar (Eyden, 2003; Shoukrey and Tabbara, 
1993), burn scar tissue (Eddy et al., 1988), contracture of capsules around breast implants 
(Hwang et al., 2010) and Dupuytren’s contracture (Schurch et al., 1990). 
1.10  Cytoskeletal and cell surface markers 
Myofibroblasts characteristically express α-SMA which is the actin isoform typical of 
vascular smooth muscle cells (Skalli et al., 1986), in addition to the β- and γ-cytoplasmic 
actins that are traditionally found in fibroblasts.  Fibroblast to myofibroblast differentiation 
is proposed to be a two-step process whereby in response to changes in compostion of the 
matrix, fibroblasts develop de novo contractile bundles or stress fibres that are composed of 
β- and γ-cytoplasmic actins (Hinz, 2007). These are termed “proto-myofibroblasts” and are 
different from quiescent fibroblasts that in vivo have no contractile apparatus (Tomasek et 
al., 2002). With increasing stress in the remodelled ECM proto-myofibroblasts start 
expressing de novo α-SMA and only develop into “differentiated myofibroblasts” when this 
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α-SMA is incorporated in to stress fibres (Goffin et al., 2006).  Although this process has 
been divided into two stages, there exists a stage in between the proto-myofibroblast and 
the differentiated myofibroblast where α-SMA is found transitorially in the cytoplasm but is 
not incorporated into stress fibers (Hinz, 2006).  This process is regulated by a number of 
different factors which are summarized in Figure 1.12 and which I review below. 
To date, α-SMA is the most commonly used and the most reliable myofibroblast marker 
(Hinz, 2007).   However, whilst α-SMA has been reported to distinguish myofibroblasts from 
fibroblasts, it cannot be used in isolation to reliably distinguish between myofibroblasts and 
vascular SMCs (Christen et al., 2001). This is especially true in Dupuytren’s nodules, where 
mixed populations exist.  Therefore, other cytoskeletal and cell surface markers have been 
examined to try and distinguish between these cell populations. 
Intermediate filaments vimentin and desmin are cytoskeletal proteins that play a role in 
maintaining cell architecture and have been studied in fibroblasts, myofibroblasts and SMCs. 
Fibroblasts, myofibroblasts and SMCs all express vimentin (Gabbiani et al., 1981). 
Myofibroblasts from granulation tissue also only express vimentin but not desmin (Skalli et 
al., 1989), whereas vascular SMCs express vimentin and desmin. However, in Dupuytren’s 
disease, whilst nodules are often composed of myofibroblasts (Iwasaki et al., 1984; Schurch 
et al., 1990), up to 20% cells present around capillaries and blood vessels in proliferating 
nodules have also been shown by immunohistochemistry to express desmin (Schurch et al., 
1990; Shum and McFarlane, 1988). Furthermore, the use of desmin as a marker for SMCs is 
limited as it is lost from these cells when placed in culture, as is caldesmon smooth muscle 
myosin heavy chain (Christen et al., 2001; Serini and Gabbiani, 1999).  
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Other myofibroblast markers, including smoothelin (Chambers et al., 2003) and the 41g 
isoform of the stress fibre protein paladin (Chambers et al., 2003; Mykkanen et al., 2001) 
have been considered. However, neither is exclusively expressed in smooth muscle cells or 
myofibroblasts when analysed by gene expression profiling or western blot analysis 
respectively. 
Myofibroblasts cell surface markers have also been investigated. The expression of specific 
trans-membrane cell-cell adhesion proteins that are linked to the intracellular actin 
cytoskeleton (cadherins) has been proposed as a potential marker for differentiated 
myofibroblasts. Fibroblasts in normal dermis express almost none, if any, of the cadherin 
protein family. N-cadherin (A-cell adhesion molecule (A-CAM)) is expressed in early 
granulation tissue and in cultured fibroblasts. However, in TGF-β1 treated cells that express 
α-SMA or in differentiated myofibroblasts in granulation tissue, N-cadherins become 
replaced by OB-cadherin (Hinz et al., 2004). This transition has also been described in 
prostate cancer stromal fibroblasts (Tomita et al., 2000). Although OB cadherin is not 
expressed in SMCs, it has been shown in other cells of mesenchymal origin, and therefore, 
cannot be used as an exclusive myofibroblast marker. 
Thy-1 is a cell surface glycoprotein that has been described in fibroblasts from several 
organs (Dudas et al., 2007; Koumas et al., 2003) and reported to be absent in 
myofibroblasts. Furthermore, it has been suggested that only Thy-1 positive cells have the 
potential to undergo myofibroblastic differentiation as compared to Thy-1 negative cells, 
which cannot. Thy-1 expression has not been examined in cells derived from Dupuytren’s 
disease. 
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1.11  Origin of myofibroblasts 
In Dupuytren’s disease the origin of the myofibroblasts remains unknown. Two theories 
have dominated thinking about the origin of Dupuytren's contracture and, therefore, the 
source for myofibroblasts in Dupuytren’s disease. The ``extrinsic''  theory suggests that initial 
changes are observed in the overlying palmar dermis (Hueston, 1985; Hueston, 1963), 
whereas the ``intrinsic'' theory argues that the disease process originates within the palmar 
fascia (McFarlane, 1974). Neither of these theories has been proven and there is speculation 
that massive cellular proliferation starts following rupture of palmar fascial fibres (Yi et al., 
1999). Examination of fibroblasts from normal palmar fascia and normal dermal fibroblasts 
has suggested that cells from both sources have the potential to develop in to 
myofibroblasts (Rayan and Tomasek, 1994; Tomasek et al., 2002). Both cell types develop 
stress fibres when placed in culture on rigid substrates or in 3D collagen matrices and in the 
presence of TGF-β1 they further develop α-SMA positive stress fibres (Bisson et al., 2003; 
Desmouliere et al., 1993; Wong and Mudera, 2006). 
Pericytes and smooth muscle cells from the vasculature have also been implicated as a 
source for myofibroblasts in Dupuytren’s disease (Kischer and Speer, 1984). Desmin is 
present in parenchymal smooth muscle cells and some vascular smooth muscle cells. In 
Dupuytren’s disease nodules, the presence of desmin-positive cells around blood vessels in 
a stellate pattern has also led to the hypothes is that Dupuytren’s myofibroblasts may arise 
from migrating perivascular smooth muscle cells (Shum and McFarlane, 1988).  Pericytes 
and vascular smooth muscle cells have also been implicated in scleroderma (Rajkumar et al., 
2005)  as well as in liver and glomerular fibrosis (Desmouliere et al., 2003). 
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It is recognised that myofibroblasts often arise from resident cell populations within the 
organ system involved.  In dermal wound healing it is thought that fibroblasts are recruited 
locally from sites adjacent to the injury and differentiate into myofibroblasts in the wound 
bed (Desmouliere et al., 2005). In pulmonary fibrosis most myofibroblasts have been shown 
to arise from locally residing fibroblasts, in the liver hepatic stellate cells are the main 
contributor for liver fibrosis and media smooth muscle cells are the main contributor to 
atheromatous plaques (Hinz, 2007). 
However, it is also known that myofibroblasts may arise from fibrocytes, which are a sub-
population of bone marrow derived leucocytes with fibroblast characteristics (Abe et al., 
2001). Fibrocytes derived from bone marrow are possibly a significant source of 
myofibroblasts. This has been shown in studies by transplanting bone marrow from male to 
irradiated female mice (Direkze et al., 2003) and identifying the Y chromosome by in situ 
hybridisation and also by transplanting bone marrow from transgenic green fluorescent 
mice to irradiated wild-type animals (Hashimoto et al., 2004). These studies have shown 
that up to 30-50% of wound myofibroblasts are potentially derived from fibrocyte 
progenitors and this has been demonstrated in hepatic, renal and pulmonary fibrotic 
conditions (Direkze et al., 2003; Forbes et al., 2004; Hashimoto et al., 2004). However, it 
remains unclear whether myofibroblasts precursors in fibrotic conditions, and indeed 
Dupuytren’s disease, are recruited from several different sources.  
Chapter 1  Introduction 
 
39 
 
1.12  Contractility 
Cells exist in vivo within a dynamic environment whereby mechanical tension and load 
determine cell morphology and function. Fibroblasts in 3D collagen matrices acquire a 
similar bipolar phenotype to that seen in vivo, unlike fibroblasts cultured in monolayer 
(Elsdale and Bard, 1972). Initial experiments using fibroblast populated collagen lattices 
(FPCLs) demonstrated contraction of the lattices, which led to the use of this model in the 
study of wound contraction (Bell et al., 1979; Grinnell, 1994). Subsequently, studies have 
demonstrated dose-dependent FPCL contraction with fetal calf serum (FCS) (Brown et al., 
2002; Rayan and Tomasek, 1994; Tomasek et al., 1992) and that contraction was related to 
final FPCL collagen concentration (Bell et al., 1979). 
Whilst alternative models of cell contractility have been developed, such as wrinkling of two 
dimensional silicone substrates (Harris et al., 1980; Harris et al., 1981), three dimensional 
FPCL contraction models are most commonly employed (Grinnell and Petroll, 2010).  These 
various inter-related FPCL models have been used to study collagen matrix contraction 
(Grinnell, 2003; Grinnell and Petroll, 2010; Tomasek et al., 2002) and include free-floating 
and restrained matrices. Contraction of restrained matrices has been used to measure both 
isotonic contraction following stress-release and also to quantify real-time isometric force 
contraction using the culture force monitor (Fig. 1.10). 
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Figure 1.10. Three dimensional collagen lattice models.  Free-floating matrix contraction occurs 
when FPCLs are released from surfaces of the culture dish soon after matrix polymerization and 
placed in culture media. Mechanical tension cannot develop in free-floating lattices and fibroblasts 
exert tractional forces, resulting in slow compaction of the lattice. Restrained matrix contraction 
occurs when cells are incubated with matrices that remain attached to the surfaces of the culture 
dish. Stress-relaxation then occurs upon release of restrained FPCLs which previously developed 
tension, therefore resulting in isotonic contraction. FPCL contraction and stress-relaxation can be 
quantified by measuring the change in matrix diameter (scale bar shown = 7mm). Without detaching 
FPCLs from culture, real-time quantification of uniaxial isometric force generated in restrained FPCLs 
can be quantified using the culture force monitor (CFM). Using this model,  FPCLs (pink) are cast and 
floated in medium, tethered between two flotation bars (light grey) one of which is held stationary 
whilst the other is attached to a force transducer. As force develops, FPCLs acquire an hour glass 
shape. 
 
Floating matrix contraction occurs when FPCLs are released from the culture surfaces soon 
after matrix polymerization and is considered a low cell-matrix tension state. During and 
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after contraction, the cells exhibit few α-SMA stress fibres. Restrained matrix contraction 
occurs when FPCLs remain attached to the culture surfaces. This results in isometric 
contraction, where cell contraction is opposed by an equal load that prevents cell 
shortening. Cells develop prominent α-SMA stress fibres and this is considered a high cell-
matrix tension state (Arora and McCulloch, 1994; Hinz et al., 2001a). Stress-relaxation upon 
release of restrained FPCLs that have developed tension results in isotonic contraction as 
the cells shorten in an attempt to maintain tension.  The loss of tension during stress -
relaxation has been shown to result in rapid disassembly of stress fibres (Hinz et al., 2001b). 
More specifically, following FPCL stress-relaxation, degradation of α-SMA is observed within 
2 minutes and after 10 minutes almost all stress fibres have disappeared (Tomasek et al., 
1992). Furthermore, fibronectin matrix and fibronexus junctions are disrupted and cells and 
collagen lose their aligned orientation. FPCL contraction and stress -relaxation are frequently 
quantified by measuring the change in matrix diameter.  
Many groups have examined cell contractility using isotonic contraction models. Increased 
contractility has been shown with rat lung fibroblasts expressing high levels of α-SMA, 
compared to rat subcutaneous fibroblasts expressing low levels of α-SMA (Hinz et al., 
2001a).  However, in Dupuytren’s disease studies using isotonic contraction to compare 
nodule, cord and carpal ligament-derived cells have reported inconsistent findings.  Whilst 
some groups reported no differences in contraction (Rayan and Tomasek, 1994; Tarpila et 
al., 1996), others have reported increased contraction only with early passage (passage 4) 
but not with late passage (passage 8) nodule-derived cells (Moyer et al., 2002), or in nodule-
derived cells expressing higher levels of α-SMA as determined by immunofluorescence 
(Tomasek and Rayan, 1995). More recently, isometric contractile forces within restrained 
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FPCLs have been studied using a culture force monitor (CFM).  FPCLs were cast and floated 
in medium, tethered between two flotation bars, one of which is held stationary whilst the 
other is attached to a force transducer (Eastwood et al., 1994; Eastwood et al., 1996). This 
allows real-time quantification of uniaxial isometric forces generated by cells within 3D 
collagen matrices. FPCLs with a high aspect-ratio (ratio of length/ width/ thickness) have 
been shown to produce increased strain gradients, resulting in longitudinal fibroblast 
alignment within the collagen lattice (Eastwood et al., 1998). This best reflects cell 
morphology in Dupuytren’s cord, where fibroblasts are longitudinally aligned amongst 
collagen fibres along the major axis of the cord (Luck, 1959).  
Using this model, dermal fibroblasts seeded in FPCLs contracted and reached a plateau 
(Brown et al., 1998). This study measured forces generated by dermal fibroblasts in 
response to changes in applied load using a tensional CFM. Increased external loading was 
followed immediately by a reduction in cell-mediated contraction, whilst decreased external 
loading elicited increased contraction. In contrast, Dupuytren’s nodules and cord-derived 
cells up to cell passage five did not reach plateau and generated significantly greater 
isometric contractile force than control carpal ligament fibroblasts over a 20 hour test 
period (Bisson et al., 2004).  
Myofibroblasts contract and do not reach a plateau. The mechanism for their contraction is 
not entirely understood. Myofibroblasts can sustain a contractile force over long periods of 
time and this force is generated by contractile stress fibres which are composed of actin 
microfilaments and associated with non-muscle myosin and other actin-binding proteins 
(Burridge and Chrzanowska-Wodnicka, 1996; Serini and Gabbiani, 1999; Tomasek et al., 
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2002). Previously it has been demonstrated that contraction in myofibroblasts is regulated 
by myosin light-chain (MLC) phosphorylation and is mediated via the Rho/Rho-kinase 
pathway. In contrast, SMC rely on intracellular calcium influx for immediate and rapid 
increases in force generation (Kamm and Stull, 1989), whereas elevation of intracellular 
calcium has been shown not to promote contraction of myofibroblas ts within collagen 
lattices or granulation tissue (Parizi et al., 2000; Tomasek et al., 2006). Furthermore, 
differentiated myofibroblasts in wound granulation tissue do not contract in response to an 
agonist when treated with the Rho kinase inhibitor Y27632 (Tomasek et al., 2006). However, 
others have reported that myofibroblast contraction is regulated by changes in intracellular 
calcium concentration and MLC kinase (MLCK) (Goto et al., 1998; Levinson et al., 2004; 
Raizman et al., 2007). This difference in regulation of SMC and myofibroblast contraction 
may relate to their functional differences. SMCs contract and relax in response to their 
environment, whereas myofibroblasts need to generate continuous force over long periods 
of time and contraction might result in irreversible tissue contractures (Tomasek et al., 
2002).  
 A recent study has examined how spontaneous changes in the intracellular calcium 
concentration contribute to myofibroblast contraction. Contractile events were assessed by 
tracking stress-fibre-linked microbeads and by atomic force microscopy (Castella et al., 
2010). Myofibroblasts exhibit periodic calcium oscillations that control small and weak 
contractions. Whilst depletion of intracellular calcium reduced these micro-contractions, cell 
isometric tension was unaffected as assessed by growing cells on deformable substrates. 
Inhibition of Rho- and ROCK-mediated calcium-independent contraction demonstrated no 
effect on micro-contractions, but abolished cell tension. The authors proposed that Rho- 
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and ROCK dependent isometric tension generates slack in extracellular matrix fibrils, which 
are then accessible for the low-amplitude and high frequency contractions mediated by 
intracellular calcium. This study used atomic force microscopy to investigate isometric force 
generation in a non-3D environment and, whilst it may provide an explanation for 
contraction, the findings do not account for how contraction is further propagated once 
individual cells are fully contracted and the matrix has been remodelled (Castella et al., 
2010). 
1.13  Extracellular matrix components 
The ECM is a complex 3D environment composed of a structural network of connective 
tissue fibres that provides support and protection for cells. The ECM is dynamic, with 
constant turnover of its various components including collagen and elastin contained within 
a ground substance of various proteins, proteoglycans and hyaluronates (Alberts et al., 
2002). Myofibroblasts significantly contribute to synthesis of the constituents of the ECM.  
Collagen is a major component of the ECM and the most prevalent and ubiquitous is type I 
collagen (Prockop and Kivirikko, 1995). Types I, III, IV, V and VI collagen have been reported 
to be the most common myofibroblast products (Naugle et al., 2006; Schurch et al., 2006). 
In Dupuytren’s disease fascia there is an elevated level of total collagen and an alteration in 
the collagen III/I ratio according to the phase of the disorder (Brickley-Parsons et al., 1981). 
This study reported that initially more collagen type III was produced compared to type I 
and that the balance normalises as the tissues mature. However, the increased type III/I 
collagen ratio has also been explained by reduced type I collagen production in cell cultures 
of Dupuytren’s disease fibroblasts compared to age and sex matched control carpal 
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ligament-derived fibroblasts (Murrell et al., 1991). Type-III collagen, which is virtually absent 
from normal adult palmar fascia, has been shown to comprise up to 40% of total collagen in 
Dupuytren’s tissue. Interestingly, type-III collagen was also abundant in clinically ‘normal’ 
fascia of patients with established Dupuytren's disease, suggesting that the disease is 
widespread throughout the fascia (Brickley-Parsons et al., 1981). 
Myofibroblasts are highly active in ECM synthesis and in Dupuytren’s disease as in many 
other fibrotic diseases, matrix metalloproteinases (MMPs), a related family of MMPs, a 
disintegrin and metalloproteinase domain with thrombospondin motif (ADAMTSs) and their 
tissue inhibitors of metalloproteinases (TIMPs) play an important role. Normal ECM turn-
over depends on a balance between proteinase and inhibitor activities, whereby an 
imbalance of proteolysis may lead to fibrosis (Brinckerhoff and Matrisian, 2002). An interest 
in the role of MMPs in Dupuytren’s disease began in the 1980s following reports that the 
use of broad-spectrum MMP inhibitor (Marimastat) in clinical trials to reduce local cancer 
invasion and distant metastasis, was associated with the development of Dupuytren’s 
disease and frozen shoulder (Hutchinson et al., 1998). 
Several studies have looked at various MMPs and TIMPs in Dupuytren’s disease. MMP-1, -2, 
-9 and TIMP-1 and -2 levels were measured in the sera of patients with Dupuytren’s disease 
and compared to those who had carpal tunnel release. Significantly higher levels of TIMP-1 
were found in Dupuytren’s patients (Ulrich et al., 2003). Microarray analysis of gene 
expression in Dupuytren’s disease and Peyronie’s disease demonstrated increased 
expression of MMP-2 and -9 in the diseased tissues compared with normal palmar fascia 
and tunica albuginea (Qian et al., 2004). In contrast, a comparison of Dupuytren’s tissue 
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with frozen shoulder and control shoulder tissue showed that MMP-1, -2, -9 and TIMP-1 was 
expressed in all tissues and MMP-3 was absent from Dupuytren’s tissue, whilst MT1-MMP 
was increased in Dupuytren’s tissue compared with control normal shoulder tissue (Bunker 
et al., 2000). Interestingly, increased MMP-1, -2 and -9 expression has been reported in 
Dupuytren’s tissue in response to mechanical load using an external fixator (Bailey et al., 
1994; Tarlton et al., 1998) and this was accompanied by an increase in newly synthesised 
collagen following tissue extension and remodelling.  More recently a complete expression 
profile of MMPs in Dupuytren’s nodules compared to normal palmar fascia taken from 
patients who had carpal tunnel release was been performed using real-time reverse-
transcription polymerase chain reaction (RT-PCR). MMP-1, -7, -13, MT1-MMP, ADAMTS-14 
and TIMP-1 were all significantly increased in Dupuytren’s nodules compared to control 
tissue (Johnston et al., 2007). The same authors subsequently reported significant 
correlation between several MMPs and ADAMTSs and recurrent fixed flexion deformity over 
a 14 month follow-up period (Johnston et al., 2008).  
Recent studies have also analysed the effects of a broad spectrum MMP inhibitor (ilomastat) 
on isotonic contraction of FPCLs seeded with Dupuytren’s nodule-derived cells, cord cells 
and compared to control cells from control carpal ligament. Treatment of FPCLs with MMP 
inhibitor (100µM ilomastat) significantly reduced isotonic contraction and led to 
concomitant suppression of MMP-1 and -2 as determined by western blot analysis and 
gelatin zymography (Townley et al., 2008). The same authors also demonstrated reduced 
isometric force contraction in the CFM using cells derived from the same tissues (Townley et 
al., 2009).  
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This group also examined the differences in residual matrix tension (RMT) following the 
addition of cytochalasin D to FPCLs following 48 hours contraction in the CFM (Townley et 
al., 2009). Cytochalasin D inhibits actin-dependent processes and, therefore, uncouples 
fibroblast force generation from the collagen matrix. They found significantly greater RMT in 
nodule-derived cells compared to control cells following treatment with cytochalasin D.  
However, in FPCLs treated with ilomastat no significant difference in RMT was observed 
following addition of cytochalasin D, suggesting that isometric force generation is in part 
determined by MMP associated matrix remodelling and in part by the cell contraction.  
An essential component and a reliable marker of the myofibroblast ECM is fibronectin (FN). 
Increased FN production, and in particular the expression of fibronectin ED-A splice variant, 
has been shown to play a role in cell migration, adhesion, cell morphology and 
myofibroblast differentiation (Hynes, 1990). In Dupuytren’s tissue, fibronectin ED-A and ED-
B expression has been demonstrated using indirect immunofluorescence, 
immunohistochemistry and by PCR (Berndt et al., 1995; Halliday and Tomasek, 1995; 
Kosmehl et al., 1995). More recent studies have shown that fibronectin ED-A contains 
cryptic domains that unfold upon cell traction and is required for TGF-β1  induced 
myofibroblast differentiation (Serini et al., 1998; Vogel and Sheetz, 2006). It has, therefore, 
been proposed that tension within the ECM may promote myofibroblast differentiation by 
revealing cryptic epitopes in ECM proteins under stress. 
Tenascin-C, another glycoprotein, is also a component of the myofibroblast ECM which is 
associated with tissue repair (Chiquet-Ehrismann and Chiquet, 2003). It has been shown to 
be upregulated in Dupuytren’s nodules (Berndt et al., 1995) and in Dupuytren’s cord tissue 
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compared to control palmar fascia (Kuhn et al., 2002; Lee et al., 2006; Shih et al., 2009b). It 
is also upregulated in other fibrotic diseases, including keloid and hypertrophic scars 
(Dalkowski et al., 1999; Kaarteenaho-Wiik et al., 2000). Retinoids appear to downregulate 
the tension of fibroblasts in FPCLs by the induction of tenascin-C (Yamada et al., 1999). 
Conversely, tenascin-C stimulates migration, differentiation and contractility of cardiac 
myofibroblasts derived from tenascin-C null mice show reduced myofibroblast development 
after cardiac injury. Therefore, the effects of tenascin-C remain unclear and this multi-
domain hexameric molecule may have different effects in different systems.   
Periostin is an ECM component of many collagen-rich connective tissues that are subjected 
to mechanical stress-tension (Norris et al., 2007) and periostin mRNA levels are highly up-
regulated in Dupuytren’s nodule and cord tissue relative to normal palmar fascia (Shih et al., 
2009b). A recent study on the effects of periostin on fibroblasts derived from whole 
Dupuytren’s cord compared to normal fascia has suggested that perisotin treatment may 
promote the myofibroblast phenotype through increased α-SMA expression by western blot 
analysis and increased isotonic contraction of FPCLs seeded with Dupuytren’s’s cells 
compared to normal fascia (Vi et al., 2009). 
1.14  AGEs and RAGE 
Recently studies have suggested that advanced glycation end-products (AGEs) and the 
receptor for advanced glycation end-products (RAGE) are implicated in cell dysfunction, 
fibrosis (Li et al., 2004; Oldfield et al., 2001)  and mechanisms of inflammatory disease (van 
Beijnum et al., 2008). RAGE is a multiligand receptor that has also specifically been 
implicated in driving sterile inflammation (Sims et al., 2010). There is widespread expression 
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of RAGE on vascular endothelial cells, neutrophils, monocytes/macrophages, lymphocytes  
(Brett et al., 1993) and dermal fibroblasts (Niu et al., 2008). RAGE expression is amplified in 
circumstances when ligands, such as AGEs, and inflammatory mediators accumulate 
(Schmidt et al., 1993). Activation of RAGE had been shown to mediate signalling pathways 
upstream of pro-inflammatory mediators such as TNF-α (Vlassara et al., 1988) thus 
prompting the hypothesis that this receptor may be key to the initiation of inflammation. 
The RAGE promoter contains multiple functional NF-κB and SP-1 transcription factor–
binding sites (Huttunen et al., 1999; Li et al., 1998), and therefore, ligands and 
proinflammatory cytokines can also further promote the expression of RAGE. 
AGE-modified proteins are the final products formed from the irreversible non-enzymatic 
glycation between reducing sugars and polypeptides (Vlassara et al., 1994) and have been 
shown to exert their influence by forming protein cross links that alter ECM structure and 
function as well as interacting with cell surface receptors (Neeper et al., 1992).  AGEs are 
found in the plasma and accumulate in various tissues during ageing (Brett et al., 1993) and 
occur at higher levels in diabetes (Makita et al., 1991; Makita et al., 1992). The interaction 
between AGEs and their binding proteins also activates multiple signal transduction 
pathways, leading to the secretion of inflammatory cytokines, up-regulation of adhesion 
molecules and the production of cytokines, including TGF-β1 and platelet derived growth 
factor (PDGF) (Throckmorton et al., 1995), tumour necrosis factor alpha (TNF-α) and 
interleukin-1 (IL-1) (Vlassara et al., 1988). 
The interaction of AGE with RAGE has also been shown to induce a TGF-β1 dependent 
epithelial-myofibroblast transdifferentiation in a proximal renal tubule cell line (Li et al., 
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2004; Oldfield et al., 2001) and has also been suggested to induce the myofibroblast 
phenotype in peritoneal fibrosis (De Vriese et al., 2006). It has been demonstrated that 
specific binding of 125I-AGE-BSA to cell membranes in a rat proximal tubule cell line showed 
the binding site was RAGE. Furthermore, AGE exposure induced dose-dependent 
myofibroblast differentiation determined by morphological changes and de novo α-SMA 
expression, and these effects were blocked with antibodies against RAGE of TGF-β1 (Oldfield 
et al., 2001). This group further confirmed de novo α-SMA expression by 
immunocytochemistry, mRNA and protein levels (Li et al., 2004). This study also 
demonstrated that AGEs activate the RAGE-ERK1/2 MAP kinase pathway to mediate the 
early myofibroblast differentiation process. When these findings are considered in 
combination with the previously reported association between diabetes and Dupuytren’s 
contracture (Arkkila et al., 1996), they suggest a possible role for AGE dependent 
differentiation of myofibroblasts in Dupuytren’s disease. 
1.15  Growth factors and cytokines 
There is now considerable evidence demonstrating raised levels of various cytokines and 
growth factors in Dupuytren’s disease. These include Interleukin-1 (IL-1), basic fibroblasts 
growth factor (bFGF), TGF-β1, TGF-β2, epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF) and connective tissue growth factor (CTGF) (Baird et al., 1993; Bunker 
et al., 2000; Igarashi et al., 1996; Kuhn et al., 2001; Terek et al., 1995). This has led to studies 
of their role in Dupuytren’s disease in stimulating cell proliferation, contraction and ECM 
production. 
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PDGF expression is higher in Dupuytren’s tissue compared to normal fascia as determined 
by southern blotting and immunohistochemistry (Terek et al., 1995). It has also been shown 
that PDGF is highly expressed in myofibroblast-rich nodules (Badalamente et al., 1992). Cells 
from Dupuytren’s tissue and control normal palmar fascia exposed to PDGF and bFGF also 
demonstrated increased proliferation rates and increased collagen synthesis. An early study 
on 12 Dupuytren’s disease cords and 12 normal palmar fascia controls found significantly 
increased expression of IL-1α, IL-1β, TGF-β1 and bFGF by RT-PCR. However, no siginificant 
difference in PDGF-α or -β were found (Baird et al., 1993).  
Using RNA in situ hybridisation and immunhistochemistry, it has been demonstrated that 
TGF-β1, TGF-β2, bFGF and fibronectin ED-A and B are localised in proliferating α-SMA 
positive nodules. Furthermore, the expression of TGF-β1, 3 and bFGF in peri-nodular tissues 
was also increased, implying a role for these growth factors in recruitment of quiescent 
fibroblasts (Berndt et al., 1995). TGF-β1 is recognised as the major growth factor promoting 
myofibroblast differentiation by inducing expression of α-SMA (Desmouliere et al., 1993) as 
well as ECM proteins, including collagen (Alioto et al., 1994; Werner and Grose, 2003), 
integrins (Riikonen et al., 1995) and a number of cytoskeletal proteins that make up the 
myofibroblast contractile apparatus (Malmstrom et al., 2004). The TGF-β family exerts its 
effects mainly through Smad signal transduction pathways to regulate α-SMA expression 
(Derynck and Zhang, 2003). 
Upregulation of all three isoforms of TGF-β is seen on immunohistochemical staining of 
Dupuytren’s specimens (Badalamente et al., 1996) and also by DNA microarray analysis in 
Dupuytren’s cord and para-cord fascia when compared to normal control palmar fascia. In 
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this study there was a 10-20 fold increase in TGF-β2 expression in cord tissue as assessed by 
RT-PCR (Lee et al., 2006). Three forms of TGF-β receptor (I, II and III) have also been 
demonstrated in Dupuytren’s fibroblasts compared to normal adult skin fibroblast controls 
(Kloen et al., 1995). TGF-β1 and 2 are potent stimulators for cell proliferation in Dupuytren’s 
disease (Badalamente et al., 1996) and in FPCLs seeded with Dupuytren’s nodule-derived 
fibroblasts, both have also been shown to be associated with greater isotonic and isometric 
force contraction as compared to FPCLs with fibroblasts from normal fascia when treated 
with TGF-β1 (Bisson et al., 2009; Brown et al., 2002; Kuhn et al., 2002; Wong and Mudera, 
2006). Whilst these studies show dose dependent contractile differences between these cell 
types, increased contractility of FPCLs in response to TGF-β1 were found in all cell types and 
have also been reported by many authors using normal dermal fibroblasts (Arora et al., 
1999; Grinnell and Ho, 2002; Liu et al., 2001; Vaughan et al., 2000). 
TGF-β1 has also been shown to act synergistically with other cytokines, including EGF and 
connective tissue growth factor (CTGF) (Folger et al., 2001; Kloen et al., 1995). CTGF 
potentiates the profibrotic action of TGF-β1  and also induces fibroblast proliferation, but 
does not substitute for the action of TGF-1 as α-SMA remains unchanged after the addition 
of CTGF to cultures of corneal fibroblast (Folger et al., 2001). 
Certain soluble factors have also been shown to antagonise TGF-β1 and hence reduce 
myofibroblast differentiation. The inflammatory mediator, IL-1 has been shown to inhibit 
TGF-β1 induced α-SMA expression in cultured dermal fibroblasts when added as a 
recombinant protein. Controlled secretion of IL-1 alpha and beta by keratinocytes when co-
cultured with fibroblasts may be a mechanism for suppressing myofibroblast differentiation 
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in early wounds (Shephard et al., 2004). IL-1 beta has been shown to be abundantly 
expressed in Dupuytren’s fascia (Baird et al., 1993).  IFN-γ, a cytokine produced by T cells, 
has also been shown to reduce α-SMA mRNA and protein expression in cultured rat 
subcutaneous fibroblasts (Desmouliere et al., 1992) and Dupuytren’s myofibroblasts 
(Tanaka et al., 2007). In an earlier clinical trial, IFN-γ was injected into hypertrophic scars 
and Dupuytren’s contracture of 14 patients and demonstrated some therapeutic effects 
with a decrease in size of the lesions, although not complete resolution. Using 
immunofluorescence techniques, the authors also showed that IFN-γ qualitatively 
decreased α-SMA expression level in these contractile lesions (Pittet et al., 1994). 
TNF-α is another potent inflammatory cytokine and high levels of TNF-α mRNA have been 
reported in Dupuytren’s cord tissue compared to tissue from frozen shoulder and control 
shoulder tissue (Bunker et al., 2000). TNF-α  has been shown to inhibit TGF-β1  induced 
expression of α-SMA and collagen 1A, via inhibition of Smad3 phosphorylation of JNK 
pathway in human dermal fibroblasts using both western blot analysis and RT-PCR. Cells in 
this study were derived from normal adult skin. Furthermore, this study demonstrated a 
decrease in collagen matrix stiffness and isotonic contraction after 5 days in culture 
(Goldberg et al., 2007). Similar findings have also been reported using myofibroblasts 
derived from human hip joint tissue (Mattyasovszky et al., 2010). Although in this study TNF-
α demonstrated a suppressive effect on myofibroblasts derived from hip joint capsule, it 
was also found to promote cell proliferation and viability in the same study. Furthermore, 
increased proliferation of human dermal microvascular endothelial cells with TNF-α has also 
been reported, suggesting that TNF-α may play a role in myofibroblast induction (Chaudhuri 
et al., 2007). 
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Finally, significant time-dependent upregulation of vasoactive prostaglandin E2 (PGE2) 
synthesis has been shown in myofibroblast rich tissue (Mattyasovszky et al., 2010). 
Vasoactive prostaglandins including PGE2 have previously been shown by 
immunohistochemistry to localise to myofibroblast-rich Dupuytren’s nodules and the 
increased expression of PGE2 in Dupuytren’s nodules compared to control normal fascia has 
been previously demonstrated by radioimmunoassay (Badalamente et al., 1988).The 
consequences of PGE2 in Dupuytren’s disease have not been further examined.  
1.16  Matrix cell Adhesions and stress perception 
Ultrastructural analysis of myofibroblasts in Dupuytren’s disease, granulation tissue and 
other fibrotic conditions has shown extensive cell-matrix attachment sites, called fibronexi 
(Dugina et al., 2001; Tomasek et al., 1987; Tomasek and Haaksma, 1991). Fibronexi are 
specialised adhesion complexes that use transmembrane integrins to link intracellular actin 
with extracellular fibronectin fibrils and can help distinguish myofibroblasts from fibroblasts 
and SMCs (Eyden, 2005; Tomasek et al., 1999).  Actin bundles terminate at the 
myofibroblast surface at these fibronexi and functionally provide a mechano-transduction 
system, whereby force generated by stress fibres can be transmitted to the surrounding 
extracellular matrix and, equally, stress within the matrix can be perceived by 
myofibroblasts. 
In vitro, myofibroblasts develop specialised “supermature” focal adhesions (FAs), so called 
because they are significantly longer (8-30 µm) (Dugina et al., 2001), compared to “classical” 
FAs (2-6 µm) of α-SMA negative fibroblasts (Geiger et al., 2001). What also marks out these 
supermature FAs in myofibroblasts is that they co-express high levels of vinculin, paxillin, 
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tensin, αvβ3 and α5β1 integrins, unlike classical FAs of fibroblasts which do not express 
tensin and α5β1 integrin (Dugina et al., 2001; Hinz et al., 2003). Separately, fibrillar 
adhesions express tensin and and α5β1 integrin, but not vinculin, paxillin and αvβ3 integrin 
(Geiger et al., 2001).  
Establishing these supermature FAs depends on the intracellular contractility generated by 
α-SMA and on stress resistance provided by the ECM (Hinz, 2006). When myofibroblasts are 
cultured on soft substrates and in newly polymerised collagen gels, they convert 
supermature FAs into smaller classical FAs (Goffin et al., 2006; Hinz, 2006). Specifically, it 
has been shown that myofibroblasts cultured on less than 6µm adhesion islets rapidly lose 
α-SMA, whereas dynamically enlarging these islets to 8.1µm islets on extendable 
membranes was shown to result in reincorporation of α-SMA in to stress fibres (Goffin et al., 
2006). In this key study, arrays of fibronectin islets were created on glass by microcontact 
printing whereas non-printed regions were chemically modified against cell attachment. 
Furthermore, resizing classical to supermature FAs was shown to allow application of 
approximately 4 fold greater stress (Goffin et al., 2006), making myofibroblasts very 
adhesive to the ECM (Hinz et al., 2003). These findings suggest that α-SMA is a 
mechanosensitive protein that is recruited to stress fibres under high tension and that 
myofibroblasts sense the mechanical environment of the ECM by assessing tension in stress 
fibres, which in turn is determined by the size of their matrix adhesions. However, it remains 
uncertain whether the primary event is α-SMA stress fibre generated tension or FA 
supermaturation. Regardless, effective myofibroblast contraction only occurs when the ECM 
has been sufficiently remodelled.  
Chapter 1  Introduction 
 
56 
 
1.17  The mechanical environment and myofibroblasts 
The myofibroblast phenotype is critically influenced by the mechanical microenvironment. 
In particular the organisation and stiffness of the ECM plays a key role in differentitation of 
fibroblasts into myofibroblasts (reviewed in Hinz, 2007). Resident or quiescent fibroblasts in 
intact tissues are considered to be “stress-shielded” by the ECM and lack the contractile 
stress fibres observed in myofibroblasts but instead have actin microfilaments organised 
predominantly in to a cortical meshwork (reviewed in Tomasek et al., 2002). When the 
protective mechanical microenvironment of the ECM is altered or lost through injury, 
fibroblasts try and re-establish matrix tension by increased ECM remodelling (Marenzana et 
al., 2006) and In mechanically restrained gels tension gradually increases and first induces 
the formation of α-SMA negative stress fibres (Marenzana et al., 2006; Tamariz and Grinnell, 
2002). Quiescent fibroblasts respond to changes in ECM organisation, composition and 
mechanical properties following tissue damage (Hinz and Gabbiani, 2003) and acquire a 
migratory phenotype by developing de novo contractile bundles or stress fibres that are 
composed of cytoplasmic actins and capable of generating small tractional forces (Hinz et 
al., 2001b). These activated fibroblasts have been given the term “proto-myofibroblasts”, 
distinguishing them from quiescent fibroblasts that lack these stress fibres (Tomasek et al., 
2002).  Increasing matrix stiffness due to remodelling by proto-myofibroblasts, leads to 
myofibroblast differentiation and de novo expression of α-SMA which organises transitorily 
in the cytoplasm, and only once a significant intracellular threshold tension has been 
reached is α-SMA incorporated to stress fibres (Goffin et al., 2006; Hinz, 2006). In vivo the 
appearance of proto-myofibroblasts has been shown in 5 to 6 day old granulation tissue and 
after 8-9 days in wounds in a rat model (Hinz et al., 2001b).  
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Whilst myofibroblast differentiation is precisely regulated by TGF-B1 (Desmouliere et al., 
1993) and FN ED-A (Serini and Gabbiani, 1999), the mechanical environment is also crucial 
as α-SMA is a mechanosensitive protein that is recruited to stress fibres only under 
significant mechanical load (Goffin et al., 2006). Increasing the matrix rigidity using collagen 
or polyacryamide gel substrates of varying stiffness led to increased α-SMA expression in 
cultured fibroblasts (Arora et al., 1999; Hinz et al., 2003), whereas reducing stress fibre 
tension by reducing substrate stiffness has been shown to lead to disassembly of α-SMA 
from stress fibres and accumulates in cytosolic aggregates that resemble short rods (Goffin 
et al., 2006). Similarly in vivo, preventing wound closure by mechanically splinting the edges 
of experimental wounds accelerates expression of α-SMA compared with normally healing 
wounds and stress release by removing these mechanical splints leads to a reduction in α-
SMA expression (Hinz et al., 2001b). 
Threshold stiffness for incorporation of α-SMA in stress fibres has also been examined in 
contractile wound granulation tissue and in myofibroblasts cultured on elastic substrates 
and shown to be around 20,000Pa (Goffin et al., 2006). For comparison matrix stiffness 
measured in granulation tissue towards the end of wound healing and has been shown to 
be greater than 50,000Pa (Goffin et al., 2006), whereas the stiffness of provisional ECM 
wounds has been shown to be comparable to newly polymerised gels and approximately 10-
100Pa (Kaufman et al., 2005).   
In Dupuytren’s disease, it has been observed clinically that after simple division of 
Dupuytren’s tissue (fasciotomy), cords which are no longer under tension, soften and 
temporarily disappear (Hueston, 1992). Reducing skin tension following fasciotomy by a 
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single Z-plasty has also shown a significant reduction in recurrence at 2 years (Citron and 
Hearnden, 2003). Using the CFM to measure isometric force generated by FPCLs, nodule-
derived cells reacted to initial mechanical overloading with increased force development, 
instead of the relaxation seen with control carpal ligament cells. The failure of nodule-
derived cells to reach ‘tensional homeostasis’ suggests that Dupuytren’s myofibroblasts 
favour a higher baseline level of matrix stress for tensional homeostasis, or that the 
phenomenon of tensional homeostasis may be absent in Dupuytren’s nodule-derived cells 
(Bisson et al., 2004).  It may be that Dupuytren’s nodule-derived cells are unable to 
appropriately detect the level of extracellular load and subsequently over-estimate actual 
stress which in turn results in over contraction. It was subsequently shown that the addition 
of TGF-β1, resulted in significant increase in force from all cell types seen particularly during 
the early phase of fibroblast attachment and with an overall increased rate of FPCL 
contraction in response to overloading (Bisson et al., 2009).  
The differences in isometric force contraction between Dupuytren’s myofibroblasts and 
control fibroblasts lend further support to the notion that myofibroblasts are influenced by 
their mechanical environment, although these observations have not been correlated with 
levels of α-SMA expression using this model. 
1.18  Apoptosis 
It has been shown that myofibroblasts are abundant in Dupuytren’s nodules, especially 
during active disease (Chiu and McFarlane, 1978) and the proliferative and involutional 
phase of disease (Schurch et al., 1990). In contrast, reduced numbers of fibroblasts and 
myofibroblasts have been reported in advanced disease (Chiu and McFarlane, 1978), 
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whereas residual phase nodules have been described as hypocellular with mature 
fibroblasts (fibrocytes) present (Schurch., et al. 1990). The fate of the numerous 
myofibroblasts remains unclear.  
In vitro, several studies have tried to reverse differentiated myofibroblasts in an attempt to 
develop therapeutic targets to inhibit their formation. Down-regulation of α-SMA has been 
shown in response to TGF-β1 antagonists, various growth factors, cell density and matrix 
compliance (Hinz, 2007).  
However, in vivo, reversal of the myofibroblast phenotype is not seen and instead during 
wound healing, massive apoptosis occurs following re-epithelialisation (Desmouliere et al., 
1995). Whilst the process that leads to apoptosis remains unclear, it has been proposed that 
at the end of physiological tissue repair, cell release from stress or increased formation of 
cell-cell contacts may account for this ‘group’ myofibroblast disappearance. Once fully 
repaired, the ECM regains its original mechanical properties and ‘stress -shields’ the resident 
fibroblasts. In a rat model, where the wound was splinted with a sutured metal template, 
thereby preventing tension release, myofibroblast apoptosis was inhibited and subsequent 
splint removal was followed by a reduction in myofibroblast numbers  (Carlson et al., 2003).  
Myofibroblast apoptosis has also been shown in vitro by relaxing stressed FPCLs seeded with 
human foreskin derived fibroblasts (Grinnell et al., 1999). These authors found that 
approximately 15% of cells apoptosed within 3 to 6 hours and reached a plateau by 24 
hours. Although the pathways linking stress and apoptosis remain unclear, it is likely to 
involve cell matrix junctions and similar stress perception mechanisms used in the transition 
from fibroblast to myofibroblast (Reddig and Juliano, 2005; Stupack and Cheresh, 2002). 
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1.19  Summary model of key steps in myofibroblast differentiation. 
Figure 1.11 below summarises key relations between matrix stiffness, adhesion maturation, 
α-SMA expression during differentiation of a fibroblast to proto-myofibroblast and finally in 
to a fully differentiated myofibroblast. 
 
 
Figure 1.11. Summary model of fibroblast to myofibroblast differentiation.  In most normal tissues 
and on compliant substrates, fibroblasts express immature if any cell-matrix contacts and have no 
stress fibres. These small complexes (immature FAs) are sufficient to initiate local cell remodelling 
activity that leads to gradual increase in matrix stiffness and tension development. The formation of 
the proto-myofibroblast phenotype is dependent on this increasing matrix tension and is 
characterised by the development of mature focal adhesions (FA) and contractile  stress fibres that 
are composed of only cytoplasmic actins. These stress fibres exert further contractile force and in 
turn further increase matrix tension, leading to the maturation of FAs. The co-ordinated action of 
tension, TGF-β1 and ED-A FN induce de novo expression of α-SMA which organises transitorily in 
cytoplasmic rod-like structures. As adhesions grow to the size of supermature FAs, intracellular 
tension reaches a critical level that allows incorporation of α-SMA in to the pre-existing stress fibres. 
This defines myofibroblast differentiation and results in further contractile force generation 
(adapted from Hinz B, European Jouran of Cell Biology, 2006). 
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1.20  Hypothesis 
This thesis sets out to test the hypothesis that in Dupuytren’s disease the myofibroblast 
phenotype is regulated by dermal fibroblasts and inflammatory mediators, specifically 
advanced glycation end products (AGEs) and TNF-α.  
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1.21  Aims and objectives of this study 
1. I aim to systematically characterise the distribution of α-SMA positive cells 
throughout excised Dupuytren’s tissue and examine if the presence of α-SMA rich nodules 
correlates with fixed flexion deformity and primary or recurrent disease.  
2. I aim to establish a reliable in vitro model of Dupuytren’s disease by comparing the 
isotonic and isometric contractile profiles of matched cells isolated from Dupuytren’s 
nodules, non-palmar and palmar skin samples within 3D collagen lattices. Using this model I 
will compare α-SMA expression in Dupuytren’s cells and dermal fibroblasts and based on 
the observation that recurrence is significantly reduced following dermofasciectomy, I will 
examine whether dermal fibroblasts can modulate Dupuytren’s myofibroblast contracti lity.  
3. Inflammatory mediators play a role in the pathogenesis of Dupuytren’s disease and 
there is recent data that AGE-RAGE interaction may induce the myofibroblast phenotype in 
various cell types. The effects of both TNF-α and AGEs have not been examined in 
Dupuytren’s disease. I aim to examine Dupuytren’s tissue for inflammatory cells and RAGE 
expression, and based on the observation that early signs of Dupuytren’s disease are often 
seen in the palmar skin, determine if AGEs or TNF-α can modulate the contractile phenotype 
of palmar skin fibroblasts. 
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2.1  Reagents 
2.1.1  General reagents 
General reagents were purchased from the following sources: 10×phosphate buffered saline 
(PBS), sodium carbonate, sodium chloride, sodium hydroxide, methanol, isopropanol and 
acetic acid from VWR International GmbH (Darmstadt, Germany); sulphuric acid from BDH 
(VWR International); Trizma base (minimum 99.9% titration), glycine, 
ehtylenediaminetetraacetic acid (EDTA), Tween-20, bovine serum albumin (BSA),  sodium n-
dodecyl sulphate (SDS) and 38% paraformaldehyde (BioChemika) from Sigma-Aldrich 
(Dorset, UK).  
2.1.2  Tissue culture reagents 
All reagents used were of tissue culture grade and sterile.  Reagents were purchased from 
the following sources: Dulbecco’s modified Eagle’s medium (DMEM) with high Glucose 4.5 
g/l, L-Glutamine and Sodium Pyruvate, Ham’s F-12 medium with L-glutamine, 1xRPMI-1640 
with L-Glutamine, 100 X penicillin and streptomyocin (1000 U/ml penicillin and 10 mg/ml 
streptomycin), amphoterecin (250 µg/ml) and 1xTrypsin-EDTA solution from PAA 
Laboratories Ltd. (Somerset, UK); 10xRPMI-1640 medium, sterile dimethyl sulphoxide 
(DMSO) from Sigma-Aldrich Ltd (Dorset, UK); Heat Inactivated Foetal Bovine Serum (FBS) 
from Gibco (Invitrogen, Paisley, UK); Type I collagen (rat tail acid extracted) from First Link 
(UK); Glass slides from Menzel-Glaser (Braunschweig, Germany); Glass coverslips from VWR 
International; all plastic-ware for tissue culture from Invitrogen (Paisley, UK), BD Biosciences 
(Oxford, UK) and Corning BV  (Amsterdam, The Netherlands), Trypan Blue Solution from 
Sigma-Aldrich (Dorset, UK).  
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2.1.3  SDS-PAGE reagents 
Reagents were purchased from the following sources: bromophenyl blue, glycerol, N, N, N’, 
N’ Tetramethylethylenediamine (TEMED) from Merck Biosciences (UK); 30% (w/v) 
acrylamide/bis-acrylamide from Severn Biotech Ltd.; ammonium persulfate (APS) from 
Acros Organics; dithiothreitol (DTT) from AXXORA, Nottingham, UK;  Prestained Precision 
Plus Protein standards from Bio-Rad Laboratories, Hemel Hempstead, UK. 
2.1.4  Western blotting reagents 
Reagents were purchased from the following sources: Dot blotting filter paper from Bio-Rad 
Laboratories, Hemel Hempstead, UK; nitrocellulose from GE Healthcare, Buckinghamshire, 
UK; polyvinylidene difluoride (PVDF) membrane, ECL substrate and Hyperfilm™ from 
Amersham Pharmacia Biotech, Little Chalfont, UK; Re-Blot Plus Strong Solution (10x) from 
Chemicon International (USA); dried skimmed milk from Tescos (UK). 
2.1.5  General indirect immunofluorescence staining reagents  
Reagents were purchased from the following sources: Alexa Fluor-488 phalloidin (A12379), 
Alexa Fluor-568 phalloidin (A12380) and Prolong Gold Antifade reagent from Invitrogen 
(Paisley, UK); DAPI staining for cell nuclei and 3.8% paraformaldehyde from Sigma-Aldrich 
(Dorset, UK); Triton X-100 from BDH (VWR International GmbH, Darmstadt, Germany).  
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2.1.6  FACS analysis reagents  
Reagents were purchased from the following sources: goat serum (Sigma UK), normal 
human AB heat inactivated serum (PAA laboratories Ltd., Somerset, UK) and normal rabbit 
IgG (Santa Cruz Biotechnology, Inc., USA).  
2.1.7  RT-PCR reagents 
Reagents were purchased from the following sources: puReTaq Ready-To-Go PCR beads 
from GE Healthcare (UK); dATP, dCTP, dTTP, dGTP, random primers and UltraPure™ agarose 
from Invitrogen, Paisley, UK; Stratascript buffer, RNAse block, Stratascript reverse 
transcriptase from Stratagene, UK; ethidium bromide from BDH, (VWR International GmbH, 
Darmstadt, Germany); Loading sample buffer, 500 bp and 1 kb DNA ladders from Bio-Rad, 
Hemel Hempstead, UK. For real-time PCR, TaqMan Universal PCR Master Mix was purchased 
from AppliedBiosystems (UK). 
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2.2  Antibodies 
Table 2.1.  Summary of antibodies used in this study 
Antigen Specificity 
Antibody 
type 
Use Dilutions 
Raised 
in 
Company, # no., 
(clone) 
α-SMA Human MAb IF 400 Mouse 
Sigma, A-2547 
(clone 1A4) 
α-SMA 
Hu, rabbit, 
mouse, 
chicken, goat 
MAb 
IHC 2000 
Mouse 
Sigma, A-5228 
(Clone 1A4) 
WB 600 
IF 400 
Desmin Human MAb IHC 200 Mouse 
DAKO, M0760 
(Clone D33) 
RAGE Hu, mouse PAb IHC 2000 Goat 
Abcam, ab7764 
 
RAGE 
Hu, mouse, 
rat, cow 
PAb 
IF 200 
Rabbit 
Abcam, ab37647 
 
WB 1000 
FACs 100 
Vimentin 
Hu, chicken, 
goat, mouse, 
rat 
MAb WB 1000 Mouse 
Abcam, ab8978 
(Clone RV202) 
CD3 Human MAb IHC 300 Mouse 
Vision Biosystems, 
NCL-CD3PS1    
(clone PS1) 
CD4 Human MAb IHC 50 Mouse 
Vision Biosystems, 
NCL-CD4IF6      
(Clone IF6) 
CD68 Human MAb IHC 250 Mouse 
DAKO, M0876      
(Clone PGMI) 
Mast cell tryptase Human MAb IHC 400 Mouse 
Vision Biosystems, 
NCL-MCT428 
(Clone 10D11)  
Neutrophil elastase Human MAb IHC 200 Mouse 
DAKO, M0752 
(Clone NP57) 
Alexa Fluor-488               
anti-rabbit 
Rabbit PAb 
IF 1000 
Goat Invitrogen, A11034 
FACs 1000 
Alexa Fluor-568               
anti-mouse 
Mouse PAb IF 1000 Goat Invitrogen, A11031 
HRP conjugated               
anti-rabbit 
Rabbit PAb WB 3000 Donkey 
GE Healthcare, 
NA9340V 
HRP conjugated               
anti-mouse 
Mouse PAb WB 3000 Sheep 
GE Healthcare, 
NA9310V 
AP, alkaline phosphatase; HRP, hydrogen peroxide; MAb, monoclonal antibody; PAb, polyclonal antibody; WB, 
Western blot; IF, immunofluorescence;  IHC, immunohistochemistry; FACS, fluorescence activated cell sorting  
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2.3  Surgical model and sample collection 
Dupuytren’s tissue samples were obtained from patients undergoing elective surgery for 
either fasciectomy of dermofasciectomy for Dupuytren’s disease between September 2006 
and 2008 with informed consent (COREC no. 06/Q0403/95). The samples were collected 
from patients operated on by either Professor Jagdeep Nanchahal at Charing Cross hospital 
or by Ms. Dominique Davidson at St John’s hospital in Livingston, Scotland. Both surgeons 
agreed and adopted a standardised method for the surgery. The procedure and implications 
of tissue donation were discussed with all patients and they were given an information 
sheet to read. Either myself or the clinicians mentioned above were present to answer any 
questions. Tissue samples were harvested and transported to London by overnight courier 
in sterile containers containing 20ml DMEM, 1x penicillin-streptomycin and 10% FBS. The 
samples were processed the following morning upon arrival. All samples were anonymised 
as per local ethics protocols and assigned a number, prefixed “SM” (Charing Cross hospital, 
London) or “ED” (St. Johns hospital, Edinburgh). Clinical details on disease progression were 
also collected for each patient using a standard Dupuytren’s proforma and are also kept 
anonymised (Fig. 3.1). 
For dermofasciectomy samples, three types of tissue were obtained from each patient: 
Dupuytren’s tissue, palmar skin (uninvolved skin overlying Dupuytren’s tissue) and non-
palmar skin (full-thickness skin harvested from the groin). All palmar skin and Dupuytren’s 
tissue samples were orientated with a distal marking suture. In Dupuytren’s tissue samples 
the corresponding level of the proximal interphalangeal joint was also marked with a suture.  
 
Chapter 2  Materials and Methods 
 
 69 
Note, the cells that I isolated were from surgical samples received from Charing Cross 
hospital or St John’s hospital in Edinburgh (prefixed “SM” or “ED” as outlined in the previous 
section). However, also available for use in this project were Dupuytren’s matched cells 
from Australia. These cells were isolated from patient samples obtained by Professor 
Nanchahal while he was based in Sydney (2006). These were anonymised and prefixed with 
the letter “D”. 
2.4  Cell isolation and tissue culture 
2.4.1  Preparation of surgical samples 
Dupuytren’s tissue samples were processed in the lab and washed in sterile DMEM and 
cleaned of surrounding fatty and loose connective tissue. Skin samples were also washed 
and defatted up to the level of the dermis. In total 103 excised digital cord samples were 
processed for use in this study. Out of these, the latter 53 samples were marked intra -
operatively with a distal marking suture and also a PIPJ marking suture. Cord tissue samples 
were either processed for histology and cell culture.  
2.4.2  Cell isolation from matched tissue samples 
Non-palmar and palmar dermal fibroblasts were isolated from whole skin samples. Matched 
Dupuytren’s tissue (nodule or cord), palmar and non-palmar skin samples were thoroughly 
dissected into small pieces with sterile scissors, scalpel and forceps. The resultant finely 
“diced” tissue was digested in 20ml DMEM containing 5% FBS, 2mg/ml of type I collagenase 
(Worthington), and 0.15 mg/ml of DNase I (Roche) per 0.5g tissue for up to 3 hours at 37°C. 
Supernatant from the digested tissue was pipetted into a sterile falcon tube. Cell pellets 
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were obtained from the resultant suspension by centrifugation and then re-suspended in 20 
ml DMEM with 10% FBS and plated in 175 cm2 culture flasks for 24 hours. Cells were 
reviewed daily, with media changes every 3 to 4 days until they reached confluence. At this 
point cells were either harvested for experiments or frozen down for later use. 
2.4.3   Cell culture 
Unless stated otherwise, all cells were cultured in DMEM supplemented with penicillin-
streptomycin (1x) and 10% FBS, in a 37˚C humidified incubator supplied with 5% CO2. The 
fibroblasts were passaged upon ~80% confluence by trypsinisation. Cells between passages 
1 and 5 were used for the experiments except where stated otherwise.  
For indirect immunofluorescence studies, RT-PCR and western blotting, fibroblasts were 
plated in 24 well plates at a density of 4x105/ml (unless stated otherwise), on sterilised 13 
mm diameter glass coverslips and cultured in DMEM supplemented with 10% FBS and 
penicillin-streptomycin (1x) and incubated at 37˚C, 5% CO2.  In experiments carried out to 
assess the effects of TGF-β1, TNF-α or AGE-BSA on palmar skin fibroblasts over time, DMEM 
was supplemented with 2% FBS and penicillin-streptomycin (1x). In these experiments, cells 
were incubated for 2 hours before TGF-β1, TNF-α, AGE-BSA or BSA (buffer volume) was 
added directly to the media at the specified concentration and incubated for the required 
time period.  The dishes were then removed from incubation and examined under x10 
magnification on a light microscope (Olympus ULWCD 0.30, Japan) and changes in cell shape 
or confluence were noted before processing further.   
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2.4.4  Dupuytren’s nodule-derived cell line (sourced from Japan) 
Three myofibroblast cell lines sourced from Japan and derived from Dupuytren’s nodules 
were also available for use in this study. These cells were described in the literature as 
having been derived by sub-culturing Dupuytren’s nodule-derived cells over 2 years and to 
comprise a homogenous population of myofibroblasts (Tanaka et al., 2007; Yuba et al., 
2007). I therefore set up collaboration with Dr Tanaka (Kinki University School of Medicine, 
Osaka, Japan) and was supplied with these cell lines for use in this project. All three cell lines 
were cultured in MEM (with Earle’s Salts and L-Glutamine), penicillin-streptomycin (1x) and 
20% FCS, and incubated at 37˚C, 5% CO2. The culture media and conditions used were 
exactly as advised by the collaborators.   
2.4.5  Cell Counting 
Cells were counted using a haemocytometer (Improved Neubaur by Hawksley) prior to use 
in experiments. The number of cells counted in the sixteen-square area of the 
haemocytometer was multiplied by 1x104 to give the total number of cells per ml. This 
figure was then multiplied by the volume (ml) in the culture to give the total number of 
cells. 
2.4.6  Cell viability 
Cell viability was checked using Trypan Blue Solution exclusion studies. Trypan Blue Solution 
is a dye excluded from viable cells but taken up by those that are not. Uptake of Trypan Blue 
Solution in to cells is verified by studying cells under the microscope (Olympus ULWCD 0.30, 
Japan) . Cells were diluted 1:1 with Trypan Blue Solution and placed in a haemocytometer 
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for counting. The final count calculated was multiplied by 2 to allow for dilution in Trypan 
Blue Solution. 
2.4.7 Freezing and thawing cells 
Cells were frozen in FBS supplemented with 10% DMSO in 1ml cryovials. Approximately 1-3 
x106 cells per ml were frozen in cyrovials and placed in a NALGENETM Cryo 1°C Freezing 
Container (containing Iso-propylalcohol) at -70°C for 24 hours. After 24 hours cryovials were 
transferred to long term liquid nitrogen stores. To thaw, cells were warmed up rapidly in a 
37°C waterbath and washed in culture media to remove DMSO as soon as possible to 
prevent DMSO toxicity to cells as they warmed up. Cells were counted and viability checked 
using Trypan Blue Solution. 
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2.5  Immunohistochemistry  
Immunohistochemistry staining was used to analyse α-SMA, desmin, RAGE, CD3, CD4, CD68, 
mast cell tryptase and neutrophil elastase expression in the Dupuytren’s cord, palmar and 
non-palmar skin.  
Dupuytren’s tissue samples were longitudinally bisected, fixed in 10% neutral buffered 
formalin (Cellstor, Cellpath, Powys, UK), embedded in paraffin wax and 7 µm sections from 
the cut surface processed for immunohistochemistry. Palmar and non-palmar skin samples 
were cut in cross-section, and similarly fixed in 10% neutral buffered formalin, embedded in 
paraffin wax and 7 µm sections from the cut surface processed for immunohistochemistry.  
Sequential sections were stained with Haematoxylin and Eosin (H&E) and also with the 
panel of antibodies outlined in Table 2. Outlined in this table are also methods used for 
antibody detection and retrieval. Species appropriate serum was used at the same protein 
concentration as the antibody solutions for negative controls. Tissue blocks were processed 
by David Essex according to standard Charing Cross hospital departmental protocols. 
Specific methodology employed to analyse processed histological section and details of 
relevant controls used are outlined in detail in chapters three and five where 
immunohistochemistry results are presented.  
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2.6  Isotonic force contraction 
Cells were cultured within stabilised collagen lattices and FPCL contraction assessed using a 
stress-release model (Grinnell, 1994, 2003; Tomasek et al., 1992). Collagen gel was prepared 
by mixing 10 volumes of ice-cold Collagen Type I (Cellmatrix type I-A, Kyowa Chemical 
Products, Japan) supplemented with 1 volume 10xRPMI, and titrated with 1M NaOH to 
adjust the solution to a neutral pH.  Mixing was done rapidly on ice.  Following 
trypsinisation, 1 x 105 cells were seeded in 250μl of neutralised collagen (FirstLink). FPCLs 
were allowed to polymerise at 37°C for 30 minutes in 24-well tissue culture plates and then 
cultured with 1ml DMEM (with 10% FBS) at 37°C in 5% CO2 for 24 hours. Gels were cultured 
for 24 hours with 1ml DMEM supplemented with 10% FCS and penicillin-streptomycin (1x). 
At 24 hours, constructs were mechanically released from the plate using a sterile needle and 
lattice contraction was digitally recorded at regular time intervals over 48 hours. Gel 
contraction was quantified by measuring changes in lattice surface area using Openlab 
(Openlab Software, Massachusetts, USA). 
With co-culture experiments, FPCLs seeded with Dupuytren’s cells were allowed to 
polymerise and then overlaid with 1 x 105 dermal fibroblasts in 1ml of DMEM with 10% FBS, 
from either palmar skin or non-palmar skin. Constructs was then cultured at 37°C in 5% CO2 
for 24 hours. At 24 hours, the constructs were mechanically released from the plate using a 
sterile needle and lattice contraction was digitally recorded at regular time intervals over 48 
hours (Fig. 2.1). Gel contraction was quantified by measuring changes in lattice surface area. 
Standardised photographic images were recorded using a digital camera (SONY Cybershot 
DSC-T30, SONY, Japan). 
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Figure 2.1. The co-culture construct.  Cells are isolated from surgical samples by collagenase 
digestion. Myofibroblasts are seeded into a type I collagen gel.  This construct is overlaid with 
dermal fibroblasts either from palmar skin or non-glabrous skin and cultured for 24h. Gel contraction 
is assessed by measuring the surface areas 
 
The images were then quantified using OPENLAB software analysis through tracing the 
diameter of each magnified image and measuring the surface area in mm2. A standard 
internal diameter of 15 mm for each 24 well culture dish was used to calibrate each image, 
and the decreasing surface area of each gel was expressed as a percentage of total gel 
contraction over time. The formula used to calculate percentage gel contraction was:  
% contraction = 100 – ( gel surface area  x 100 ) 
      Well surface area 
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2.7  Isometric force contraction – culture force monitor (CFM) 
Measurement of the contractile forces generated by FPCLs was performed as previously 
described (Eastwood et al., 1996; Tomasek et al., 2002).  This project had access to a 4 
channel CFM through collaboration with Professor Mark Eastwood at The University of 
Westminster, London (Eastwood et al., 1996).  Separate 4 cell chambers (moulds) for CFM 
based cell culture were manufactured from ertacetal C copolymer (Engineering & Design 
plates UK Ltd). Circular disc shaped ertacetal C blocks were cut from a cylinder bar stock 
(disc size: 6.1 cm diameter, 1.2 mm thickness) and a central rectangular mould of dimension 
20 x 40 x 10mm was drilled out using a mill (Bridgeport Vertical Mills, UK). Ertacetal C is 
hydrophobic and hence inhibited cell attachment. Attachment bars to connect the CFM 
gages to the polymerised FPCL were made from hydrophillic microsporous Vyon (Porvair 
Ltd, Kings Lynn, Norfolk, U.K.). Stock sheets were 5 mm thick and were cut into strips of 5 x 
10 mm bars. These bars were sterilised by autoclaving at 120oC for 20 minutes. This also 
removed any volatile residues. The hydrophillic nature of the vyon and the hydrophobic 
nature of the cell channel encouraged cell and substrate attachment only to the vyon 
attachment bars. Attachment bars were connected to the CFM strain gages through two "A" 
frames of stainless steel suture wire (0.35mm diameter). The "A frame" was configured with 
a loop at one end to provide a hook to attach to the CFM strain gage. The stainless steel 
wires were easily inserted into the vyon attachment bars and these were sufficiently 
buoyant to support the mass of the wire "A" frames.  
Collagen gel was prepared by mixing ice-cold Type I Collagen with 1 volume 10xRPMI, which 
was then neutralised drop-wise with 1M NaOH to adjust the solution to a neutral pH.  
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Mixing was done rapidly on ice. In total, either 1.5x106 nodule-derived cells, palmar or non-
palmar fibroblasts were re-suspended in 0.5 ml DMEM with 10% FBS per gel. Cells were 
then seeded in 2 ml of neutralised collagen (final volume 2.5 ml, final concentration 1.8 
mg/ml) and poured between the A frames within each mould. Each mould was then placed 
in the incubator for 5 mins to allow for the FPCL to gel. The long axis of the FPCL was then 
detached using a sterile needle and 3 ml DMEM (with 10% FBS) was gently added on top of 
the FPCLs. Each CFM mould was covered with a plastic petri dish lid and they were then 
placed into the humidified CFM incubator at 37oC. The A frames were attached to the CFM 
strain gages and force measurements were begun after 15 minutes to allow the incubator 
temperature to normalise. The floating FPCLs and attachment bars provided an almost 
friction-free bearing surface and allowed the system to reliably measure force generated. 
Therefore once set up in the CFM, FPCLs were tethered between two flotation bars and held 
stationary at one end whilst the other end attached to a force transducer contracted against 
a "fixed" point. FPCL generated tensional forces were continuously measured and data 
logged every 15 seconds (Dynes: 1 x 10-5N) (Eastwood et al., 1994).  
FPCLs attached to the CFM were also stimulated for 24 hours with control BSA (150µg/ml) 
or AGE-BSA (150µg/ml) (gift from Professor Vlassara, Mount Sinai Hospital, USA); TNF-α 
(1ng/ml) or TGF-β1(10ng/ml) (both from Pepro Tech, UK ). The final concentration of these 
products was added to the media in which the FPCLs were floating. Separately, palmar skin 
fibrobalsts were also cultured in the presence of AGE-BSA (150µg/ml) for 5 days prior to 
trypsinisation and seeding in to FPCLs in the CFM.  
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2.8  Immunofluorescence 
2.8.1  Immunofluorescent staining of cells in monolayer 
For monolayer studies 10,000 nodule-derived cells, non-palmar fibroblasts or palmar 
fibroblasts were cultured on glass coverslips in DMEM and 10% FBS for 24 hours. After 24 
hours in culture, cells were washed once in 1xPBS and then fixed for 15 minutes with 3% 
paraformaldehyde in PBS and permeabilised with 0.2% Triton X-100 (Sigma) for 5 minutes. 
Cells were then washed three times, 5 minutes per wash in 1xPBS and then incubated with 
mouse monoclonal α-SMA or rabbit polyclonal RAGE primary antibodies diluted in 2% BSA-
PBS for 1 hour. Cells were washed a further three times, 10 minutes per wash in 1xPBS 
followed by incubation with appropriate secondary Alexa Fluor 568-conjugated anti-mouse 
or anti-rabbit antibodies. F-actin was probed with Phalloidin-Alexa Fluor 488 and DNA with 
DAPI diluted in 2% BSA-PBS for a further 1 hour, and followed by a final set of three washes, 
10 minutes per wash in 1xPBS. Coverlips were mounted onto glass slides with ProLong Gold 
Antifade Reagent. Slides were imaged under a fluorescent microscope at x40 or x60 
magnification (Nikon TE2000-E light/fluorescent microscope (Nikon Co., Japan)). All 
immunofluorescent staining was carried out at room temperature. Secondary antibodies 
alone were used as an immunolabelling control.  
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2.8.2  Immunofluorescent staining of FPCLs following contraction in the CFM 
Following 24 hour contraction in the CFM, FPCLs were fixed whilst under tension for 30 
minutes in 3% paraformaldehyde, washed three times in 1xPBS for 10 minutes per wash. 
FPCLs were then bisected and embedded in paraffin wax. Slides with 10 μm cut sections 
were then “ring-fenced” with a PAP pen (DAKO) to create a hydrophobic ring around the 
section and retain staining solutions. Next immunofluorescent staining was performed as 
described above for monolayer. Sections were embedded in ProLong Gold Antifade Reagent 
protected with a glass coverslip and images were acquired using oil immersion objectives. 
Images were processed using the Volocity® 3D Imaging Software (Invitrogen, Paisley, UK).  
Microscopes used were Nikon TE2000-E light/fluorescent microscope (Nikon Co., Japan) 
with a Hamamatsu camera (Hertfordshire, UK) and Ultraview Nipkow scanning disc Nikon 
TE2000-U confocal microscope (Nikon Co., Japan).   
2.9  Western blotting 
2.9.1  Sample preparation 
Nodule-derived cells, palmar and non-palmar fibroblasts were cultured in monolayer for 24 
hours. In total 1x105 cells were plated per well in a 24 well culture plate. Cell extracts were 
prepared with 150µl SDS sample buffer and boiled for 3 minutes at 95ºC. Equal volumes of 
cell lysates were separated on 7.5% or 10% SDS-PAGE gel.  
Protein was also extracted from fibroblasts within 3-D collagen matrices following 24 hours 
contraction. FPCLs were harvested, washed in sterile 1xPBS and sheared using a sterile 21 
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gauge needle. Proteins were then extracted with 500 µl SDS sample buffer, boiled for 3 
minutes at 95ºC and processed as outlined above for monolayer studies. 
2.9.2  Tris-glycine sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(sds-page) 
For gel recipes, please see section 18.53 of Molecular Cloning (Sambrook et al., 1989).  
Proteins were separated by 7.5% or 10% Tris-glycine SDS-PAGE dependent on the size of the 
protein band being investigated.  Samples were added to 2xSDS loading sample buffer with 
0.2 M dithiothreitol (DTT) in a 1:1 ratio with sample and boiled for 5 min before loading.  5 
μl Prestained Precision Plus Protein standards were loaded alongside the samples to allow 
determination of protein band sizes.  Gels were run in protein gel tanks (Mighty Small II, 
Amersham) in 1x tris-glycine running buffer for approximately 1 hour at 150 mV.   
2x loading sample buffer 
1.7 % (w/v) SDS 
42.52 % (v/v) upper gel buffer 
8.5 % (v/v) bromophenol blue (0.1%)  
34.01 % (v/v) glycerol 
0.25 M EDTA 
 
10x Tris-glycine running buffer 
0.06 M Tris base 
0.48 M glycine 
1 % (w/v) SDS 
 
2.9.3  Transfer of proteins to PVDF membrane 
After electrophoresis, the separated proteins were transferred onto a polyvinylidene 
difluoride membrane (PVDF) (Amersham Biosciences, Bucks, UK) in transfer buffer using the 
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X cell II blot module (Invitrogen, Paisley, UK) at 25 V for 90 minutes. Membranes were 
blocked at room temperature for 1 hour in 10% milk for HRP.   
Blocking solution was removed and primary antibody solution applied directly.  The primary 
antibody was diluted in 10% milk for HRP, and incubated at room temperature for 1 hour.  
The membranes were washed for 3 x 15 minutes in wash buffer. Diluted secondary antibody 
was then applied to the membrane.  Appropriate horse radish peroxidase (HRP) conjugated 
secondary antibodies were diluted in 10% milk and incubated at room temperature for 1 
hour.   
The membranes were washed in wash buffer for 3 x 15 minutes and enhanced 
chemiluminescence (ECL) substrate (Amersham) was applied and bands detected by film.  A 
shaker was used to ensure optimal antibody coverage and membrane washing. Semi-
quantitative analysis of protein expression was performed using densitometry analysis 
software (Phoretics International). 
Transfer buffer 
0.72% (w/v) glycine 
0.15% (w/v) Trizma base 
20% (v/v) methanol  
Water up to 1 litre  
Wash buffer  
0.25 M Tris pH7.5 
1.5 M NaCl 
1% Tween-20 
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2.10  Reverse transcription polymerase chain reaction  
2.10.1  mRNA isolation  
The QIAmp RNA blood mini kit (QIAGEN, Crawley, UK) was used – see kit manual for full 
details.  Cells were cultured in monolayer as described earlier in the chapter.  Conditioned 
medium was aspirated off and cells were lysed with lysis buffer RLT containing β -
mercaptoethanol (QIAGEN, Crawley, UK).  The lysate was either frozen at -80°C for 
processing later or it was processed using the QIAmp RNA blood mini kit to isolate mRNA 
according to the manufacturer’s instructions (QIAGEN, Crawley, UK). The RNA was then 
stored immediately at -80°C or underwent a reverse transcriptase reaction.  The quality of 
the isolated RNA was determined by measuring the OD of a 3:7 dilution of the RNA at 230, 
260, 280 and 320 nm.  By determining the 260/280 ratio > 1.8, this ensures low protein 
contamination and 260/280 >2 indicates pure RNA isolation.  230 nm and 320 nm readings 
measure small peptide contamination and hence should be low.   
Following 24 hours contraction in the CFM, mRNA was also isolated from FPCLs. Cells within 
3D Collagen lattices were lysed using a 1:1 volume ratio of RLT buffer to collagen gel. The 
lysate was then processed as per the remaining steps as outlined above for monolayer 
cultures. 
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2.10.2  RT-PCR 
The reverse transcriptase reaction was performed as described in Table 3. The dNTP mix 
was made by mixing dATP, dCTP, dTTP and dGTP to a total concentration of 100 mM.   
        Table 2.2.   Steps involved in RT-PCR 
Step Reagent Volume (μl) 
Incubate at 65°C for 5 
min then cool at RT for 
10 min 
0.5 μg RNA X 
300 ng random primers  3 
Autoclaved H2O 50-(X+3) 
 
Heat in 42°C for 1 h 
then heat in 100°C 
heatblock for 5 min. 
Stratascript buffer (10x) 5 
RNAse block (40U/μl) 1 
dNTP mix 2 
Stratascript reverse transcriptase 
(50U/μl) 
1 
Aliquot and store at -20°C 
 
The RNA was then used in PCR reactions with primers specific for the GAPDH house-keeping 
gene and primers designed specifically against α-SMA (Table 4).  For PCR, puReTaq Ready-
To-Go PCR beads (Amersham Pharmacia Biotech, Little Chalfont, UK) were used.  Beads 
were reconstituted in 21 μl water, 1 μl of the forward primer, 1 μl of the reverse primer and 
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2 μl of cDNA template or water (negative control) or  cDNA from isolated from Dupuytren’s 
cord explants (positive control).  5 μl aliquots of each PCR product was then loaded in 
loading sample buffer and resolved on 1% agarose gels containing ethidium bromide.  500 
bp and 1 kb DNA ladders were included on each gel.   
Primers were designed specific for the GAPDH housekeeping gene and human α-SMA gene.  
For each primer set, the optimum annealing temperature was determined by a temperature 
gradient reaction for 40 cycles.  The optimum cycle number was determined by a cycle 
curve to ensure the reaction occurs within the linear range of the PCR:  the GAPDH primer 
required 26 cycles and the α-SMA primer required 30 cycles for optimal amplification within 
the linear range.   
Table 2.3.   Primer sequences 
Primer Sequence PCR product size (bp) 
GAPDH forward primer catggagaaggctggggctc 672 
GAPDH reverse primer atgaggtccaccaccctgtt 
α-SMA forward primer ttctacaatgagcttcgtgttgcc 478 
α-SMA reverse primer ggtgatcacttgcccatcag 
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2.10.3  Real time PCR 
Levels of α-SMA and RAGE mRNA were also analysed by quantitative real-time PCR.  These 
experiments were performed using a Corbett Rotor-gene 6000 machine (Corbett Research 
Ltd, Cambridgeshire, UK) and analysed using Corbett Rotogene 6000 software.  TaqMan® 
PreAmp Master Mix (Applied Biosystems) and ABI TaqMan probes specific for α-SMA 
(Hs00426835-g1) (Applied Biosystems) were used as per the manufacturer’s instructions.  
Reactions were carried out in triplicate, each in 10 µl volumes.  Thermocycling conditions 
were as follows: 10 minutes at 95°C; then 10 seconds at 95°C and 35 seconds at 60°C for 45 
cycles. The Ct values of both the gene of interest and the house-keeping gene were 
converted into concentrations according to their respective standard curve.  α-SMA 
expression levels were normalised to levels of ribosomal protein control RPLPO (Taq man 
probe set 4310879E) and to the level of gene expression in unrelated non-palmar skin 
fibroblasts which were assigned the value of 1 (ΔΔCT method).  
2.11  Fluorescence activated cell sorting (FACS) 
In total 1x105 cells from each matched nodule-derived cells, non-palmar and palmar 
fibroblasts were used to examine RAGE expression on the cell surface. Cells were blocked 
with 2% normal human serum in 100µl FACS buffer (1% FBS in PBS) for 10 minutes at room 
temperature before incubated with either FACS buffer alone, control 1% rabbit IgG or 1 
μg/ml RAGE antibody for 1 hour at 4°C. Afterwards cells were washed once in FACS buffer 
before re-suspended in 100 μl FACS buffer containing 2% goat serum for 10 minutes at 4°C. 
After blocking with goat serum, cells were incubated with Alexa Fluor-488 anti-rabbit 
secondary antibody for 30 minutes at 4°C. Finally, cells were washed twice in FACS buffer to 
Chapter 2  Materials and Methods 
 
 86 
remove excessive antibody and re-suspended in 200µl FACS buffer before analysed on a BD 
FACSCanto Flow Cytometer (BD Biosciences, Oxford, UK).  Routinely 10,000 events were 
acquired. 
2.12  Cell tracing studies 
Monolayer experiments with 2,500 cells cultured on coverslips were performed with 
fluorescently labelled nodule-derived cells and stained with DAPI to determine proliferation 
rates of cells when in co-culture with either non-palmar or palmar fibroblasts. A stock 
solution 0.5 mM fluorescent probe (Vybrant CFDA SE Cell Tracer Kit, Invitrogen, UK) was 
prepared in dimethyl sulphoxide (DMSO). Nodule-derived cells were trypsinised, washed 
and re-suspended in 1xPBS containing probe and incubated for 15 minutes at 37°C. These 
cells were then washed in pre-warmed DMEM with 10% FBS and incubated for a further 30 
minutes prior to re-suspending. Experiments were performed to optimize labelling and dye 
concentration for 5 days in culture. Nodule-derived cells, non-palmar and palmar fibroblasts 
were then counted and in total 2.5x103 cells plated per glass coverslip either as individual 
cells types alone or co-cultures at different ratios for 5 days. After 5 days, cells were fixed, 
labelled with DAPI and examined under a fluorescence microscope. In each construct, the 
overall proportion of cells with positive fluorescent dye after 5 days was compared to the 
relative ratios of nodule-derived cells, palmar and non-palmar fibroblasts plated at the start 
of the experiment. 
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2.13  MTT assay  ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) 
To assess cell viability in co-cultures, nodule-derived cells, non-palmar and palmar 
fibroblasts were plated at 1x104/ml in a 96 well culture dish for 24 hours and for 5 days. 
Cells were either cultured alone or in co-cultures with nodule-derived cells and either 
palmar or non-palmar skin fibroblasts.  After the required period of incubation at 37°C, 5% 
CO2, conditioned medium was aspirated and 100 µl fresh serum-free medium containing 0.5 
mg/ml MTT (Sigma-Aldrich) was applied and cells incubated for 2 hours before addition of 
100 µl MTT stop solution and incubation overnight at 37°C.  Plates were then read at 574 
nm on a Labsystems plate reader (Multiskan BIOCHROMATIC, UK) 
MTT stop solution 
10% SDS 
0.01M HCl  
 
2.14  Statistical analysis  
Histological nodularity was compared with total flexion deformity in all samples, and within 
subgroups of primary and recurrent disease, geographical site and gender. These analyses 
were done using either a Mann-Whitney non-parametric test, or an unpaired t-test 
depending on Gaussian distribution (determined by the Kolmogorov-Smirnov test). Analysis 
of single variance was performed when comparing nodule surface area with fasciectomy or 
dermofasciectomy, further divided by primary or recurrent disease. The association 
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between total flexion deformity and total nodular or cord surface area were assessed using 
Spearman correlation.  
The rate of FPCL contraction (dynes/ hr) was calculated by measuring the average gradient 
of the curve between 6 -24 hours. Contraction gradients and different aspect-ratio FPCLs 
were compared using unpaired t-tests. Analysis of single variance was used for comparisons 
of matched set contraction profiles and percentage stress fibres, and also for comparisons 
of co-cultures.  
Finally, analysis of single variance was used for comparisons of RAGE expression levels 
between matched sets. A paired t-test was used to compare RAGE expression levels 
between palmar and non-palmar skin. Analysis of single variance was performed using a 
Dunnett multiple comparison test to compare contractility of control untreated FPCLs and 
FPCLS stimulated with TNF- or AGE-BSA, or both in combination or with TGF-β1. 
All statistical analyses were performed using software (Prism; GraphPad Software, San 
Diego, CA). Significance was achieved if p<0.05.
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CHAPTER THREE 
Characterisation of myofibroblast distribution in 
Dupuytren’s cords 
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3.1  INTRODUCTION 
Histologically, Dupuytren’s contracture has classically been described as comprising 
hypercellular nodules, which mature as the disease progresses to form almost acellular 
tendon-like cords (Luck, 1959).  Disease recurrence following fasciectomy has been 
correlated with increased tissue cellularity as shown by light microscopy (Balaguer et al., 
2009; Rombouts et al., 1989).  
The cell that primarily contributes to digital contraction is thought to be the myofibroblast.  
Dupuytren’s tissue has been analysed for the presence of myofibroblasts by electron 
microscopy (Chiu and McFarlane, 1978; Gabbiani and Majno, 1972; Iwasaki et al., 1984). 
Disease recurrence following fasciectomy has also been correlated myofibroblasts identified 
ultrastructurally in histological nodules (Gelberman et al., 1980; Rudolph and Vande Berg, 
1991). 
The most frequently employed marker that characterises myofibroblasts is α-smooth 
muscle actin (α-SMA) (reviewed in Hinz, 2007) and the distribution of α-SMA in Dupuytren’s 
tissue has also been examined by immunohistochemistry (Hindman et al., 2003; McCann et 
al., 1993).  However, clinical data of disease activity in terms of pre-operative digital 
contracture have not been correlated with α-SMA expression or myofibroblast distribution 
throughout Dupuytren’s tissue. It would also be interesting to compare any differences in 
the presence of myofibroblasts in samples following surgery for both primary and recurrent 
contracture. 
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The first aim of this part of the study was to systematically characterise the distribution of α-
SMA positive cells throughout excised Dupuytren’s tissue. The next objective was to 
determine whether there was a correlation between the presence of α-SMA positive 
myofibroblasts and the degree of pre-operative flexion contracture and finally, to determine 
any differences between the presence of myofibroblasts in samples from primary or 
recurrent disease.  
3.2  RESULTS 
3.2.1  Patients and samples 
In total, 103 digital cords were excised from 80 patients. The surgery was performed 
between 2006 and 2008. Patients were recruited to the study after providing written 
consent (SMREC06/Q0403/95). Specimens were collected from 2 sites: London and 
Edinburgh. Fasciectomy samples accounted for 70% (n=72) and dermofasciectomy 30% 
(n=31).  All samples were from active or advanced disease with digital contracture. No early 
disease palmar nodules without digital contracture were available for analysis in this study. 
The majority of samples were from Edinburgh (n=74) and the remainder from London 
(n=29). The mean age in both groups was 64 years (range, 33–88), with an overall ratio of 
men to women of 3:1. Digital cords were mainly from ulnar-sided disease (62– little finger, 
30– ring finger, 7– middle finger, 2– index finger, and 2 from the thumb).  
Overall, 53 patients were treated for both MCP and PIP joint contractures in the same digit, 
11 patients for isolated metacarpophalangeal (MCP) joint contracture and 29 for isolated 
proximal interphalangeal (PIP) joint contracture. Combined MCP, PIP and distal 
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interphalangeal (DIP) joint contractures in the same digit affected 5 patients and both PIP 
joint and DIP joint contractures in the same digit were seen in 5 patients.   
The indications for surgery included functional disability, PIPJ contracture >30 degrees and 
progression of contracture. The same surgical selection criteria and operative protocols 
were used by both surgeons. Of the 103 excised digital cords, the PIPJ was identified intra -
operatively and marked in the later 53 samples. Marking the cord at the level of the PIPJ 
was done intra-operatively prior to excision of the affected fascia whilst the digit was still 
flexed. The MCPJ was similarly identified and marked intra-operatively in only 2 cases and 
the DIPJ in only one sample. Clinical data for each patient were recorded concurrently using 
the clinical proforma shown overleaf (Fig. 3.1). The data collected using this proforma are 
presented for each site to compare differences between the two groups in terms of 
diathesis (as defined by (Hindocha et al., 2006)), previous surgery and pre-operative flexion 
contracture (Table 3.1). 
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DUPUYTREN’S CLINICAL PROFORMA 
 
Hospital no.       
Sample no.       
DOB        
 
Diathesis 
Gender     Male / Female 
Bilateral disease   Yes / No 
Early onset (<50 yrs)   Yes / No 
Garrods pads    Yes / No 
FHx (1st degree relatives):   Yes / No  details: 
   
 Relevant past surgical history 
Past Dupuytren’s surgery  Yes / No details: 
  Dates: 
 
Recurrence    Yes / No details: 
Extension    Yes / No details: 
       
Pre-operative range of movement (degrees) 
 
 
Thumb Index Middle Ring Little
MCPJ
PIPJ
DIPJ
Thumb Index Middle Ring Little
MCPJ
PIPJ
DIPJ
LEFT
RIGHT
 
        
Operation (date)  
Details: 
Scar tissue from previous operation: 
Other: 
 
Figure 3.1. Dupuytren’s clinical proforma used to prospectively collect patient data on 
diathesis, previous surgery and pre-operative flexion contracture. 
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Comparing Dupuytren’s samples from Edinburgh and London highlighted differences 
between patients from the 2 sites (Table 3.1). The majority of patients were from Edinburgh 
(n=74) and the remainder from London (n=29). In London, 90% of patients were male, the 
digits tended to be less flexed (mean flexion deformity: 63±26°) and the majority of patients 
presented with primary disease (76%). Most of the patients (26/29) were treated by 
fasciectomy and the remaining 3 by dermofasciectomy. In comparison, 70% of patients in 
Edinburgh were male and the overall mean flexion deformity amongst Edinburgh patients 
was significantly greater (mean flexion deformity: 93±40°) (p= 0.01). There were 
comparatively more female patients in the Edinburgh cohort and they presented with a 
significantly greater mean flexion deformity than men (female mean flexion deformity: 
111±38°; male mean flexion deformity: 84±39°) (p=0.02). This may reflect delayed 
presentation in female patients, rather than selection bias. Approximately one-third of 
samples from Edinburgh were obtained from patients with recurrence following previous 
surgery and half of these were following previous fasciotomy. Although previous 
fasciectomy accounted for most of the remaining recurrences, both sites had 1 recurrence 
following a firebreak dermofasciectomy.  There was no difference in digital distribution 
between Edinburgh and London and the diathesis was similar. Recurrence was seen in the 
ring and little fingers but not in the middle finger, index finger or thumb.  
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Table 3.1.  Differences in diathesis and pre-operative contractures are compared in 
samples from Edinburgh and London. Samples were grouped by either primary disease or 
recurrence (following previous surgical procedure as indicated). 
 
 Edinburgh London Combined 
Diathesis (% incidence)    
     Male 70 90 76 
     Family history (1st degree relative) 38 28 34 
     Early onset <50 yrs 46 41 44 
     Bilateral disease 75 83 78 
     Garrod’s pads 38 44 40 
Pre-operative flexion deformity (degrees)    
     Mean MCPJ 40 ± 19 39 ± 18 40 ± 18 
     Mean PIPJ  65 ± 27 55 ± 15 62 ± 24 
     Mean DIPJ 33 ± 16 18 ± 0 32 ± 16 
     Mean total flexion deformity 93 ± 41 63 ± 26 83 ± 39 
Fasciectomy (sample nos.) 46 26 72 
Primary 36 22 58 
Secondary, following previous: 10 4 14 
     Fasciotomy 7 0 7 
     Fasciectomy 3 4 7 
Dermofasciectomy 28 3 31 
Primary 13 0 13 
Secondary, following previous: 15 3 18 
     Fasciotomy 6 0 6 
     Fasciectomy 6 2 8 
     Dermofasciectomy – scar  2 0 2 
     Dermofasciectomy – firebreak  1 1 2 
 
Total no. samples 74 29 103 
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3.2.2  Immunohistochemistry 
Excised digital cord samples were longitudinally bisected, fixed in formalin, embedded in 
paraffin wax and 7µm sections from the cut surface processed for immunohistochemistry 
(Fig. 3.2). Sequential sections were stained with Haematoxylin and Eosin (H&E), mouse 
monoclonal anti α-SMA antibody (Sigma, A2547), mouse monoclonal anti-desmin (DAKO, 
M0760) antibody and mouse serum (Sigma, M5905). As both myofibroblasts and smooth 
muscle cells in blood vessels stain positive for α-SMA, desmin was used to help distinguish 
α-SMA positive vascular areas especially within the histological nodules. Mouse serum at 
the same protein concentration as the monoclonal antibody solutions was used as a 
negative control.   
In serial sections stained for α-SMA, desmin and mouse serum control the same area of 
tissue (highlighted by the black box in Figure 3.2B) has been magnified from each of the 
sections.   Figure 3.2C shows α-SMA staining of this area, figure 3.2D shows desmin staining 
of the same area and figure 3.2E depicts staining of this area when using the mouse serum 
control.   In areas where there were few or no α-SMA positive fibroblasts α-SMA staining in 
blood vessel walls was used as an internal positive control.  An example of an area with few 
α-SMA positive cells within the cord, but with a highly stained vascular area is depicted in 
the red box in Figure 3.2 and magnified in figure 3.2F.  
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Figure 3.2. Immunohistochemical analysis of Dupuytren’s tissue.  (A) Digital cords were 
longitudinally bisected as shown by the dotted line.   (B) Serial sections taken from the cut surface 
stained for H&E (left panel), α-SMA (right panel). (C) Magnified view of the box highlighted with a 
black arrow in panel B stained for α-SMA.  (D)  View of the same area depicted by the box 
highlighted with a black arrow in panel B but from a serial section stained for desmin.   (E) View of 
the same area depicted by the box highlighted with a black arrow in panel B but from a serial section 
stained as a negative control with mouse serum only. (F) Positive control of α-SMA staining in blood 
vessel wall in an area of cord with little α-SMA staining (magnified view of box in B corresponding to 
red arrow). Magnification: (B) x4 and (C-F) x40. 
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3.2.3  Histological nodularity 
Histologically a nodule is defined as a collection of cells in a whorled pattern (McGrouther, 
2005). Many areas of cellular activity in diseased Dupuytren’s tissue have been reported and 
these histological nodules have been reported to vary significantly in size from tiny foci of 
cells to larger well defined nodules (Chiu and McFarlane, 1978; Luck, 1959).   Some reports 
suggest that few nodules are large enough to be palpated clinically but that most are 
microscopic in size (Chiu and McFarlane, 1978), whilst other studies suggest that most 
histological nodules can be palpated (Luck, 1959).  
I systematically characterised the distribution of α- SMA positive cells throughout 
longitudinal sections of 103 excised Dupuytren’s cords. Patient samples were grouped by 
the presence or absence of “histological nodules” which were defined microscopically  as a 
focal ‘condensation of cells’ that could also be seen on the histological section as a 
macroscopically distinct area of α-SMA staining (Skalli et al., 1986).  
Using these criteria, I found that 66% of all samples had histological nodules. The size and 
number of nodules was extremely variable, with marked heterogeneity between samples. 
Nodular cords were divided into 3 categories (1, 2 or 3+ nodules) (Fig. 3.3). Of the nodular 
samples, 55% had 1 nodule, 33% had 2 discrete nodules and 12% had 3 or more nodules. In 
total, 90% of samples from London were nodular compared to 55% from Edinburgh. 
Nodular cords were seen in 70% of men and 52% of women.  
Chapter 3                                  Characterisation of myofibroblast distribution in Dupuytren’s cords  
99 
 
 
Figure 3.3. Quantification of nodules in excised digital cords.  Histological sections were taken from 
the cut surface of excised Dupuytren’s cord and stained for α-SMA. Digital cords were either nodular 
or non-nodular. A nodule was defined as a macroscopically distinct area of α -SMA staining. Nodular 
cords were further subdivided according to the number of nodules (1, 2, 3+).  
 
The total nodule surface area and total cord surface area were traced and calculated using a 
Windows based histomorphometry system (OsteoMetrics, Decatur, USA). A pilot study was 
carried out with myself and two other independent observers to ensure the methodology 
was reliable and reproducible. Histological sections, enlarged on a computer screen were 
traced by hand around the perimeter of each nodule and the surface area calculated in 
mm2. In total 10 different patient samples were examined and good correlation between 
observers was observed. Having established this, I then carried out the analysis on the 
remaining samples. 
The mean total nodular surface area was 23mm2 (range: 1.3-105mm2) and the mean total 
cord surface area was 143mm2 (range: 20-388mm2). There was no difference in nodule 
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(p=0.3) or cord (p=0.4) surface area between gender, (men mean nodule, 24 mm2; mean 
cord, 147 mm2), and (women mean nodule, 19 mm2; mean cord, 130 mm2). Between 
geographical sites there was also no significant difference in the total nodular surface area 
(p=0.9) and total cord surface area (p=0.6): Edinburgh (mean nodule:  25mm2; mean cord: 
146mm2), and London (mean nodule: 20mm2; mean cord: 137mm2). There was no 
significant difference (p=0.3) in mean cord surface area between nodular samples  (149mm2) 
and non-nodular samples (129mm2). 
Together these data show that cord is not acellular, approximately two-thirds of excised 
digital cords had α-SMA rich nodules, which in almost half of all cases existed as multiple 
nodules and were extremely variable in size. More men presented with nodular cords as 
compared to females and there was geographical variation with proportionally more 
nodular cords seen in London as compared to Scotland. However, there was no difference in 
the total nodule or cord surface areas between geographical areas and with gender. 
Furthermore, the total surface area of cord was not different in nodular or non-nodular 
samples. 
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3.2.4  Relationship between α-SMA rich nodules and the proximal interphalangeal 
joint 
Previously it has been reported that clinical nodules occur along lines of tension in the hand 
and in some cases have been observed in the vicinity of interphalangeal joints of the digits 
(Chiu and McFarlane, 1978; Luck, 1959). Therefore, excised digital cords were examined to 
quantify whether histological nodules also co-localise with the interphalangeal joints.  
Of the 103 excised digital cords, only in the latter 53 samples was the PIPJ identified intra-
operatively and its position marked relative to cord prior to excision of the cord and with 
the digit flexed. 38 of these 53 samples were nodular and in 36 (95%) of these, a nodule was 
found in the vicinity of the the PIPJ.  Two samples were also marked intra-operatively for the 
MCPJ and both showed a nodule in relation to the MCPJ. Six of the 10 patient samples with 
DIPJ contractures were nodular, of which 3 had multiple nodules. However, only one cord 
sample was marked intra-operatively for the DIPJ that showed a nodule near the joint. An 
example of PIPJ co-localisation is shown in Figure 3.4  
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Figure 3.4.  Relationship between α-SMA rich nodules and the PIPJ.   (A) Dupuytren’s fasciectomy with PIPJ and the distal end of digital cord marked 
intra-operatively with ink. Marking of the cord at the level of the PIPJ was done with the digit flexed prior to excision of the affected fascia. The dotted line 
outlines the excised digital cord.  (B) Histological section stained for α-SMA with ink marked at the level of the PIPJ (green ink marking).  (C) Magnified views 
of the α-SMA positive cells seen in the box highlighted in panel B.  
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3.2.5  Analysis of α-SMA distribution throughout Dupuytren’s tissue 
Immunohistochemical analysis of excised Dupuytren’s cord samples from 8 patients has 
shown hypercellular zones within nodules comprised up to 40% α-SMA positive cells, 
compared to 20% in less cellular regions of the same specimen (Hindman et al., 2003). In 
addition, analysis of Dupuytren’s tissue by immunohistochemistry has reported that 12 out 
15 patient dermofasciectomy samples had α-SMA positive hypercellular Dupuytren’s tissue 
extended into the dermis. The pattern of staining varied from intensely stained foci to 
weakly stained and dispersed patches of these cells (McCann et al., 1993).  
To determine the distribution of α-SMA positive cells throughout Dupuytren’s tissue, a 
number of different areas were systematically analysed in excised digital cords. In nodular 
cord, three areas were analysed for α-SMA positive cell distribution: the nodule(s), peri-
nodule (adjacent to the nodule) and cord distal to nodule (fibrous tissue furthest from any 
nodule) (Fig 3.5A). In non-nodular cord, two areas were analysed: distal cord and proximal 
cord (Fig 3.5B). These areas were agreed upon in collaboration with Dr. Ann Sandison 
(consultant histopathologist) and a pilot study was conducted with myself and two other 
independent observers. In total 10 different patient samples were examined to establish a 
good correlation between observers and that the methodology was reliable and 
reproducible. Once this was established, I then analysed the remaining histolog ical sections. 
In each sample individual cells were counted in 6 fields of view within each defined region of 
interest at 20 times magnification. For each region of interest, the total number of cells and 
the number of α-SMA positive cells were counted. From this, the percentage of the cells 
stained positive for α-SMA was calculated. Vascular areas were excluded from the α-SMA 
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positive cell count, as smooth muscle cells in vessel walls also stain positive for α-SMA. 
Therefore, in nodules with dense α-SMA staining, corresponding H&E sections were used to 
count the total number of cells and desmin was used to help delineate vasculature seen on 
sequential sections stained with H&E and for α-SMA (Christen et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Systematic regional analysis of histological sections of nodular and non -nodular 
cord.   (A) Areas analysed for nodular cord were: the nodule(s), peri-nodule (adjacent to the 
nodule) and cord-distal to nodule (fibrous tissue furthest from any nodule).   (B) In non-
nodular cord, two areas were analysed: distal cord and proximal cord.   
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Table 2 shows examples of the total number of cells and the number of α-SMA positive cells 
counted in systematically selected regions of interest in 5 nodular and 5 non-nodular cords. 
Counts are also expressed as the percentage α-SMA positive cells (myofibroblasts).  
These data show at a cellular level Dupuytren’s tissue is also very heterogenous (Fig. 3.6A-
G). In nodular cords, the nodules (Fig. 3.6A) were consistently hyper-cellular (mean: 2374 
±1021 cells/mm2), with cells densely packed together in ’whorls’ and a mean of 97% cells 
staining positive for α-SMA. In the peri-nodular area (Fig. 3.6B), there were relatively fewer 
cells (mean: 763 ±313 cells/mm2) and, on average, 32% of these were positive for α-SMA. 
Cord distal from any nodule (Fig. 3.6C) was least cellular (mean: 495 ±246 mm2), with a 
mean of 8% α-SMA positive cells. Cells in cord distal from a nodule were aligned with the 
collagen fibres. Non-nodular cord was relatively cellular throughout (mean distal cord: 663 
±392 cells/mm2 and mean proximal cord: 475 ±221 cells/mm2) and more α-SMA positive 
cells (17%) were seen at the distal end (Fig. 6D) compared to 9% in proximal cord (Fig. 3.6E). 
Data from all samples including the mean total cell counts and mean percentage α-SMA 
positive cells (myofibroblasts) are shown for each region of analysis in nodular and non-
nodular cords (Fig. 3.6F, G).  
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Table 3.2.   Examples of cell counts in excised Dupuytren’s tissue. The total number of cells and the number of α-SMA positive cells were 
counted in systematically selected regions of interest in nodular and non-nodular cords. Five examples of non-nodular and nodular cords are 
shown below. For nodular cord, examples are shown for a single nodule, +1 nodule, +2 nodules, and +3nodules. Six random fields of view were 
counted within each region (at x20 magnification), and expressed as the average number of α-SMA positive cells (SMA), the average number of 
total cells (Total) and % α-SMA positive cells (% SMA). 
 
Lab no SMA Total % SMA SMA Total % SMA
ED025 40 884 5% 8 643 1%
ED040 12 500 2% 10 343 3%
ED042 40 488 8% 13 703 2%
ED042 10 400 3% 14 668 2%
ED057 363 1069 34% 0 502 0%
Lab no SMA Total % SMA SMA Total % SMA SMA Total % SMA SMA Total % SMA SMA Total % SMA SMA Total % SMA
ED018 1358 1388 98% 116 294 39% 35 142 25%
ED025 1434 1434 100% 146 918 16% 20 556 4%
ED026 1722 1722 100% 1394 1504 93% 64 728 9% 12 536 2%
ED046 3720 3720 100% 2104 2104 100% 1992 1992 100% 144 672 21% 8 356 2%
ED050 1696 1696 100% 4032 4032 100% 3400 3400 100% 3296 3296 100% 623 1287 48% 4 592 1%
Distal nodule Distal to nodule
NON-NODULAR
NODULAR
Total cell count per mm
2
 (%SMA)
Total cell count per mm
2
 (%SMA)
Nodule +1 Nodule +2 Nodule +3 Peri-nodule
Distal cord Proximal cord
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Figure 3.6.   α-SMA distribution in Dupuytren’s tissue.  Histological sections of Dupuytren’s tissue were 
stained with α-SMA. Representative panels (at x40 magnification) from systematically analysed regions of 
nodular cord:  (A) nodule,  (B) peri-nodule and  (C) cord-distal to nodule.  Representative panels from non-
nodular cord:  (D) distal cord,  (E) proximal cord.   (F) Total cell counts from analysed regions of nodular 
and non-nodular cord. (G) Corresponding percentages of α-SMA positive cells (G). Bars represent mean 
values. 
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3.2.6  Histological nodularity correlated with digital contracture 
Ultrastructural examination of Dupuytren’s tissue has also implied that myofibroblasts may 
be transient throughout the course of  Dupuytren’s tissue (Schurch et al., 1990), and an 
abundance of myofibroblasts has also been reported in active disease with decreased 
numbers of these cells in advanced disease (Chiu and McFarlane, 1978).  
Therefore, I examined the relationship between my histological findings with the degree of 
pre-operative digital flexion contracture. There was a significant correlation (p<0.0001) 
between non-nodular cords and digital contracture (mean flexion deformity: 114±39°) 
compared to nodular cords (mean flexion deformity: 70±31°) (Fig. 3.7A). As post-operative 
cutaneous scarring may contribute to flexion deformity in recurrent disease, it was 
important to establish that this significant difference was maintained with samples from 
primary disease alone (p=0.01) (Fig. 3.7B).  
Pre-operatively, women had a significantly greater (p=0.002) mean total flexion contracture 
than men (women: 107±39°, men: 75±36°). A greater flexion contracture was seen in both 
male (p<0.01) and female (p<0.05) non-nodular cords when compared to nodular cords. In 
men, the mean flexion contracture was 102±39° in non-nodular, and 67±32° in nodular 
samples. In women, the mean non-nodular flexion contracture was 132±34° in non-nodular, 
and 81±25° in nodular samples (Fig. 3.7C). 
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Figure 3.7.  Dupuytren’s tissue nodularity correlated with flexion contracture.  (A) Flexion 
deformity for all nodular and non-nodular samples.  (B) Flexion deformity for nodular and non-
nodular samples from primary disease alone.  (C) Flexion deformity for both men and women in all 
nodular and non-nodular samples. Bars represent mean values. 
 
Nodular cords showed no difference (p=0.11) in degree of contracture between 
geographical sites (Edinburgh: 76±33°, London: 62±26°), whereas non-nodular cords were 
almost exclusively from Edinburgh (n= 33/36).  
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Analysis was also carried out to examine if there was any further correlation between 
nodule size and digital flexion contracture. However, there was no correlation between 
digital contracture and either total nodule surface area (p=0.2) or total cord surface area 
(p=0.3) (Fig. 3.8). 
 
   p=0.2                p=0.3 
 
 
Figure 3.8. Nodule and cord surface area compared with flexion deformity. (A) Flexion deformity 
and total nodular surface area.  (B) Flexion deformity and total cord surface area. 
 
 
Together these data show that non-nodular cord samples were associated with significantly 
greater digital flexion contracture than nodular samples. This difference was maintained 
with gender and following surgery for either primary or recurrent disease. However, with 
nodular samples alone, no further correlation was found between the total nodule size and 
degree of flexion contracture.  
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3.2.7  Histological nodularity correlated with primary or recurrent disease 
Previous studies have shown that highly cellular Dupuytren’s tissue seen histologically in 
primary disease samples correlates significantly with disease recurrence when compared to 
less cellular tissue samples (Balaguer et al., 2009; Rombouts et al., 1989). Therefore, I set 
out to examine if myofibroblast-rich histological nodules were seen more commonly in 
primary or recurrent disease samples and whether nodularity was associated with the type 
of previous surgical procedure.  
Nodules were seen as frequently in fasciectomy samples (67%) as they were in 
dermofasciectomy samples (66%). When further subdivided into primary or recurrent 
disease, approximately two thirds in both groups were still classified as nodular (Table 3.3). 
Two dermofasciectomy samples were excluded as the surgery was performed for cutaneous 
scar contracture and not true recurrence.  Importantly, there was no significant difference 
(p=0.09) in flexion deformity between samples from primary (mean: 76±41°) and recurrent 
disease (mean: 88±37°). 
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Table 3.3.  Nodular and non-nodular cords grouped by primary procedure or secondary 
procedure (for recurrent disease). Mean nodule surface areas (SA) for primary and 
recurrent disease are also included 
 Total (n) Non-
nodular 
Nodular Nodular SA 
(mm2) 
Fasciectomy 72 33% 67%  
Primary 58 19 (33%) 39 (67%) 23±21 
Secondary, following previous: 14 5 (36%) 9 (64%) 17±16 
     Fasciotomy 7 2 5  
     Fasciectomy 7 3 4  
     
Dermofasciectomy 31 34% 66%  
Primary 13 5 (38%) 8 (62%) 33±29 
Secondary, following previous: 18 5 (31%) 11 (69%) 22±30 
     Fasciotomy 6 3 3  
     Fasciectomy 8 2 6  
     Dermofasciectomy – scar tissue* 2 2   
     Dermofasciectomy – firebreak  2  2  
 
Total no. samples 103 34% 66% 24±23 
*excluded from non-nodular count 
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The overall mean total nodular surface area (sum of the surface area of all the nodules in a 
single specimen) was not significantly different (p=0.5) between primary (mean: 24±23mm2) 
and recurrent disease (mean: 20±24mm2). Total cord surface area was also not significantly 
different (p=0.5) between primary (mean: 144±71mm2) and recurrent disease (mean: 
140±98mm2).  
The total nodular surface area was not significantly different (p=0.54) in primary 
dermofasciectomy samples (mean: 33±29mm2) as compared to either primary fasciectomy 
(mean: 23±21mm2), secondary fasciectomy (mean: 17±16mm2) and dermofasciectomy 
following recurrent disease (mean: 22±30mm2) (Table 3.3).  
These data suggest that nodules were seen equally in Dupuytren’s samples following 
primary or recurrent surgery. Furthermore, nodular recurrence was seen following 
fasciotomy, fasciectomy, firebreak dermofasciectomy but not following radical 
dermofasciectomy. 
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3.3  DISCUSSION 
The characterisation and systematic analysis of Dupuytren’s tissue showed that two thirds 
of the 103 excised digital cords had histological nodules defined as a focal condensation of 
cells that was rich in α-SMA. These nodules varied in size and were found throughout 
Dupuytren’s tissue. Nodules were also often seen within the vicinity of the PIPJ. I found cord 
tissue was cellular and also had variable numbers of myofibroblasts dispersed in amongst 
collagen bundles. Interestingly, non-nodular cords correlated significantly with greater 
digital contracture and this difference was maintained with primary disease samples alone. 
Non-nodular cords were mainly seen in Edinburgh, where patients presented with more 
advanced digital contractures. I observed no difference between nodularity in either 
primary or recurrent disease.  
Clinical nodules have been reported to exist as solitary or multiple nodules and occur at 
various sites in the hand including the palm (Chiu and McFarlane, 1978; Luck, 1959). 
However, even in the absence of clinical nodules, small clusters of cells containing 
myofibroblasts have been reported in advanced tendon-like cords (Chiu and McFarlane, 
1978).  In agreement with Chiu (Chiu and McFarlane, 1978), I observed numerous 
hypercellular α-SMA-rich areas throughout Dupuytren’s tissue that did not coincide with 
palpable clinical nodules. 
I defined histological nodules based on their appearance under a light microscope as α-SMA 
rich focal condensations of cells.  Overall, I found a single histological nodule (55%), 2 
nodules (33%) and often multiple nodules (12%) within mature cords. Two thirds of cords 
had nodules that often existed as tiny foci of cells or as larger single or even multiple 
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nodules. The total nodular surface area range varied from 1.3 – 105mm2. Nodular cords 
were also not significantly different in size compared to non-nodular cords. It is likely that 
multiple nodules may act in concert to contribute to digital contraction and, in response to 
increased tension, normal bands hypertrophy and thicken to form cords. The development 
of a longitudinal cord as a result of hypertrophy of several anatomical bands has been 
suggested previously (McFarlane, 1974).  
Next I quantifed α-SMA expression in Dupuytren’s tissue. Although α-SMA is the most 
frequently employed marker for myofibroblasts, bundles of contractile actin microfilaments 
alone cannot reliably distinguish between myofibroblasts and vascular smooth muscle cells 
(SMCs), especially in the nodule where mixed populations exist. The two cell populations 
can be distinguished at an ultrastructural level by the presence of fibronexi (Tomasek and 
Haaksma, 1991) specialised areas on the surface of myofibroblasts.  However, as my 
objective was to assess myofibroblast distribution throughout cord tissue, ultrastructural 
imaging would have limited analysis to very small areas of tissue. Desmin is an established 
marker for SMCs in blood vessel walls (Christen et al., 2001) although a proportion of 
desmin-positive myofibroblasts have also been shown to be present around capillaries and 
blood vessels in proliferating Dupuytren’s nodules (Schurch et al., 1990; Shum and 
McFarlane, 1988).  I used desmin staining to delineate vascular areas seen on sequential 
sections stained with H&E and for α-SMA, and therefore, stromal α-SMA positive 
myofibroblasts were more reliably indentified and counted.  
At a cellular level, I found that nodules were hypercellular (2374 cells/mm2), with a mean of 
97% α-SMA positive cells. These results are in line with previous ultrastructural studies that 
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have reported nodules comprise mainly of myofibroblasts (Chiu and McFarlane, 1978; 
Gabbiani and Majno, 1972; Iwasaki et al., 1984). The immunohistochemical analysis of 
myofibroblast distribution in Dupuytren’s tissue using α-SMA to identify myofibroblasts has 
also been carried out in a small study of 8 patient samples (Hindman et al., 2003). However, 
in this study the nodular areas with one or more blood vessels were excluded from analysis 
in this study and may account for why a lower percentage in α-SMA positive cells (40%) was 
seen in hypercellular areas such as nodules, which are often vascular.    
Non-nodular cord was also cellular throughout, with on average 9% (proximal) and 17% 
(distal) cells positive for α-SMA. I have also confirmed that α-SMA positive cells were 
distributed in amongst collagen fibres, aligned along a longitudinal axis in line with previous 
findings (Chiu and McFarlane, 1978). This heterogeneity is of some methodological 
importance, as comparisons between nodule and cord have been made in previous studies 
only on the basis of gross tissue morphology (Bisson et al., 2003; Bisson et al., 2004; Dave et 
al., 2001; Rayan and Tomasek, 1994; Townley et al., 2009).  
When comparing histological findings and the patients clinical status, we found that non-
nodular cords were associated with greater digital contractures, compared to nodular cords 
(p<0.0001). This significantly greater digital contracture in non-nodular cords was also 
evident when only considering primary disease samples and in both men and women. This 
implies that non-nodular cords may reflect the end stage process following extracellular 
matrix remodelling, whereas the presence of myofibroblast rich nodules may represent 
more active and less contracted digital cords. However, in nodular samples, no further 
correlation was found between nodule size and digital contracture and this may represent 
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different stages of disease in patients at time of surgery. Unfortunately, it is not possible to 
verify the progression of myofibroblast numbers and distribution in a given patient over 
time. 
I also found that 95% (36/38) of nodules were in the vicinity of the PIPJ and nodules were 
also observed over the MCPJ in the only two cases marked intra-operatively for the MCPJ 
and one case marked for the DIPJ. The presence of clinical nodules in line with digital rays 
and in close proximity to the PIPJ and MCPJ has been previously described (Chiu and 
McFarlane, 1978; Luck, 1959). One explanation for the relative proximity of the PIPJ and 
histological nodules is based on the understanding that myofibroblasts perceive and thrive 
on tension (Gabbiani, 2003; Goffin et al., 2006; Hinz, 2006, 2007; Tomasek et al., 2002). In 
early or active disease, tension may act intermittently on Dupuytren's tissue as active 
extension of the PIPJ offers resistance against the thickened, contracted palmar fascia. The 
increased tension sensed by cells may promote myofibroblast differentiation through 
recruitment of α-SMA to stress fibres and specialised attachment site formation under strict 
control of TGF-β1 (Desmouliere et al., 1993) and fibronectin-EDA (Serini et al., 1998). This in 
turn leads to greater force generation. A densely packed cellular nodule could then 
theoretically exert sufficient force to promote or sustain digital contracture . The cells then 
remodel the surrounding matrix to a more shortened configuration. This would be 
supported by the increased expression of matrix metalloproteinases in Dupuytren’s nodules 
and cord (Johnston et al., 2007; Johnston et al., 2008; Tarlton et al., 1998; Ulrich et al., 
2003). The resulting increased flexion deformity would impair function and the reduced 
movement at the joint would in turn lead to a reduction in tension sensed by nodular 
myofibroblasts. This can be considered as a form of ‘stress -shielding’, which in wound 
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healing has been shown by morphometry using electron microscopy and in situ end-
labelling of fragmented DNA to result in myofibroblast apoptosis after re-epithelialisation 
(Desmouliere et al., 1995). Furthermore, in a rat model where the wound was splinted with 
a sutured metal template, thereby preventing tension release, myofibroblast apoptosis as 
determined by TUNEL assay was inhibited and subsequent splint removal was followed by a 
reduction in myofibroblast numbers (Carlson et al., 2003). It is, therefore, conceivable that 
with advanced digital contractures, reduced tension through limited active joint extension 
may similarly lead to myofibroblast apoptosis, whereby myofibroblast rich nodules fail to 
persist. This may explain the progression from nodular to non-nodular cords and would also 
explain why patients with non-nodular cords tended to have more severe flexion 
deformities.  
Studies have previously shown that recurrence following fasciectomy is correlated with 
electron microscopy findings of myofibroblasts present in histologically nodules (Gelberman 
et al., 1980; Rudolph and Vande Berg, 1991). Recurrence following primary fasciectomy has 
also been correlated with increased tissue cellularity as shown by light microscopy (Balaguer 
et al., 2009; Rombouts et al., 1989). In this study I have shown that histological nodules 
were seen as frequently in samples from both primary and recurrent disease (two-thirds of 
cords in each case) and there was also no significant difference in digital contracture 
between primary and recurrent disease. Recurrence was seen following previous 
fasciectomy (n=15), fasciotomy (n=13) and in 2 cases, following firebreak dermofasciectomy 
for previous recurrence, both cords being nodular. There was also no difference in nodular 
surface area between primary dermofasciectomy samples, primary fasciectomy, secondary 
fasciectomy or dermofaciectomy following recurrent disease (p=0.5). These histological 
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findings suggest similar pathogenesis in both primary and recurrent disease and that 
nodularity is not down-regulated following previous surgery. Indeed, the increased motion 
following initial surgery may facilitate myofibroblast differentiation and persistence. It is 
possible that residual unexcised Dupuytren’s tissue following fasciotomy, fasciectomy and 
firebreak dermofasciectomy, may serve as a trigger for recurrence. This may also explain 
why radical dermofasciectomy has a lower rate of recurrence (1-5%) (Brotherston et al., 
1994; Hall et al., 1997; Tonkin et al., 1984) than ‘firebreak’ dermofasciectomy (12%) (Ullah 
et al., 2009) or fasciectomy (40-50%) (Foucher et al., 1992; Hueston, 1961; Tonkin et al., 
1984). It would be interesting to compare the myofibroblast distribution in the cords of any 
of our fasciectomy patients who develop recurrence in the future with the primary excision 
specimens. 
In conclusion, the quantification of total cell numbers and α-SMA positive cells throughout 
excised Dupuytren’s cord tissue confirms  that myofbroblasts are mainly distributed in 
hypercellular nodules and are less numerous, but also present in variable numbers outside 
nodules and within cellular cord tissue. Myofibroblast aggregation in nodules in the vicinity 
of joints may lead to digital contracture and with subsequent matrix remodelling result in 
shortening of the affected fascia. Eventually fixed flexion deformity develops leading to an 
altered mechanical environment with loss of tension, myofibroblast apoptosis and thus may 
explain residual non-nodular cords. 
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4.1  INTRODUCTION 
The pathogenesis of Dupuytren’s disease is poorly understood. Currently, the commonest 
treatment for patients with significant Dupuytren’s contracture is surgery, although 
recurrence rates following fasciectomy are approximately 40-50% (Foucher et al., 1992; 
Hueston, 1961; Tonkin et al., 1984). However, recurrence following dermofasciectomy has 
been reported to be as low as 1-8% (Brotherston et al., 1994; Hall et al., 1997; Tonkin et al., 
1984). The mechanism of reduced recurrence following dermofasciectomy also remains 
unexplained. To investigate further these features of this common disease requires a 
reliable disease model. The lack of an animal model for Dupuytren’s disease underlines the 
necessity for a good in vitro system. Methodological considerations that must be addressed 
include the Dupuytren’s myofibroblast source, choice of control cell types and assays to 
measure myofibroblast mediated collagen lattice contraction.  
Many investigators have studied myofibroblasts derived from rat cutaneous and lung 
fibroblasts treated with TGF-β1. It is widely accepted that myofibroblasts are characterised 
by the presence of highly contractile α-SMA (Hinz, 2007; Tomasek et al., 2002). Compared to 
untreated control rat fibroblasts, these groups observed recruitment of α-SMA to stress 
fibres by immunofluoresence staining and increased expression of α-SMA protein by 
western blot analysis in the TGF-β1  treated myofibroblasts (Dugina et al., 2001; Follonier et 
al., 2008; Goffin et al., 2006). Dupuytren’s cells  derived from clinical nodules have been 
shown in monolayer cultures to express high levels of α-SMA protein compared to 
Dupuytren’s cord cells and a human foreskin fibroblast cell line (Dave et al., 2001) and also, 
when compared to normal fibroblasts from mesenchymal tissues, epithelial cells and cardiac 
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and skeletal muscle cells (Benzonana et al., 1988). However, α-SMA expression in cells 
derived from genetically matched samples of Dupuytren’s tissue and normal palmar and 
non-palmar dermal fibroblasts have not been compared.   
A number of assays have been used to assess myofibroblast contractility. Attempts to 
correlate α-SMA expression and contraction using an isotonic collagen-gel contraction 
system have yielded inconsistent findings. Some authors reported no differences in 
contraction between Dupuytren’s nodule, cord and carpal ligament-derived cells (Rayan and 
Tomasek, 1994; Tarpila et al., 1996), whilst others suggested increased contraction only with 
early passage nodule-derived cells (Moyer et al., 2002) or in nodule-derived cells expressing 
higher levels of α-SMA (Tomasek and Rayan, 1995). Isometric contractile forces within 
constrained FPCLs have also been studied using a culture force monitor (CFM) (Eastwood et 
al., 1994; Eastwood et al., 1996). Using this model, dermal fibroblasts reached a plateau of 
contraction (Brown et al., 1998) whilst neither Dupuytren’s nodules or cord-derived cells 
reached a plateau and generated significantly greater isometric contractile force than 
control carpal ligament fibroblasts over a 20 hour test period (Bisson et al., 2004). However, 
comparisons of genetically matched Dupuytren’s nodule-derived cells and normal dermal 
fibroblasts in both isotonic and isometric model systems have not been done. Furthermore, 
correlation of α-SMA expression with isometric contractility has not been undertaken in any 
cell type.  
Therefore, this part of the study compares the isotonic and isometric contractile profiles of 
genetically matched cells isolated from Dupuytren’s tissue, non-palmar and palmar skin 
samples in three dimensional collagen lattices. α-SMA mRNA levels, α-SMA protein 
Chapter 4                                                   Establishing an in-vitro model to study Dupuytren’s disease  
123 
 
expression and α-SMA distribution are assessed in these lattices. Finally, based on the 
established surgical observation that recurrence rates are significantly reduced following 
dermofasciectomy, Dupuytren’s cells were co-cultured with dermal fibroblasts to investigate 
whether the contractility of Dupuytren’s cells is down regulated by non-palmar dermal 
fibroblasts.  
 
4.2  RESULTS 
My first aim was to identify a reliable source of myofibroblasts in order to study Dupuytren’s 
disease. I also wanted to use human cells that would provide information most relevant to 
human disease and avoid confounding effects of species differences. 
4.2.1  Human myofibroblast cell lines 
I investigated which human myofibroblasts cell lines were available. There are limited well 
characterised human myofibroblast cell lines available commercially and of these none are 
isolated from Dupuytren’s tissue. Myofibroblast cell lines that are available are derived from 
prostate tissue (WPMY-1 from ATCC) and fetal lung tissue (MRC-5 from Riken). However, 
three myofibroblast cell lines derived from Dupuytren’s nodules are described in the 
literature (Tanaka et al., 2007; Yuba et al., 2007). They are reported as having been derived 
by sub-culturing Dupuytren’s cord-derived cells over 2 years and to comprise a homogenous 
population of myofibroblasts. Ultrastructural analysis of these cell lines also reported that 
the myofibroblast characteristics are maintained and the karyotype analysis remained 
unchanged. These established cell lines also maintain the production of α-SMA mRNA and 
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protein and TGF-β1 . This study also showed that when xenografted into 5-week old null 
mice (BALB/c nu), these cell lines produced a palpable nodule, which developed at the site 
of inoculation (Yuba et al., 2007). I, therefore, set up collaboration with Dr Tanaka and was 
supplied with these cell lines for use in this project. 
To characterise these cells and confirm they were a homogenous population of 
myofibroblasts, cells were cultured on glass coverslips for 24 hours and then ana lysed by 
immunofluorescence for α-SMA rich stress fibres. Cells were stained with α-SMA followed 
by Alexa Fluor 568 secondary antibody.  F-actin was probed with Phalloidin-Alexa Fluor 488 
and DNA with DAPI. The number of cells with positive α-SMA stress fibres were counted and 
expressed as a percentage of total cells (Hinz et al., 2001a). F actin staining was apparent in 
all cells (Fig. 1A) and α-SMA was seen in the peri-nuclear cytosol but only localised to stress 
fibres in a proportion of cells (Fig. 4.1A-C).  Although the 3 cell lines did not consist of a 
homogenous population of myofibroblasts, a relatively high mean of 43% of cells had α-SMA 
positive stress fibres.  
However, when these 3 cell lines were cultured using the same culture media and 
conditions as recommended (Yuba et al), none of them reached confluence after 5 months, 
with sub-populations of cells dying within each culture flask. Mycoplasma infection was 
tested for by pcr and excluded from all 3 cell-lines. It was due to their slow growth that I 
concluded these cells could not be used for further experiments.  
Chapter 4                                                   Establishing an in-vitro model to study Dupuytren’s disease  
125 
 
Figure 4.1. α-SMA distibution in Dupuytren’s nodule-derived cell lines.  Cells were cultured on glass 
coverslips for 24 hours, fixed and then immunofluorescently labelled using α-SMA antibodies (red), 
phalloidin (green) and DAPI (blue).  (A) Representative images shown for triple stained Dupuytren’s 
nodule-derived cell lines.  (B,C) α-SMA (red) alone is shown to demonstrate cells with α-SMA positive 
stress fibres.  Scale bar: 20μm.  White arrows indicate cells with α-SMA positive stress fibres (merged 
staining of phalloidin (green) and α-SMA (red) in panel A, and α-SMA alone seen as red stress fibres 
in B and C)).  
 
I next investigated primary human myofibroblasts from Dupuytren’s patients for which I had 
access to abundant samples from Edinburgh and London. Dupuytren’s cord samples 
processed for histology as seen in the previous chapter showed an abundance of nodules 
with α-SMA rich cells. 
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4.2.2  Cells from Dupuytren’s patient samples 
Tissue samples used for experiments in this chapter were obtained from 10 patients 
undergoing dermofasciectomy for Dupuytren’s disease. The mean age of these patients was 
58 yrs (range: 38-72yrs) and the male-to-female ratio was 7:3.  Three types of tissue were 
obtained from each patient: Dupuytren’s cord, palmar skin (uninvolved skin overlying 
Dupuytren’s tissue) and non-palmar skin (full-thickness skin harvested from the groin).  Cells 
were isolated from tissue samples by collagenase digestion and maintained in culture with 
DMEM supplemented with 10% FBS and 1x penicillin-streptomycin at 37˚C in a humidified 
incubator with 5% CO2.  
4.2.3  Cells derived from whole Dupuytren’s cord 
In order to characterise the cells isolated from excised Dupuytren’s cord and to determine 
what proportion of these cells are myofibroblasts, α-SMA distribution in stress fibres was 
examined by immunofluoresence in cells (passage 1 and 2) derived from whole Dupuytren’s 
tissue (Hinz et al., 2001a). Non-palmar and palmar skin fibroblasts were used as genetically 
matched controls. Cells were stained with α-SMA followed by Alexa Fluor 568 secondary 
antibody and DNA with DAPI.   In non-palmar and palmar fibroblasts, α-SMA was 
consistently seen in the peri-nuclear cytosol (Fig. 4.2A,B), whereas in Dupuytren’s cord cells 
α-SMA was more frequently localised to stress fibres (Fig. 4.2C). The number of cells with α -
SMA positive stress fibres was counted and expressed as a percentage of total cells (Hinz et 
al., 2001a). Using this methodology, the mean percentage of α-SMA  positive cells in whole 
cord was 9% ±3, compared to 4% ±1.7 in non-palmar skin and 4% ± 1.7 in palmar skin 
(p=0.04) (Fig. 4.2D). 
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Figure 4.2. α-SMA distribution in cells from whole dupuytren’s tissue and dermal fibroblasts. Cells 
were cultured on glass coverslips for 24 hours, fixed and then immunofluorescently labelled using α -
SMA antibody (white) and DAPI (blue).  Representative images are shown for (A) non-palmar skin 
fibroblasts, (B) palmar skin fibroblasts and, (C) Whole Dupuytren’s cord cells.  α-SMA localisation to 
stress fibres is seen in the central cell of panel (C). Scale bar: 30μm.  (D) The numbers of cells with α-
SMA positive stress fibres in non-palmar fibroblasts, palmar fibroblasts and whole Dupuytren’s cord 
cells were counted on digital images and expressed as a percentage of total cells (original 
magnification x 60). 
 
These data show that although there are more myofibroblasts in whole Dupuytren’s tissue 
compared to control dermal fibroblasts, the overall percentage of myofibroblasts is still 
relatively low (Tomasek and Rayan, 1995). 
4.2.4  Nodule-derived versus non-nodular fibroblasts 
To ensure a reliable source of Dupuytren’s cells with proportionally more α-SMA positive 
stress fibres, methodology using primary Dupuytren’s tissue samples was developed. The 
previous chapter demonstrated that in longitudinal histology sections of cord a very high 
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percentage of samples had PIPJ nodules. Therefore, all PIPJ marked digital cords were 
routinely bisected. One half was subdivided and used to isolate cells specifically from the 
PIPJ area which I have shown to frequently contain α-SMA rich nodules, whilst the cut 
surface of the mirror half was processed by histology to confirm the presence of these α-
SMA rich nodules (Verjee et al., 2009) (Fig. 4.3). Cells isolated from the PIPJ were also 
examined by immunofluorescence and the percentage of α-SMA positive stress fibres was 
correlated with the presence of histological nodules. 
 
 
Figure 4.3. Methodology used to isolate Dupuytren’s cells from nodular versus non-nodular cord.  
(A) Digital cords were longitudinally bisected as shown by the dotted line.  (B) One half was fixed in 
formalin and histological sections taken from the cut surface were stained for α-SMA. Using the 
mirror half of the bisected cord, cells were also isolated specifically from the marked PIPJ region by 
collagenase digestion. (C) PIPJ cells were cultured on glass coverslips for 24 hours, fixed and then 
immunofluorescently labelled using α-SMA antibody (white) and DAPI (blue).  Representative images 
are shown for non-nodular and nodular samples and compared to histological  sections taken from 
the mirror half of the same excised cord sample. 
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In nodule-derived cells, α-SMA protein frequently localised to cytoskeletal stress fibres (Fig. 
4.4A-C), whereas in dermal fibroblasts α-SMA protein was typically seen in the peri-nuclear 
cytoplasm (Fig. 4.4D,E). The percentage of cells with positive α-SMA stress fibres were 
counted in 3 nodular matched patient samples. Nodule-derived cells had significantly more 
cells with α-SMA stress fibres than dermal fibroblasts (mean α-SMA stress fibres: nodule-
derived cells = 35% ± 13; dermal fibroblasts = 3% ± 0.5) (Fig. 4.4F). The percentage of cells 
with positive α-SMA stress fibres were also counted in 3 non-nodular matched patient 
samples (Fig. 4.4G). Non-nodular samples had 10% ±3% cells with α-SMA stress fibres. These 
data suggest that α-SMA is more frequently seen to localise to stress fibres in nodule-
derived cells.  
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Figure 4.4. Quantification of α-SMA localisation to stress fibres in dermal fibroblasts, Dupuytren’s 
nodule-derived and non-nodular cells. Cells were cultured on glass coverslips for 24 hours, fixed and 
then immunofluorescently labelled using α-SMA antibodies (red), phalloidin (green) and DAPI (blue). 
(A) Representative images are shown for Dupuytren’s nodule-derived cell, non-palmar fibroblast and 
palmar fibroblast. The higher panels show staining for phalloidin (green) and DAPI (blue). The middle 
panels show α-SMA (red) and DAPI (blue), and the lower panels represent merged images with α-
SMA (red), phalloidin (green) and DAPI (blue) staining. Scale bar: 20μm. (B, C) The numbers of cells 
with α-SMA positive stress fibres from nodular and non-nodular samples, palmar and non-palmar 
skin were counted on digital images (over 300 cells counted per cell type) and expressed as a 
percentage of total cells (original magnification x 60). * p = 0.03 (nodule-derived vs. non-nodular 
cells). Experiments were performed in triplicate and data are shown as the mean (±SEM) from a total 
of 3 different nodular and non-nodular matched patient samples. 
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4.2.5  Cell passage 
It is recognised that cells change phenotype when cultured in vitro (Bell et al., 1979; Moyer 
et al., 2002). Therefore, to determine the optimal cell passage at which to examine 
Dupuytren’s derived myofibroblasts, I analysed the effect of passage on the number of α-
SMA positive stress fibres in both nodule-derived cells and dermal fibroblasts. Cells between 
passage 1 and 5 were cultured on glass coverslips and immunofluoresently labelled. Nodule-
derived cells demonstrated a consistent decrease in α-SMA stress fibres over time, whereas 
no change was seen with dermal fibroblasts (Fig. 4.5). 
 
 
 
 
 
 
 
Figure 4.5. The effect of cell passage on α-SMA stress fibres in Dupuytren’s nodule-derived cells 
and dermal fibroblasts.   20,000 nodule-derived cells and dermal fibroblasts from passage 1, 2, 3 and 
5 were cultured on glass coverslips for 24 hours, fixed and then immunofluorescently labelled using 
α-SMA antibody and DAPI. The numbers of cells with α-SMA positive stress fibres in nodule-derived 
cells (nodule), palmar (PS) and non-palmar skin fibroblasts (NPS) were expressed as a percentage of 
total cells (deterimined by DAPI). Cells were counted in 10 fields of view at x40 magnification. 
Experiments were performed in triplicate and data are shown from one representativepatient as the 
mean (± SD). 
 
In summary, these data show that isolating cells from Dupuytren’s nodules is reliable 
technique for obtaining a higher percentage of myofibroblasts, which mainta in their 
phenotype at lower cell passage. 
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4.2.6  FPCL contraction 
Next I proceeded to determine the optimal in vitro contraction model for Dupuytren’s 
myofibroblasts. 
4.2.6.1  Isotonic contraction of FPCLs 
Attempts to compare contractility of Dupuytren’s nodule-derived cells, cord and carpal 
ligament-derived cells using isotonic contraction have in the past yielded inconsistent 
findings (Moyer et al., 2002; Rayan and Tomasek, 1994; Tomasek and Rayan, 1995). 
Therefore, initial experiments were carried out to examine the differences in isotonic 
contraction between Dupuytren’s cells, non-palmar and palmar fibroblasts from matched 
patient samples using a simple stress-release model of FPCL contraction (Grinnell, 1994; 
Tomasek et al., 1992).  
Following trypsinisation, 1 x 105 cells were seeded in 250µl of collagen.  FPCLs were allowed 
to polymerise at 37°C for 30 minutes in 24-well tissue culture plates and then cultured with 
1ml DMEM (with 10% FBS) at 37°C in 5% CO2 for 24 hours.  After 24 hours, FPCLs were 
mechanically released from the plate edges using a sterile needle, and FPCL surface area 
contraction measured using digital images at regular intervals over 48 hours. Polymerised 
collagen alone without cells consistently demonstrated only minimal surface area 
contraction (<3%) (Fig. 4.6A, B). Cells isolated from Dupuytren’s tissue, non-palmar and 
palmar skin contracted rapidly over time to the same extent (Fig. 6A), and no significant 
difference in contraction was observed between these cells at 48 hours (Fig. 4.6C -E). 
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Figure 4.6. Isotonic contraction of collagen gels by dermal fibroblasts and Dupuytren’s nodule-
derived cells.  Collagen gels were seeded with non-palmar fibroblasts, palmar fibroblasts or 
Dupuytren’s nodule cells and cultured for 24h.  Control gels were cultured for 24h in the absence of 
any cell type.  (A) After 24h collagen gels were released from the edge of the culture dish and gel 
contraction was assessed by quantifying change in gel surface area over time up to 48h. Data are 
shown as the mean % contraction (± SEM) from triplicate experiments using cells derived from one 
patient and are representative of values from a total of 5 different patients. (B-D) Representative 
images of collagen gels without cells (B) or seeded with non-palmar fibroblasts (C), palmar fibroblasts 
(D) or Dupuytren’s nodule cells (E) after 48h of contraction. The dashed black line indicates the outer 
edge of each collagen gel. Scale bar = 5mm.   
 
 
 
These data suggest that despite there being significantly more α-SMA stress fibres in 
Dupuytren’s cells and dermal fibroblasts, their isotonic force contraction is not significantly 
different at 48 hours. 
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4.2.6.2  Isometric contraction of FPCLs 
One limitation of isotonic FPCL contraction is that in detaching the constructs, matrix 
stiffness is lost and this has been shown to result in loss of α-SMA stress fibres within 10 
minutes (Tomasek et al., 1992). This in turn would disguise any differential contraction 
between populations of fibroblasts and myofibroblasts. Therefore, I next used the culture 
force monitor (CFM) to measure isometric contractile forces generated by constrained 
FPCLs as previously described (Fig. 4.7) (Eastwood et al., 1996).  
 
Figure 4.7.  The culture force monitor (CFM).  (A) Rectangular seeded collagen gels were cast and 
floated in medium, tethered between two flotation bars one of which is held stationary whilst the 
other is attached to a force transducer.  (B) Cell-generated tensional forces in the collagen gel are 
detected by the force transducer, and live data are logged every 15 seconds providing a continuous 
output of force (dynes, 1x105 N) generated.  (C) After 24 hour contraction, gels are harvested and 
processed for α-SMA mRNA, protein and immunofluorescence.  (D) Cells were routinely seeded in 
gels with a high aspect-ratio collagen lattice, although low aspect-ratio lattices (E) were also used in 
experiments to compare effects of less strain on cell contractility. 
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Dupuytren’s nodule-derived cells, non-palmar and palmar fibroblasts from matched patient 
samples were seeded in high aspect-ratio FPCLs, attached to a CFM force transducer and 
isometric force generated was quantified in real time.  FPCLs seeded with 1.5 mi llion non-
palmar fibroblasts (Fig. 4.8A) or palmar fibroblasts (Fig. 4.8B) initially contracted (mean: 0.5 
± 0.2 dynes/hr) and reached a plateau on average after 15hr (range: 4-20hrs), with a 
maximum force of 52 dynes. The same number of nodule-derived cells continued to 
contract to a maximum of 173 dynes (mean: 3.5 ± 1.1 dynes/hr) and did not reach tensional 
homeostasis (Fig. 4.8C). 
Figure 4.8. Isometric contraction of collagen gels by dermal fibroblasts and Dupuytren’s nodule-
derived cells.   (A-C) Collagen gels were seeded with 1.5 million non-palmar fibroblasts (A), palmar 
fibroblasts (B) or Dupuytren’s nodule-derived cells (C), cultured for 24h in the CFM and real-time 
isometric force contraction was quantified. Data shown represent triplicate experiments using cells 
derived from one patient.  
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To compare isometric force generated by cells isolated from α-SMA rich nodules (Fig. 4.9A) 
and non-nodular tissue samples (Fig. 4.9D), FPCLs were seeded with either nodule-derived 
cells or non-nodular cells and attached to the CFM for 24 hours. Nodule-derived cells and 
non-nodular cells were compared to collagen gels seeded with matched non-palmar and 
palmar skin fibroblasts (Fig. 4.9B,E). Whilst both nodule-derived cells and non-nodular cells 
continued to contract over 24 hours and neither reached a plateau, nodule-derived cells 
contracted at a greater rate than non-nodular cells (Fig. 4.9C, F). 
Figure 4.9. Isometric force generated by PIPJ nodular (A-C) and non-nodular (D-F) cells.   (A) 
Histological section from a nodular sample stained for α-SMA.   (B) Matched nodule-derived cells, 
non-palmar skin and palmar skin fibroblasts were seeded in collagen gels and isometric force 
contraction measured over 24 hours and, (C) measured as the average rate of contraction be tween 6 
and 24 hours.   (D) Histological section from a non-nodular sample stained for α-SMA.   (E) Matched 
non-nodular cells, non-palmar skin and palmar skin fibroblasts were seeded in collagen gels and 
isometric force contraction measured over 24 hours and, (F) measured as the average rate of 
contraction between 6 and 24 hours. Values represent the mean of 3 experiments (± SEM) from one 
nodular and non-nodular patient sample (C+F).  
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These experiments were repeated in 5 nodular (nodule-derived) and 3 non-nodular 
matched patient samples. Although the absolute rate of force contraction varied between 
patients, nodule-derived cells consistently generated significantly higher force than non-
nodular cells (p = 0.03) and neither reached a plateau over the 24h test period. In all 
matched samples, both nodule-derived and non-nodular cells also generated significantly 
higher force than dermal fibroblasts (Fig. 4.10).  
 
Figure 4.10. Isometric contraction in FPCLs from 5 nodular and 3 non-nodular matched patient 
samples.   The average rate of contraction between 6 and 24 hours for nodule-derived cells 
(nodular), non-nodular Dupuytren’s cells (non-nodular), non-palmar (NPS) and palmar fibroblasts (PS) 
is shown.  (A) Five different “nodular” matched patient samples. (B) Three different “non-nodular” 
matched samples. Horizontal bars represent mean rates of contraction (dynes/hr).   
 
To ensure nodule-derived cells were within the linear range of contraction and to verify at 
what cell density they reached a plateau, FPCLs were also seeded with reducing cell 
densities (1.125, 0.75, 0.375 and 0.15x106 million cells) in the same final volume of collagen 
gel (2.5ml). The rate of nodule-derived cell contraction was proportional to cell number (Fig. 
4.11). 
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Figure 4.11. Isometric force contraction in collagen gels seeded with decreasing numbers of 
Dupuytren’s nodule-derived cells.   Collagen gels were seeded with decreasing numbers of nodule-
derived cells (1.5m, 1.125m, 0.75m, 0.375m, 0.15m) and either non-palmar (NPS) or palmar 
fibroblasts (PS) (1.5m each). Collagen alone with no cells was included as a control. The average rate 
of contraction (dynes/hr) between 6 and 24 hours was quantified. Data are shown as the mean of 
triplicate experiments (± SEM) using cells derived from one patient and representative of results 
from 3 different patient samples.   
 
Earlier monolayer studies demonstrated that decrease in α-SMA stress fibres by 
immunofluoresence over time in culture (Fig. 4.5). Therefore, using isometric force 
contraction as a read-out, the effect of passage on cell contractility was analysed in both 
nodule-derived cells and dermal fibroblasts. Collagen gels seeded with cells at passage 1 and 
5 were attached to the CFM for 24 hours. Using nodule-derived cells, isometric force 
generation significantly decreased between passage 1 and 5, whereas mean isometric force 
generation increased with non-palmar skin fibroblasts (Fig. 4.12).  
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Figure 4.12. The effect of cell passage on the contractility of Dupuytren’s nodule-derived cells and 
dermal fibroblasts.  (A) 1.5 million nodule-derived cells (nodule) and dermal fibroblasts (NPS) from 
cell passage 1 and 5 were seeded in collagen gels and analysed for isometric force contraction. Data 
are shown as mean (± SEM) from triplicate experiments using cells derived from one patient.   
 
 
These data show that differences in contraction between nodule-derived cells and dermal 
fibroblasts at 24 hours are only seen under isometric and not isotonic conditions. Compared 
with dermal fibroblasts, nodule-derived cells continued to contract in a dose dependent 
manner and did not reach a plateau. These contractile differences were seen consistently 
between different patients. Furthermore, with increasing cell passage, nodule-derived cells 
lost their contractility whereas dermal fibroblasts became more contractile. 
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4.2.7  Post-transcriptional regulation of α-SMA drives myofibroblast contractility 
To correlate α-SMA expression in nodule-derived cells and dermal fibroblasts from matched 
patient samples with contraction, collagen gels seeded with each cell type underwent 
isometric contraction for 24h. Nodule-derived cells contracted at a significantly greater rate 
over the 24h test period than dermal fibroblasts (mean rate of contraction, nodule-derived 
cells = 4.3 dynes/hr; non-palmar fibroblasts= 0.5 dynes/hr; palmar fibroblast = 0.6 dynes/hr) 
(Fig. 4.13A). After 24 hours contraction, cells were then harvested from FPCLs and α-SMA 
mRNA levels and α-SMA protein levels determined by pcr and western blot respectively; α-
SMA localisation was assessed by immunofluoresence.  
No significant difference (p=0.9) was seen in total α-SMA mRNA levels when compared to 
RPLPO (Fig. 4.13B) and GAPDH (Fig. 4.13C).  However, nodule-derived cells expressed more 
α-SMA protein than dermal fibroblasts compared to vimentin. Vimentin was used as a 
control as it is expressed equally in myofibroblasts and fibroblasts (Hinz et al., 2001a) (Fig. 
4.13D). The ratio of α-SMA-to-vimentin was 1.74: 0.66: 0.42 (nodule-derived cells: non-
palmar fibroblasts: palmar fibroblasts) as assessed by densitometry. Furthermore, whilst 
non-palmar and palmar fibroblasts frequently demonstrated α-SMA staining in a cytosolic 
peri-nuclear arrangement, in nodule cells α-SMA was typically distributed throughout the 
cell processes in stress fibres up to the sites of cell-matrix attachment (Fig. 4.13E). These 
data suggest change that post-transcriptional changes in α-SMA regulate contractility of 
Dupuytren’s nodule-derived cells. 
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Figure 4.13.  Contractility of Dupuytren’s nodule-derived cells is regulated by post-transcriptional 
changes in α-SMA.  (A) Isometric force contraction in collagen gels seeded with nodule-derived cells 
(nodule), non-palmar (NPS) and palmar fibroblasts (PS) over 24 hours. Experiments were performed 
in triplicate and values represent the mean ± SEM. After 24 hours cells were isolated from gels and 
levels of (B) α-SMA mRNA compared to RPLPO by quantitative RT-pcr (C) α-SMA mRNA compared to 
GAPDH, (D) levels of α- SMA protein compared with vimentin and, (E) α-SMA protein localisation 
analysed by immunofluorescence. (E) Representative immunofluorescence images of nodule-derived 
cells, palmar and non-palmar fibroblasts are taken from 7μm thick sections fixed and stained with α 
SMA antibodies (red), phalloidin (green) and DAPI (blue) are shown in the higher panels. The lower 
panels are images of the same cells showing only α-SMA staining (red) and DAPI (blue). Scale bar: 
30μm. Data are shown from experiments using cells derived from one matched patient sample and 
are representative of a total of 3 different patients. 
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4.2.8  Dermal fibroblasts co-cultured with nodule-derived cells show no difference 
in isometric force contraction 
Recurrence following dermofasciectomy has been reported to be as low as 1% (Tonkin et al., 
1984). However, the mechanism of reduced recurrence following dermofasciectomy 
remains unexplained. Therefore, co-culture experiments were performed to test the 
hypothesis that the contractility of Dupuytren’s nodule-derived cells is negatively regulated 
by non-palmar dermal fibroblasts. A co-culture system was used to investigate how dermal 
components regulate the behaviour of Dupuytren’s myofibroblasts. Initially, using the 
stress-released model, collagen gels containing Dupuytren’s  cells from patient D13 were 
then overlaid with matched non-palmar dermal fibroblasts contracted significantly less than 
gels overlaid with palmar skin fibroblasts (figure 4.14A). However, the gel contraction assays 
using D13 cells was repeated a further three times. In these experiments no significant 
differences were observed in the rate or level of contraction of cord cells in co-culture with 
palmar or non palmar dermal fibroblasts (Fig. 4.14B). 
These gel contraction experiments have been repeated in three further matched patient 
samples (D18, ED011 and ED013).  Again no significant differences were observed in the 
rate or level of contraction of cord cells in co-culture with matched palmar or non palmar 
dermal fibroblasts (Fig. 4.14C-E).   
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Figure 4.14. Isotonic contraction of stress released FPCLs using matched cells isolated from 4 
patients. FPCLs containing Dupuytren’s cells overlaid with non-palmar dermal fibroblasts contracted 
significantly less than Dupuytren’s cells overlaid with palmar fibroblasts isolated from the same 
patient (A). However, in repeat experiments from the same patient FPCLs containing Dupuytren’s 
cells overlaid with non-palmar dermal fibroblasts contracted to an equal extent to cord cells overlaid 
with palmar fibroblasts isolated from patient (B). Data shown are the average values from 3 
independent experiments +/-SEM. Isotonic contraction of FPCLs was assessed in 3 further matched 
patient samples: D18 (C), ED013 (D) or ED011 (E), and again no differences in contraction were seen. 
Data shown are the average values from 3 independent experiments +/-SEM (D18), values from 2 
independent experiments +/-SEM (ED011), or the average values from a single experiment (ED013). 
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The inhibitory effect of non palmar fibroblasts on cord contraction seen initially with co-
culture contraction (Fig. 4.14A) has not been reproducible in 4 different patient samples.  
These experiments were repeated exhaustively controlling for user variability, collagen type, 
cell passage number, pH and cell number and the results remain variable: in some 
experiments using cells from patient D13 non-palmar fibroblasts inhibited contraction, in 
others they did not. The inhibition by non-palmar fibroblasts was never observed with cells 
from patients: D18, ED011 and ED013. 
Isometric force contraction was also used as a read-out to examine co-cultures of nodule-
derived cells and dermal fibroblasts. FPCLs were seeded with co-cultures of 1.5 million 
nodule-derived cells and dermal fibroblasts, with different cell proportions (75% nodule-
derived cells+ 25% non-palmar or palmar fibroblasts; 25% nodule-derived cells+ 75% non-
palmar or palmar fibroblasts) and attached to the CFM for 24 hours.  As nodule cells were 
the contractile cell type, isometric forces generated from co-culture FPCLs were compared 
with control FPCLs seeded with equivalent densities of nodule cells (ie. 25% nodule cells co-
culture was compared with 375,000 PIPJ nodule cells and 75% with 1.125m cells). No 
significant difference was observed in isometric force contraction with different ratios of the 
matched cells over 24 hours (Fig. 4.15A). 
To further investigate the potential effects of longer term co-cultures, cells were co-cultured 
together for 5 days at the same cell ratios as described above. After 5 days, isometric forces 
generated were measured over 24 hours (Fig. 4.15B). No significant difference was observed 
with these co-cultures (75% nodule-derived cells+25% dermal fibroblasts; 25% nodule-
derived cells+75% dermal fibroblasts).  
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Figure 4.15. Isometric contraction of collagen gels seeded with co-cultures of dermal fibroblasts 
and Dupuytren’s nodule-derived cells.   (A) Co-cultures of nodule-derived cells and dermal 
fibroblasts (either palmar or non-palmar) were seeded in collagen gels at different cell ratios of 
nodule to dermal fibroblasts. A total of 1.5m cells were seeded in gels with co-cultures or dermal 
fibroblasts alone. Nodule-derived cells were seeded at equivalent cell densities to nodule-derived 
cells in co-culture (1.125m nodule cells = 75% nodule cells in co-culture; 0.375m nodule cells = 25% 
nodule cells in co-culture). Contractile profiles of co-cultures were then compared to nodule-derived 
cells of equivalent cell densities.  (B) Co-cultures were also pre-plated for 5 days using the same cell 
ratios, then seeded in collagen gels and isometric force contraction measured over 24 hours. Data 
are shown as the mean (± SEM) from triplicate experiments using cells derived from one patient, and 
are representative of values from a total of 3 different patients 
 
To ensure that each cell type proliferated at the same rate, parallel experiments were 
carried out with fluorescently labelled nodule-derived cells (Vybrant CFDA cell tracer kit, 
Invitrogen). In these experiments 20,000 cells were co-cultured on 18mm glass coverslips 
for 5 days and then fixed and stained with DAPI. Total cell numbers were determined by 
DAPI staining and fluorescent labelled nodule-derived cells were calculated as a percentage 
of the total. There was no difference in both proliferation rates of the individual cell types 
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(p=0.6) and the relative proportion of nodule cells to dermal fibroblasts in each co-culture 
construct (p=0.2, p=0.7) (Fig. 4.16A).  
To support the data, a MTT based assay using the same proportion of cells as described 
above, demonstrated no difference in metabolic activity with co-culture constructs (p=0.3) 
(Fig. 4.16B). 
Figure 4.16. Five day co-culture proliferations studies and cell viability assay:  (A) Monolayer 
experiments with 2,500 cells cultured on coverslips were performed with fluorescently labelled 
nodule cells and stained with DAPI to determine proliferation rates of cells when in co-culture.  
Fluorescently labelled nodule-derived cells were counted and are presented as a percentage of total 
cells (B) Using 5000 cells in 96 well plates, cell viability was analysed after 5 days in co-culture using a 
MTT assay (optical density at 540 nm). Experiments were performed in triplicate. Data are shown as 
mean ±SEM. 
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Co-cultures in both low and high aspect-ratio FPCLs were also compared to examine the 
dependence of strain on cell contractility as, high aspect-ratio FPCLs (Fig. 1D) have been 
shown to generate high strain patterns and better reflect cellular activity of Dupuytren’s 
tissue (Eastwood et al., 1998). Identical co-cultures of 50% dermal fibroblasts and 50% 
nodule cells were seeded in collagen gels and compared with high and low aspect-ratio 
lattices. No significant difference in the rate of isometric force generation (p=0.1) was 
observed between FPCLs with different aspect-ratios (high aspect-ratio=2 ± 0.2 dynes/h; low 
aspect-ratio=1.6 ± 0.1 dynes/h) (Fig. 4.17). However, overall force generation was 
significantly greater (p=0.005) with high aspect-ratio FPCLs after 24 hours contraction (mean 
high aspect-ratio= 91±1 dynes/24h, and mean low aspect-ratio mean=77±4 dynes/24h).  
 
 
 
 
 
 
 
Figure 4.17. Rate of contraction and maximum isometric force contraction with different FPCL aspect-
ratios.  High and Low aspect-ratio FPCLs were seeded with identical co-cultures of 1.5 million cells (NPS 
50% + nodule cells 50%).  The rate of contraction in dynes/hr is shown for 24h.   
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4.3  DISCUSSION 
Myofibroblasts are best studied in 3D collagen lattices under isometric conditions. Although 
several authors have studied myofibroblasts, cells have often been derived from rat 
subcutaneous and lung tissue (Follonier et al., 2008; Goffin et al., 2006; Hinz et al., 2001a; 
Hinz, 2007) with or without treatment with TGF-β1 (Arora et al., 1999; Dugina et al., 2001). 
Whilst previous studies have compared Dupuytren’s nodule and cord cells, they have also 
used non-matched carpal ligament cells as controls (Bisson et al., 2003; Bisson et al., 2004; 
Brickley-Parsons et al., 1981; Murrell, 1991; Rayan and Tomasek, 1994; Tomasek and Rayan, 
1995). This study has for the first time compared genetically matched cells from 
Dupuytren’s nodules, non-palmar and palmar skin with regards to their contractile 
phenotypes in 3D collagen lattices. I also chose to compare nodule-derived cells with control 
dermal fibroblasts because it has been demonstrated that dermal fibroblasts are capable of 
transition to myofibroblasts (Hinz, 2007). Furthermore, it was possible to isolate numerous 
dermal fibroblasts from tissue samples making experiments in the CFM that required large 
numbers of cells possible. 
In the previous chapter I showed that excised Dupuytren’s cords often contained multiple α-
SMA-rich histological nodules, which were variable in size and that a proportion of 
myofibroblasts were also found distributed throughout cord tissue outside nodules (Verjee 
et al., 2009). Whilst this heterogeneity may account for differences in contractility observed 
between samples with variable proportions of α-SMA-rich cells, it also represents a 
significant methodological issue in Dupuytren’s cell-culture based studies as no reliable 
myofibroblast cell lines are available. Therefore, in this study, novel methodology was 
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established to ensure that proportionally more α-SMA-rich cells were isolated from tissue 
samples. Digital cords were bisected and half processed for cell culture, whilst the cut 
surface of the mirror half was processed to identify samples with α-SMA-rich nodules 
(condensation of cells) by immunohistochemistry. Subsequent quantification by 
immunofluorescence demonstrated on average 35% of cells express α-SMA stress fibres in 
histology confirmed nodular samples, as compared to 10% α-SMA stress fibres in non-
nodular samples. Although this still does not constitute a homogenous population of 
myofibroblasts, this method of sampling α-SMA-rich cells represents a significant 
improvement on previous studies, which have reported on average between 9.7% and 15% 
α-SMA-positive cells isolated from clinical and not histologically defined nodules (Bisson et 
al., 2003; Tomasek and Rayan, 1995). Worth noting is that my immunohistochemical data 
from the previous chapter demonstrated that approxiamtely 97% cells within the nodule 
and 32% in the peri-nodular region were α-SMA positive. In contrast my 
immunofluorescence data in this chapter has shown a mean of 35% nodule-derived cells 
contained α-SMA positive stress fibres. It is difficult to compare these immunofluorescence 
results with previous immunohistochemical studies as the characteristics of cells grown on 
glass coverslips and maintained in culture are likely to have changed from their in vivo 
environment. Also tissue sampling must be considered whereby despite isolating cells from 
histologically confirmed tissue, cells from less α-SMA rich peri-nodular tissue may have also 
been included. 
My findings also demonstrated that between 1-4% of dermal fibroblasts had α-SMA positive 
stress fibres. This is in line with previous monolayer immunofluoresecence studies that used 
control cells isolated from flexor retinaculum and showed 1.3% α-SMA positive cells (Bisson 
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et al., 2003) and 1-9% α-SMA positive cells (Tomasek and Rayan, 1995).  Again, this 
difference may be explained by the phenotypic characteristics acquired by these cells as a 
result of cell culture on a rigid plastic substrate.  
Initially, I analysed isotonic contraction in stress-released circular collagen lattices and found 
no differences in contraction between Dupuytren’s cells and dermal fibroblasts. Several 
authors have used this model to examine Dupuytren’s cells and similar findings to ours have 
been reported (Rayan and Tomasek, 1994). Although others have demonstrated increased 
contraction with nodule cells compared to cord cells or control carpal ligament fibroblasts 
(Moyer et al., 2002; Tomasek and Rayan, 1995), these differences were only maintained in 
earlier cell passage (Moyer et al., 2002) and when nodule derived cells were subdivided in to 
high α-SMA expression groups (Tomasek and Rayan, 1995). Interestingly, one study 
demonstrated increased contraction by dermal fibroblasts compared to nodule-derived cells 
(Tarpila et al., 1996) and attributed this to late stage Dupuytren’s disease samples that had 
lost their contractile phenotype.  
It is well recognised that in 3D collagen lattices, migrating fibroblasts develop tractional 
forces that increase matrix stiffness by reorganising the loose collagen matrix (Grinnell, 
2003). The presence of TGF-β1 (Desmouliere et al., 1993), ED-A fibronectin (Serini et al., 
1998) and continued high levels of extracellular stress (Arora et al., 1999; Hinz et al., 2001a) 
in constrained FPCLs leads to the incorporation of α-SMA  in to stress fibres, development of 
prominent matrix focal adhesions and myofibroblast differentiation (Hinz, 2007). However, 
upon release of FPCLs, cell-generated tension within the lattice is immediately lost, with 
subsequent change in fibroblast morphology as rapid isotonic contraction occurs (Grinnell, 
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2003; Tomasek et al., 1992). This has been likened to wound healing and granulation tissue 
contraction (Grinnell, 1994) and more importantly, the loss of tension has been shown to 
result in rapid disassembly of stress fibres and degradation of α-SMA (Hinz et al., 2001a). 
Such changes in stress fibres following release have been observed within 2 minutes and 
after 10 minutes almost all stress fibres have disappeared (Tomasek et al., 1992). 
In contrast, the culture force monitor permits real-time quantification of uniaxial isometric 
forces generated in constrained high aspect-ratio rectangular FPCLs (Bisson et al., 2004; 
Eastwood et al., 1996). This more representative model should also preserve the 
myofibroblast phenotype and hence more closely emulate the in vivo situation whereby 
Dupuytren’s myofibroblasts perceive strain along lines of longitudinal tension.  Therefore, I 
used this system to compare Dupuytren’s nodule-derived cells with matched dermal 
fibroblasts. In line with previous studies, dermal fibroblasts reached a plateau, whereas 
nodule-derived cells continued to contract in a dose-dependent manner over a 24 hour test 
period (Bisson et al., 2004; Brown et al., 1998). In addition, by harvesting FPCLs following 24 
hours contraction in the CFM, comparisons were made between α-SMA mRNA levels, α-
SMA protein expression and α-SMA protein localisation by immunofluorescence in the 
matched cell types. Interestingly, no differences in α-SMA mRNA levels were seen between 
nodule-derived cells and dermal fibroblasts, although approximately 3-fold greater α-SMA 
protein levels were seen in nodule-derived cells compared with matched dermal fibroblasts. 
Furthermore, using immunofluorescence I found that in dermal fibroblasts, α-SMA was 
typically distributed in a ‘halo’ within the peri-nucleur cytoplasm, whereas in nodule-derived 
cells, α-SMA was frequently localised in stress fibres throughout the cell processes up to 
cell-matrix attachment sites. The presence of cytosolic α-SMA in fibroblasts is not seen in 
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vivo, although when fibroblasts are cultured on rigid plastic substrate in the presence of 
foetal bovine serum they have been described to acquire proto-myofibroblast features with 
transitory expression of cytosolic α-SMA (Hinz, 2007; Tomasek et al., 2002). My monolyer 
immunofluoresence studies also demonstrate that palmar and non-palmar fibroblasts when 
cultured in monolayer acquired a proto-myofibroblast phenotype with the expression of de 
novo cytosolic α-SMA. In contrast, significantly more differentiated myofibroblasts with α-
SMA incorporated to stress fibres were seen in nodule-derived cells (Fig. 4.3).  These 
differences seen with nodule-derived, non-palmar and palmar skin cells from matched 
samples have not been previously reported. Previous studies have reported only differences 
in α-SMA protein expression and localization between nodule- or cord-derived Dupuytren’s 
cells when compared to non-matched control carpal ligament cells. The comparative levels 
of α-SMA mRNA in these cell types have not been analysed (Benzonana et al., 1988; Dave et 
al., 2001). Here we simultaneously examined α-SMA protein levels, protein localization and 
mRNA levels in cells isolated from the same patient. Our findings suggest post 
transcriptional changes in α-SMA occur in genetically matched cells to mediate the 
Dupuytren’s myofibroblast cell phenotype. Recent studies on cellular mechanisms of local 
protein synthesis have now also suggested that, not only is mRNA subject to translation, but 
that cells can instruct the cytoskeleton and translation apparatus where to transport and 
when to translate the intended protein (Rodriguez et al., 2008). Therefore, post-
transcriptional changes in α-SMA expression may include mRNA stability, mRNA localisation, 
translation, cytoskeletal localisation and stress fibre formation. Further studies using 
Dupuytren’s matched cells are required to investigate these possibilities. 
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It has been reported in previous studies that nodule-derived cells maintain significant 
contractile differences up to cell passage 4-5 when compared to control fibroblasts (Bisson 
et al., 2004; Moyer et al., 2002). However, the data from this study suggests that 
contractility of nodule cells significantly decreases by cell passage 5. It was demonstrated 
that increasing cell passage was correlated with a consistent decrease in α-SMA stress 
fibres. The opposite was observed in dermal fibroblasts, with a significant increase in 
contractility with cell passage although no change was seen in α-SMA stress fibres. This 
suggests that culturing dermal fibroblasts on rigid plastic substrates may over time lead to 
increased cell-generated tension and promote the development of a more contractile 
protomyofibroblast phenotype (Hinz, 2007; Tomasek et al., 2002). The tendency towards a 
similar contractile phenotype between nodule-derived cells and dermal fibroblasts may 
reflect contractile adjustments by these cells as a consequence of the identical in vitro 
culture conditions. Therefore experiments were performed with cells from cell passage 1 or 
2, unless stated otherwise. 
Finally, based on the surgical observation that recurrence following dermofasciectomy is 
much lower than after fasciectomy (Tonkin et al., 1984), the hypothesis that non-palmar 
dermal fibroblasts may downregulate Dupuytren’s myofibroblasts was tested. No 
differences were found in isometric force contraction with co-cultures when compared to 
controls of equivalent numbers of nodule cells alone, either over 24 hours or with longer-
term cultures. No differences in contractility were observed with different ratios of nodule-
derived cells to dermal fibroblasts and controlling for cell proliferation rates in co-culture. 
Ideally these co-cultures would be observed in the CFM for a time course longer than 24 
hours. Although in my experience there was an increased incidence of bacterial 
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contamination and pH disturbance beyond 24 hours culture and therefore, experiments 
were limited to 24 hour test periods. Our pre-plated co-cultures were only performed over a 
period of 5 days and the CFM co-culture system is limited in that it does not reflect the 
processes involved in vivo for dermofasciectomy and, recurrent disease may evolve over 
several months or years.  
It has been demonstrated previously that isometric contraction of a 3D collagen lattice by 
resident fibroblasts causes strains to develop within the lattice and these strains can be 
increased or decreased by altering the FPCL aspect-ratio (ratio of length/ width/ thickness) 
(Eastwood et al., 1998) to modulate cellular activity. Dupuytren’s cord tissue in vivo has a 
high aspect-ratio and is subjected to considerable tensile force that causes high strain 
gradients, and these may in turn dictate cellular alignment along the major axis of the cord. 
Consequently, iso-strains run parallel with the long axis, which in Dupuytren’s cord is 
reflected by fibroblasts aligned longitudinally with collagen fibres (Luck, 1959; Verjee et al., 
2009). Interestingly, it has been observed clinically that after simple division of Dupuytren’s 
tissue (fasciotomy), cords which are no longer under tension soften and temporarily 
disappear (Hueston, 1992). Furthermore, it has also been suggested that reducing skin 
tension following fasciotomy by a single Z-plasty significantly reduced recurrence at 2 years 
(Citron and Hearnden, 2003). Therefore identical co-cultures in both low and high aspect-
ratio FPCLs were compared to examine the dependence of tension and strain on cell 
contractility. Although no significant difference in the rate of contraction (dynes/ hour) was 
found between the different aspect-ratios, a significant decrease in overall force generation 
was observed with low aspect-ratio FPCLs. This implies that Dupuytren’s cells remain 
significantly more contractile than dermal fibroblasts even in the absence of high strain 
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gradients, although nodule-derived cells may prefer an environment with higher baseline 
levels of tensile force. It may be that dermofasciectomy, with resurfacing of the cutaneous 
defect in the digit with a full-thickness skin graft, may alter myofibroblast activity through a 
combination of reduced tension and more complete excision, as it can be difficult to 
accurately differentiate the surgical plane between Dupuytren’s cord and palmar skin at the 
time of fasciectomy. 
Our histological findings in the previous chapter (Verjee et al., 2009) showed that α-SMA-
rich nodules occurred with equal frequency in primary and recurrent disease samples and 
were also not significantly different in size. Recurrences were seen following previous 
fasciotomy, fasciectomy and firebreak dermofasciectomy but not radical dermofasciectomy. 
Similarly, from these results it is possible that residual unexcised Dupuytren’s tissue 
following less radical surgery may serve as a trigger for recurrence and, indeed, the 
increased motion following initial surgery may facilitate myofibroblast differentiation and 
persistence. This may also explain why radical dermofasciectomy has a lower rate of 
recurrence (1-5%) (Brotherston et al., 1994; Hall et al., 1997; Tonkin et al., 1984) than 
‘firebreak’ dermofasciectomy (12%) (Ullah et al., 2009) or fasciectomy (40-50%) (Foucher et 
al., 1992; Hueston, 1961; Tonkin et al., 1984). 
In conclusion, isometric force contraction measured by the culture force monitor represents 
the best model available for the study of cell contractility in Dupuytren’s disease. Using 
matched patient samples it has been demonstrated that post transcriptional changes of α -
SMA expression mediate the contractile phenotype of Dupuytren’s cells. The different 
possible mechanisms for post-transcriptional modification warrant further investigation. Co-
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cultures data suggests that contractility of Dupuytren’s cells is not influenced by dermal 
fibroblasts. Reduced recurrence rate following dermofasciectomy may be due to other 
factors, such as more complete excision of affected tissue combined with reduced tension 
following application of full-thickness skin grafts. 
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5.1  INTRODUCTION 
Dupuytren’s disease is a fibroproliferative condition, the pathophysiology of which remains 
unclear. Whilst Dupuytren’s tissue is populated with highly contractile myofibroblasts that 
mediate digital contracture, the presence of inflammatory cells indicates that inflammation 
may be important in the pathogenesis of Dupuytren’s disease. Studies using 
immunohistochemistry, light and electron microscopy have demonstrated a correlation 
between the numbers of macrophages and myofibroblasts in Dupuytren’s nodules (Andrew 
et al., 1991). Furthermore, large numbers of macrophages were found at the interface 
between skin and excised Dupuytren’s nodule (VandeBerg et al., 1982) and increased 
Langerhans cells, T-lymphocytes and macrophages have also been reported in nodules and 
at the dermo-epidermal junction with palmar skin (Qureshi et al., 2001). Mast cells have also 
been reported to be increased in Dupuytren’s tissue compared to control carpal ligament 
(Schubert et al., 2006). Using FACS analysis, CD3-positive T-lymphocytes have also been 
shown to be present in 25% of Dupuytren’s cells isolated from whole cord compared to 
0.5% in control palmar fascia (Baird et al., 1993).  
Growth factors and cytokines derived from inflammatory have been shown to regulate the 
myofibroblast phenotype. These cytokines and growth factors include IL-1beta, bFGF, TGF-
β1 , TGF-β2, EGF, PDGF and CTGF (Baird et al., 1993; Bunker et al., 2000; Igarashi et al., 
1996; Kuhn et al., 2001; Terek et al., 1995). High levels of TNF-α mRNA have been reported 
in Dupuytren’s cord tissue compared to tissue from frozen shoulder and control shoulder 
tissue (Bunker et al., 2000) and, more recently, TNF-α has been shown to suppress α-SMA 
expression in human non-palmar dermal fibroblasts using both western blot analysis and 
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RT-PCR. Furthermore, a decrease in collagen matrix stiffness and isotonic contraction was 
seen after 5 days in culture of myofibs with TNF-α (Goldberg et al., 2007). Similar findings 
have been reported using myofibroblasts derived from hip joint tissue (Mattyasovszky et al., 
2010), although in this study TNF-α was also shown to promote cell proliferation and 
viability. TNF-α has also been suggested to induce the transformation of human dermal 
microvascular endothelial cells to myofibroblasts (Chaudhuri et al., 2007). Therefore, the 
effect of TNF-α may vary depending on the cell type and conditions and has not been 
studied in Dupuytren’s tissue. 
Advanced glycation end-products (AGEs) and the receptor for advanced glycation end-
products (RAGE) have recently been implicated in cell dysfunction, fibrosis and mechanisms 
of inflammatory disease (Sims et al., 2010; van Beijnum et al., 2008). The interaction 
between AGEs and their binding proteins have been shown to lead to the activation of a 
range of secondary messenger systems and the increased production of cytokines including 
TGF-β1 and PDGF (Throckmorton et al., 1995), TNF-α and IL-1 (Vlassara et al., 1988). In a rat 
proximal tubular cell line, the interaction of AGEs with RAGE has been shown to induce a 
dose-dependent epithelial-myofibroblast transdifferentiation determined by morphological 
changes, de novo α-SMA expression determined by mRNA and protein levels, and loss of E-
cadherin staining (Li et al., 2004; Oldfield et al., 2001). The expression of RAGE in 
Dupuytren’s tissue and the possible role of AGE-RAGE dependent induction of 
myofibroblasts in Dupuytren’s disease have not been previously examined.  
Therefore, in the final chapter of this study I analysed matched Dupuytren’s nodule and 
cordsamples by immunohistochemistry for the presence of inflammatory cells 
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(macrophages, T cells, neutrophils, and mast cells) and RAGE expression. RAGE expression 
levels in matched fibroblasts were analysed using FACS. Co-localisation of inflammatory cells 
and RAGE with α-SMA was also examined. Finally, based on the observation that the earliest 
signs of Dupuytren’s disease may seen in the palmar skin (Hueston, 1985; Hueston, 1963; 
Rayan, 1999), I went on to assess the role of TNF-α and AGEs in promoting the 
myofibroblast contractile phenotype in palmar dermal fibroblasts. 
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5.2  RESULTS 
5.2.1  Inflammatory cells in Dupuytren’s tissue are distributed predominantly 
within nodules 
Inflammatory cells have been previously described in Dupuytren’s tissue and a correlation 
between the numbers of macrophages and myofibroblasts in Dupuytren’s nodules has been 
reported (Andrew et al., 1991). Approximately 25% of cells isolated from whole Dupuytren’s 
cord were shown by FACS analysis to be CD3-positive T-lymphocytes (Baird et al., 1993). I 
undertook systematic analysis of histological sections of Dupuytren’s tissue to confirm and 
quantify the distribution of inflammatory cells throughout Dupuytren’s tissue.  
Excised digital cord samples were longitudinally bisected, fixed in formalin and 7µm 
histological sections from the cut surface processed for immunohistochemistry. Sequential 
sections were stained with α-SMA antibody and inflammatory cell markers including, mast 
cell tryptase, neutrophil elastase, CD3 positive T-lymphocytes, CD4 positive T cells and 
macrophages (CD68 positive cells). Serum from the appropriate species in which the 
antibodies were raised was used at the same protein concentration as the monoclonal 
antibody solution for negative controls.  Histological sections from inflammatory tissue 
(tonsil for CD3 T cells, CD4 T cells, CD68 positive macrophages, mast cell tryptase and bone 
marrow for neutrophil elastase) were used as positive controls (Fig. 5.1). 
Immunohistochemical staining for inflammatory cells showed good specificity and was 
reproducible, although staining for CD4 positive T cells produced consistently less intense 
staining despite optimisation in other tissues and at different antibody concentrations.
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Figure 5.1. Positve controls - Immunohistochemistry staining for inflammatory cells. Histological sections were taken from bone marrow and stained for 
(A) neutrophil elastase. Histological sections were also taken from tonsil tissue and stained for (B) CD3 positive T cells, (C) CD4 positive T cells, (D) mast cell 
tryptase and (E) CD68 positive macrophages. 
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5.2.1.1  Nodules 
Nodules rich in α-SMA were examined from 15 patient samples and in all of these sections 
numerous cells stained positive for mast cell tryptase, CD3 positive T-lymphocytes, and 
CD68 positive macrophages. Staining was seen both around blood vessels and within the 
stromal tissue. However, there was minimal staining for neutrophil elastase and CD4 
positive T-lymphocytes in nodules (Fig. 5.2).
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Figure 5.2. Immunohistochemistry staining for inflammatory cells in Dupuytren’s nodule. Digital cord samples were longitudinally bisected and fixed in 
formalin. Histological sections were taken from the cut surface of cord and serial sections stained for (A) α -SMA, (B) neutrophil elastase, (C) CD3 positive T 
cells, (D) CD4 positive T cells, (E) CD68 positive macrophages and (F) mast cell tryptase. Images are representative from 15 patient samples.
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5.2.1.2  Cord tissue distal from the nodule  
Cord tissue distal from the nodule was also examined in the 15 nodular patient samples and 
although some cells did stain positive for α-SMA (Fig. 5.3A), in all patient samples minimal 
positive staining was observed for neutrophil elastase , CD3 and CD4 positive T cells and 
CD68 positive macrophages and mast cell tryptase (Fig. 5.3B-F).
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Figure 5.3. Immunohistochemistry staining for inflammatory cells in Dupuytren’s cord distal to nodule. Digital cord samples were longitudinally bisected 
and fixed in formalin. Histological sections were taken from the cut surface of cord and serial sections stained for (A) α-SMA (with positive control blood 
vessel staining, (B) neutrophil elastase, (C) CD3 positive T cells, (D) CD4 positive T cells, (E) CD68 positive macrophages and (F) mast cell tryptase. Images are 
representative from 15 patient samples. 
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5.2.1.3  Non-nodular cord tissue  
Non-nodular cord tissue was also examined in 10 patient samples. As with cord distal from 
the nodule, some cells stained positive for α-SMA (Fig. 5.4A) and very few cells stained 
positive for any of the panel of inflammatory markers including neutrophil elastase, CD3 
positive T-lymphocytes, CD4 positive T cells and CD68 positive macrophages, mast cell 
tryptase (Fig. 5.4B-F).  
Serum from the appropriate species in which the antibodies were raised was used at the 
same protein concentration as the monoclonal antibody solution for negative controls.  
Histological sections from inflammatory tissue (tonsil for CD3 T cells, CD4 T cells, CD68 
positive macrophages, mast cell tryptase and bone marrow for neutrophil elastase) were 
used as positive controls.
Chapter 5  Inflammatory mediators and Dupuytren’s disease 
 
168 
 
Figure 5.4. Immunohistochemistry staining for inflammatory cells in non-nodular Dupuytren’s cord. Digital cord samples were longitudinally bisected and 
fixed in formalin. Histological sections were taken from the cut surface of cord and serial sections stained for (A) α-SMA, (B) neutrophil elastase, (C) CD3 
positive T cells, (D) CD4 positive T cells, (E) CD68 positive macrophages and (F) mast cell tryptase. Images are representative from 10 patient samples. 
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5.2.1.4  Quantification of inflammatory cells found throughout Dupuytren’s tissue 
Based on the immunohistochemical sections (Fig 5.2-4), systematic analysis was also carried 
out to quantify the number of inflammatory cells observed throughout excised Dupuytren’s 
cord tissue in 10 patient samples. For each region (nodule, cord distal to nodule and non-
nodular cord), the total number of cells, the number of α-SMA positive cells and cells 
stained for neutrophil elastase, mast cell tryptase, CD3positive T cells, CD 4 positive T cells, 
CD68 positive macrophages were counted (x20 magnification) (Table 5.1). 
Table 5.1. Quantification of total cell number, α-SMA positive cells, CD3 positive T cells, 
CD4 positive T cells, CD68 positive macrophages, and cells positive for mast cell tryptase 
and neutrophil elastase throughout excised Dupuytren’s cord. Nodules, cord distal to 
nodule and non-nodular cord were analysed (presented as mean count (±SDEV) per mm2) 
Six fields of view were counted within each region. 
IHC stain Nodule Distal to nodule Non-nodular cord 
  mean SDEV mean SDEV mean SDEV 
Total cells 1515 181 416 104 504 163 
α-SMA 1493 199 12 8 8 7 
Neutrophil elastase 2 1 0 1 0 0 
CD3 positive T cells 220 99 2 2 1 2 
CD4 positive T cells 2 1 0 0 0 0 
CD68 positive macrophages 282 54 1 1 1 1 
Mast cell tryptase 48 11 1 1 0 1 
 
In summary, these data suggest that CD68 positive macrophages, CD3 T-cells and mast cell 
tryptase positive cells are common within cellular nodules and sparse within cord tissue. 
Neutrophil elastase positive cells and CD4 positive T-cells were observed infrequently 
throughout Dupuytren’s tissue. Whilst Dupuytren’s nodular tissue is populated with highly 
contractile myofibroblasts, the presence here of inflammatory cells also implies that 
inflammation may be important in pathogenesis of the disease. 
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5.2.2  RAGE expression is observed predominantly in α-SMA rich Dupuytren’s 
nodules 
AGEs are found in plasma, accumulate in various tissues with ageing and at an accelerated 
rate in diabetes (Brett et al., 1993; Makita et al., 1991).The interaction of AGEs-RAGE has 
been implicated in cell dysfunction and mechanisms of inflammatory disease (Davies et al., 
2009; De Vriese et al., 2006; Fehrenbach et al., 2001; Li et al., 2004; Oldfield et al., 2001; 
Tikellis et al., 2008; van Beijnum et al., 2008). There are some data to suggest that the AGE-
RAGE interaction is implicated in regulating myofibroblast phenotype (Oldfield et al., 2001). 
However, RAGE expression has not previously been characterised in tissue from patients 
with Dupuytren’s disease. 
Therefore, I characterised RAGE expression throughout Dupuytren’s tissue. Longitudinally 
bisected cord samples were fixed in formalin and processed for immunohistochemistry. 
Sequential histological sections were stained with α-SMA and RAGE antibodies as well as 
goat serum.  The latter was used at the same protein concentration as the RAGE antibody 
solution for a negative control. RAGE staining of vascular endothelium was used as an 
internal positive control within Dupuytren’s tissue and was also examined on histological 
sections of inflammatory liver tissue (Fig 5.5) 
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Figure 5.5. Positive/negative controls - Immunohistochemistry staining for RAGE. Histological 
sections were stained for RAGE (A and C) and with goat serum (B and D). Serial sections taken from 
lung tissue showing (A) positive control and (B) negative control. Serial sections taken from 
Dupuytren’s tissue showing (C) positive control and (D) negative control.  
 
Excised Dupuytren’s tissue samples were systematically examined to determine patterns of 
α-SMA and RAGE distribution thoughout cord: within nodules (Fig. 5.6), within the peri -
nodular region (Fig. 5.7), in cord distal to the nodules (Fig. 5.8) and in non-nodular cord (Fig. 
5.9).  These specific regions of cord tissue examined are outlined in chapter 3 (Dupuytren’s 
morphology). In total, 15 nodular and 10 non-nodular samples were examined. 
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5.2.2.1  Nodules 
Nodules rich in α-SMA were examined from 15 Dupuytren’s patient samples. Histological 
sections in all the samples demonstrated abundant α-SMA and RAGE staining in nodules. 
Serial sections demonstrated RAGE co-localisation with α-SMA (Fig. 5.6). The staining for 
both α-SMA and RAGE demonstrated a distinct ‘tide mark’ that demarcated the interface 
between well circumscribed nodules and peri-nodular regions 
 Figure 5.6. RAGE co-localises with α-SMA distribution in Dupuytren’s nodule. Digital cord samples 
were longitudinally bisected and fixed in formalin. Histological sections were taken from the cut 
surface of cord and serial sections were stained for (A, C) α-SMA and (B, D) RAGE antibodies. Scale 
bars as shown. Images are representative from 15 patient samples.  
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5.2.2.2  Peri-nodular cord tissue 
Next, peri-nodular regions were examined in serial sections from the same 15 nodular 
samples. In these areas cells also stained positive for RAGE and α-SMA. However, fewer cells 
stained positive for α-SMA and RAGE than in nodular regions. A similar distribution of α-
SMA and RAGE staining was seen in the peri-nodular areas (Fig. 5.7). 
 
Figure 5.7. RAGE and α-SMA distribution in Dupuytren’s peri-nodular region. Digital cord samples 
were longitudinally bisected and fixed in formalin. Histological sections were taken from the cut 
surface of cord and serial sections were stained for (A, C) α-SMA and (B, D) RAGE antibodies. Scale 
bars as shown. Images are representative from 15 patient samples.  
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5.2.2.3  Cord tissue distal from the nodule  
Histological sections of cord tissue distal from the nodule were also stained with α-SMA and 
RAGE antibodies. These demonstrated relatively few cells that stained positive for α-SMA 
and only a small number of cells also stained positive for RAGE (Fig. 5.8).  
 
 
Figure 5.8. RAGE expression and α-SMA distribution in Dupuytren’s cord distal from nodule. Digital 
cord samples were longitudinally bisected and fixed in formalin. Histological sections were taken 
from the cut surface of cord and serial sections were stained for (A) α-SMA and (B) RAGE antibodies. 
Scale bars are shown. Images are representative from 15 matched patient samples.  
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5.2.2.4  Non-nodular cord tissue 
Histological sections of non-nodular cord tissue were also stained with α-SMA and RAGE 
antibodies. In total 10 patient samples were examined. These consistently demonstrated 
relatively few cells staining positive for α-SMA and RAGE (Fig. 5.9) 
 
 
Figure 5.9. RAGE expression and α-SMA distribution in non-nodular Dupuytren’s cord. Digital cord 
samples were longitudinally bisected and fixed in formalin. Histological sections were taken from the 
cut surface of cord and serial sections were stained for (A, C) α-SMA and (B, D) RAGE antibodies. 
Scale bars as shown. Images are representative from 10 matched patient samples.   
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5.2.3  Cell surface expression of RAGE is significantly greater in nodule-derived 
cells than non-nodular cells and in palmar skin fibroblasts compared to non-
palmar skin fibroblasts. 
To quantify the expression of RAGE on the surface of Dupuytren’s nodule-derived cells, non-
nodular cells, non-palmar and palmar fibroblasts, were cultured for 24 hours and then 
immunofluorescently labelled with RAGE antibody and analysed by FACS (Fig. 5.10). In total 
4 nodular (Fig. 5.10A, C) and 4 non-nodular (Fig. 5.10B, D) matched patient samples were 
analysed. Cells alone, Alexa Fluor 488 secondary antibody alone and rabbit IgG were used as 
controls.  
In nodular matched samples, nodule-derived cells expressed significantly more cell surface 
RAGE (p = 0.01) than non-palmar and palmar skin fibroblasts (Fig. 5.10A,C). In nodular 
samples the largest shift in mean RAGE fluorescence intensity (MFI) is seen in nodule-
derived cells, then palmar skin fibroblasts and least in non-palmar skin fibroblasts compared 
to isotype antibody controls (Fig. 5.10C).   
In contrast, no significant difference (p =0.4) was observed between Dupuytren’s cord cells, 
non-palmar and palmar fibroblasts from non-nodular matched samples (Fig. 5.10B,D). 
However, a trend was observed with relatively increased RAGE expression in palmar skin 
fibroblasts. In non-nodular matched samples no shift was observed in mean fluorescence 
intensity between cells from non-nodular cells and dermal fibroblasts (Fig. 5.10F). A 
summary of the results for RAGE MFI, isotype control MFI and ∆ MFI for all the 8 matched 
patient samples are shown in table 5.2.
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Figure 5.10. Nodule-derived cells express higher levels of cell surface RAGE than matched dermal 
fibroblasts.  Nodule-derived cells, palmar and non-palmar fibroblasts (1x104 cells per experiment) 
were stained with RAGE antibody, fluorescently labelled and mean fluorescence intensity assessed 
by FACS analysis.  (A,C) Cell surface RAGE expression levels in nodule-derived cells as compared with 
matched dermal fibroblasts. (B,D) Cell surface RAGE expression levels in non-nodular cells as 
compared with matched dermal fibroblasts. Results in A and B are shown for 4 matched nodular 
patient and non-nodular samples (± SEM).  (E) RAGE fluorescent intensity trace showing nodule-
derived cells, non-palmar fibroblasts, palmar fibroblasts and isotype control from 1 representative 
nodular matched patient sample, and  (F) from 1 representative non-nodular matched patient 
sample.  
Chapter 5  Inflammatory mediators and Dupuytren’s disease  
 
178 
 
Table 5.2. FACS analysis to determine RAGE cell surface expression (∆ mean fluorescence intensity) 
in 4 nodular and 4 non-nodular matched patient samples. Cells isolated from Dupuytren’s nodule 
(PIPJ), non-nodular PIPJ, non-palmar skin (NPS) and palmar skin (PS). 
Sample ID Cell type Isotype MFI RAGE MFI ∆MFI 
Nodular     
ED035 PIPJ 783.59 934.23 150.64 
 NPS 730.34 842.31 111.97 
 PS 616.61 796.56 179.95 
ED044 PIPJ 546.58 861.00 314.42 
 NPS 239.81 335.98 96.17 
 PS 342.52 524.17 181.65 
ED045 PIPJ 453.12 592.55 139.43 
 NPS 356.06 398.74 42.68 
 PS 438.12 608.69 170.57 
ED066 PIPJ 685.92 968.24 282.32 
 NPS 464.68 608.48 90.06 
 PS 463.01 582.30 119.29 
Non-nodular     
ED063 PIPJ 264.55 290.24 25.69 
 NPS 273.32 295.12 21.80 
 PS 356.59 387.29 30.70 
ED074 PIPJ 251.77 311.07 59.30 
 NPS 169.95 212.94 42.99 
 PS 210.14 327.65 117.51 
ED091 PIPJ 594.17 702.33 108.16 
 NPS 632.35 795.15 162.80 
 PS 588.16 822.34 234.18 
ED091 PIPJ 257.42 379.22 121.80 
 NPS 258.51 388.65 130.14 
 PS 262.97 459.71 196.74 
 Note: MFI= mean fluorescence intensity 
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Further analysis of the FACS data was undertaken to examine differences between RAGE cell 
surface expression in non-palmar and palmar skin. RAGE cell surface expression was 
significantly higher (p = 0.0012) in palmar skin fibroblasts than non-palmar skin fibroblasts 
(Fig. 11). This analysis was carried out using cells from 8 matched patient samples. 
 
 
 
 
 
 
Figure 5.11.  RAGE cell surface expression is greater in palmar than non-palmar fibroblasts. 
Fibroblasts (1x104) from matched palmar and non-palmar skin were stained with RAGE antibody, 
fluorescently labelled and the mean fluorescence intensity analysed by FACS. Cell surface RAGE 
expression levels were consistently higher in palmar fibroblasts than non-palmar fibroblasts. Data 
are shown from 8 matched patient samples. 
 
In combination, the data from FACS analysis suggest that nodule-derived cells express 
significantly more RAGE at the cell surface compared to non-nodular derived cells and 
dermal fibroblasts. Furthermore, palmar skin fibroblasts express significantly more RAGE at 
the cell surface when compared with matched non-palmar skin fibroblasts. 
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5.2.4  Contractility of palmar fibroblasts is augmented with TNF-α, but not with 
AGEs 
Previous authors have suggested that AGEs and RAGE are implicated in regulating 
myofibroblast phenotype in a proximal renal tubule cell line (Oldfield et al., 2001) and 
human dermal microvascular endothelial cells. TNF-α has been suggested to induce the 
transformation to myofibroblasts (Chaudhuri et al., 2007).  High levels of TNF-α mRNA have 
been demonstrated in Dupuytren’s nodules compared to control tissue (Bunker et al., 2000) 
and histological data in this study has demonstrated large number of mast cells, which are 
rich in TNF-α, in Dupuytren’s nodules. However, TNF-α has also been shown to suppress α-
SMA protein and mRNA expression in human dermal fibroblasts. This was associated with a 
decrease in collagen matrix stiffness and isotonic contraction after 5 days in culture 
(Goldberg et al., 2007).  To date, the effects of AGEs on cells derived from Dupuytren’s 
patients have not been previously examined and FACS data in this study suggests that RAGE 
is differentially expressed in skin fibroblasts. Therefore, based on the observation that early 
changes in Dupuytren’s disease are seen in the palmar skin (Hueston, 1985; Hueston, 1963; 
Rayan, 1999), I tested the hypothesis that palmar skin fibroblasts develop a more contractile 
phenotype in the presence of TNF-α or AGEs. Furthermore, it has been suggested in a recent 
study that human endothelial cells pre-stimulated with AGEs demonstrated a significant 
inflammatory response with increased cytokine production (Ehlermann et al., 2006). 
Therefore, I also examined the effect of pre-stimulation with AGEs followed by TNF-α on 
palmar dermal fibroblasts. 
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I compared the differences in isometric force generated by collagen gels seeded with palmar 
fibroblasts and cultured in the presence of AGE-BSA or TNF-α. FPCLs were exposed to either 
control BSA (150µg/ml), AGE-BSA (150µg/ml), TNF-α (1ng/ml) or a combination of AGE-BSA 
(150µg/ml) and TNF-α (1ng/ml) and attached to the CFM for 24 hours. FPCLs were also 
stimulated with 10ng/ml TGF-β1 as a positive control to assess any increase in cell 
contractility. Measurement of isometric force contraction was limited to 24 hours as beyond 
this time changes in ionic concentration of the culture media were noted as a result of FPCL 
contraction (Fig. 5.12).  
Furthermore, to investigate the potential effects of pre-stimulating palmar skin fibroblasts 
with AGEs, cells were also cultured for 5 days with AGE-BSA (150µg/ml), and after 5 days, 
cells were seeded in collagen gels and cultured in the presence of TNF-α (1ng/ml) or AGE-
BSA (150µg/ml) in the CFM. Isometric force generated was measured over 24hours. 
Experiments were performed in duplicate and with cells isolated from 3 different patient 
samples. A two-fold increase in contractility was observed with palmar fibroblasts treated 
with TNF-α (1ng/ml) and a significant increase in contractility with TGF-β1 (10ng/m) 
(p=0.0001) was seen over 24 hours. However, no difference was observed with the addition 
of AGE-BSA for either 24 hours or with longer term culture in the presence of AGE-BSA. Pre-
incubation with AGE-BSA for 5 days followed by 24 hours culture in the CFM with AGE-BSA 
also showed no difference in contractility. Furthermore, pre-incubation with AGE-BSA for 5 
days followed by 24 hours culture in the CFM with TNF-α showed that the contractile effect 
of TNF-α was reduced to that of FPCLs incubated with AGE-BSA alone (Fig. 5.12).  
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Figure 5.12. Contractility of palmar skin fibroblasts is augmented by TNF-α and TGF-β1.  (A) 
Collagen gels seeded with 1.5 million palmar fibroblasts were cultured in the CFM for 24h with either 
DMEM (10%FBS) alone, control BSA (15µg/ml), AGE-BSA (150µg/ml), TNF-α (1ng/ml), or TGF-β1 
(10ng/ml) and real-time isometric force contraction was quantified. Palmar fibroblasts were also 
pre-cultured for 5 days with AGE-BSA (150µg/ml) and following trypsinisation these cells were 
seeded in collagen gels (1.5 million), and then cultured for 24h in the CFM with either TNF-α 
(1ng/ml) or AGE-BSA (150µg/ml). Collagen alone was also used as a control. Data are shown for the 
mean rate of contraction from 3 different patient samples (±SEM). *** signifies p=0.0001. 
 
 
In summary, these data suggest that a two-fold increase in contractility results following 
stimulation of palmar fibroblasts with TNF-α and a significant five-fold increase in isometric 
force contraction over 24 hours was seen with TGF-β1 (p=0.0001). No difference in 
isometric force contraction was observed with the addition of AGE-BSA to palmar skin 
fibroblasts in culture over 24 hours or with pre-exposure over 5 days.  
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5.3  DISCUSSION 
In Dupuytren’s nodules, highly contractile myofibroblasts mediate digital contracture. Whilst 
the stimulus for myofibroblast recruitment in Dupuytren’s disease remains unclear, several 
studies have shown that fibroblast to myofibroblast differentiation is regulated by both 
cytokines and mechanical stress (Hinz, 2007; Tomasek et al., 2002). There are also data to 
suggest that inflammation might play a role in the pathogenesis of Dupuytren’s disease 
based on their observations of inflammatory cells in nodules (Andrew et al., 1991; Qureshi 
et al., 2001; Schubert et al., 2006) and at the interface between nodules and palmar skin 
(VandeBerg et al., 1982). I systematically examined histological sections of Dupuytren’s 
tissue stained for a panel of inflammatory cells and, using the CFM, analysed the effects of 
the pro-inflammatory cytokine TNF-α and AGE-RAGE ligand interaction on the contractility 
of dermal fibroblasts seeded in 3D collagen lattices. To date the effects of both TNF-α and 
AGE-RAGE ligand interaction have not been investigated in the context of Dupuytren’s 
disease.   
Inflammatory cells in nodular and non-nodular Dupuytren’s tissue samples were examined 
in serial sections processed for immunohistochemistry and stained with a panel of 
inflammatory antibodies, including CD68 positive cells (macrophages), CD3 and CD4-positive 
T lymphocytes, neutrophil elastase and mast cell tryptase. In line with previous published 
findings (Andrew et al., 1991; Qureshi et al., 2001; Schubert et al., 2006) the histological 
sections demonstrated macrophages, mast cells and CD3-positive T lymphocytes amongst 
myofibroblasts within Dupuytren’s nodules, and a proportion of these cells were also 
observed around blood vessels. Interestingly, Dupuytren’s nodules were rich in mast cells, 
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which are a rich source of TNF-α (Krishnaswamy et al., 2006). In non-nodular cord, almost 
no inflammatory cells were observed and it is also of interest that virtually no cells stained 
positive for neutrophil elastase in either nodular or non-nodular cord. This is in contrast to 
inflammation during wound healing, where neutrophils are commonly seen in the wound 
where they are involved with clearance of debris and bacteria and initiating myofibroblast 
dependent wound contraction (Martin and Leibovich, 2005). 
Whilst my data and those from previous publications indicate that inflammatory cells are 
present in nodules, suggesting a key role for inflammation in Dupuytren’s disease, it is 
important to note that excised digital cord samples contain nodules from active disease but 
do not provide any information on the role of inflammation in early disease. Therefore, 
these histological findings may only pertain to established disease, when surgical 
intervention was indicated.  
More recently, AGEs have been reported to accumulate in ageing tissues and build up at an 
accelerated rate in patients with diabetes, where they are also linked to their diet (Brett et 
al., 1993; Makita et al., 1991; Makita et al., 1992). There is increasing data implicating AGE-
RAGE ligand-receptor interaction has been implicated in mechanisms of inflammatory 
disease through activation of multiple signal transduction pathways, up-regulation of 
adhesion molecules, secretion of inflammatory cytokines and the production of growth 
factors such as TGF-β1 (Throckmorton et al., 1995). Furthermore, AGE-RAGE interaction has 
been shown to induce a TGF-β1 dependent epithelial-myofibroblast transdifferentiation in a 
proximal renal tubule cell line (Oldfield et al., 2001). AGE exposure induced dose-dependent 
myofibroblast differentiation determined by morphological changes and de novo α-SMA 
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expression, and these effects wre blocked with antibodies against RAGE of TGF-β1 (Oldfield 
et al., 2001). This group further confirmed de novo α-SMA expression by 
immunoctochemistry , mRNA and protein levels (Li et al., 2004). However, these studies 
have been carried out on rat renal tubular cells and the role of AGEs or RAGE in Dupuytren’s 
disease has not been examined yet..  
Therefore, I characterised RAGE expression in Dupuytren’s matched patient samples based 
on the hypothesis that AGEs through their interaction with RAGE may promote 
myofibroblast differentiation in Dupuytren’s patients. My histological data showed that 
RAGE was expressed abundantly in myofibroblast-rich nodular and peri-nodular areas. FACS 
analysis data showed nodular cells have significantly higher levels of cell surface RAGE 
expression compared to non-nodular cells and dermal fibroblasts. Interestingly, palmar 
fibroblasts showed significantly more RAGE expression than non-palmar fibroblasts. Whilst 
the distribution of RAGE in nodules implies it may have a role in modulating myofibroblast 
activity, the significance of the different epidermal distribution and increased RAGE 
expression in palmar fibroblasts compared to non-palmar fibroblasts remains uncertain. 
However, increased RAGE expression in palmar skin and Dupuytren’s nodules compared to 
non-palmar skin, would fit with the observation that early signs of Dupuytren’s disease are 
seen in the palmar skin (Hueston, 1985; Hueston, 1963) and hence supports the hypothesis 
that the early changes seen in the palmar skin may drive the fibrotic process. Therefore, I 
used dermal fibroblasts derived from palmar skin and control matched non-palmar skin 
fibroblasts to test the hypothesis that TNF-α and the AGE-RAGE ligand interaction promote 
myofibroblast phenotype in Dupuytren’s disease.  
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I went on to examine the effects of AGEs on palmar skin fibroblast contractility in 3D 
collagen lattices. No differences were seen in contractility over 24 hours in the CFM or with 
longer term 5 day pre-incubation in the presence of AGEs in culture flasks followed by 24 
hours in the CFM. Previous studies using a rat kidney epithelial cell line have reported an 
increase in expression of α-SMA mRNA and protein expression in monolayer experiments 
over 24 hours and a linear increase in α-SMA positive cells over a 6 day period (Oldfield et 
al., 2001). Although I used similar doses of AGEs in my experiments, marked differences in 
methodology including the examination of cells in 3D lattices under isometric conditions, 
differences in cell type and cell source may account for the different results.   
Several growth factors and cytokines derived from inflammatory cells have also been shown 
to regulate the myofibroblast phenotype in Dupuytren’s disease, include IL -1, bFGF, PDGF, 
TGF-β1 , TGF-β2, EGF, PDGF and CTGF (Baird et al., 1993; Bunker et al., 2000; Igarashi et al., 
1996; Kuhn et al., 2001; Terek et al., 1995). The best studied of these is TGF-β1, which has 
been shown to induce the myofibroblast phenotype at supra-physiological concentrations in 
3D collagen lattices under isometric conditions (Bisson et al., 2009; Wong and Mudera, 
2006). My data confirms these findings and showed significant increased palmar fibroblast 
contractility (p=0.0001) with 10ng/ml TGF-β1 compared to untreated palmar fibroblasts.   
The effects of TNF-α have not been previously examined in palmar skin fibroblasts and this 
is the first report of TNF-α resulting in increased palmar fibroblast contractility under 
isometric conditions in 3D collagen lattices. Interestingly, I found that FPCLs treated with 
1ng/ml TNF-α showed a 2-fold increase in contractility over 24 hours with similar findings 
when repeated in three different patient samples. Previously, TNF-α mRNA levels have been 
Chapter 5  Inflammatory mediators and Dupuytren’s disease  
 
187 
 
shown to be increased in whole Dupuytren’s cord samples when compared to control tissue 
taken from patients with frozen shoulder and also normal control shoulders (Bunker et al., 
2000), further suggesting TNF-α may play a role in the pathogenesis of Dupuytren’s disease. 
However, in rat lung fibroblasts TNF-α has been shown to suppress α-SMA expression 
(Mariani et al., 1999) and decreased α-SMA mRNA expression with TNF-α has also been 
demonstrated in myofibroblasts from hip joint tissue (Mattyasovszky et al., 2010). In the 
inflammatory phase of wound healing TNF-α is expressed by inflammatory cells and, both 
inhibits ECM synthesis and activates MMPs (Singer and Clark, 1999). Previous authors have 
examined the effects of TNF-α (1ng/ml) in normal human dermal fibroblasts and used 
isotonic contraction model systems to measure FPCL contractility (Goldberg et al., 2007). 
This study showed a significant decrease in FPCL contraction upon stimulation with 1ng/ml 
TNF-α and a significant reduction in collagen 1A and α-SMA mRNA levels and protein levels 
were demonstrated in cells treated with TNF-α (Goldberg et al., 2007). Furthermore, they 
demonstrated that TNF-α suppressed TGF-β1 induced myofibroblast phenotypic changes.  
Similarly, TNF-α has also been shown to anatagonise TGF-β1-induced upregulation of type I 
and III collagen in fibroblasts through a JNK-dependent regulatory mechanism in mouse 
fibroblasts (Verrecchia et al., 2002). The anatgonsitic relationship between TGF-β1 and TNF-
α warrants further investigation and may play an important role in maintaining tissue 
homeostasis and ECM turn-over. However, the precise effect of TNF-α may be variable 
depending on the cell type examined. Indeed, it is worth noting these studies have also 
shown that TNF-α stimulation can lead to increased proliferation and viability of 
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myofibroblasts (Mattyasovszky et al., 2010) and human dermal microvascular endothelial 
cells (HUVEC) (Chaudhuri et al., 2007).   
Finally, I examined palmar skin fibroblast contractility following pre-stimulation with AGEs 
for 5 days, followed by 24 hour culture with TNF-α in the CFM. The rationale for these 
experiments was based on a study that suggested marked difference between AGE pre-
stimulated and control human umbilical vein endothelial cells (HUVECs). Only HUVECs 
sensitized by AGEs showed a significant pro-inflammatory response as demonstrated by 
increased cytokine release, adhesion molecules, MAP kinase and NF-kappa B cRel activation 
(Ehlermann et al., 2006). However, my data showed that AGE pre-stimulation may suppress 
the contractile stimulus of TNF-α. An explanation for this may be that RAGE is a multi-ligand 
receptor that also responds to other pro-inflammatory proteins, such as high mobility group 
protein B1 (HMGB-1) and S100 proteins (van Beijnum et al., 2008). Different permutations 
of these ligands in combination with AGEs warrant further investigation.  
In conclusion, my data suggest that in the presence of TNF-α palmar fibroblasts develop a 
more contractile phenotype. Possible sources of TNF-α are macrophages and mast cells in 
Dupuytren’s nodules. Although RAGE is abundantly expressed in Dupuytren’s nodules and 
palmar skin, the role of AGEs in Dupuytren’s disease remains uncertain. Most importantly, 
data from this chapter suggests that TNF-α may play a key role in the pathogenesis of 
Dupuytren’s disease. 
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6.1  Concluding discussion and future plans  
Many aspects of the pathophysiology of Dupuytren’s disease are still poorly understood. 
Surgery remains the mainstay of treatment and the problem of recurrence has not been 
resolved. An improved understanding of the recruitment, differentiation and contraction of 
myofibroblasts will offer the potential for less invasive means of addressing primary disease. 
Similar mechanisms may also control the activity of myofibroblasts in other fibrotic diseases. 
Any therapeutic modality developed for treating Dupuytren’s disease may, therefore, also 
have a role in the general management of fibrosis. 
I began by characterising Dupuytren’s tissue morphology with a detailed histological analysis 
of cell and myofibroblast distribution throughout Dupuytren’s tiss ue. I examined over 100 
excised digital cord samples and demonstrated that cord tissue is cellular even in non-
nodular cords.  Nodules were often hypercellular and comprised of a focal condensation of 
cells. I also showed that Dupuytren’s tissue is very heterogenous. A variable proportion of 
cells observed outside histological nodules and throughout non-nodular cord were also 
myofibroblasts (9-17%) (Verjee et al., 2009). Myofibroblasts were often seen in non-nodular 
cord as microscopic pockets of cells aligned longitudinally with collagen fibres. In nodular 
cords, myofibroblast distribution was also variable and almost half of the cords examined 
had multiple histological nodules that varied significantly in size.   
In agreement with literature describing clinical nodules in relation to the interphalangeal 
joints of the hand (Chiu and McFarlane, 1978; Luck, 1959), I found that in 95% of nodular 
samples, a nodule was observed within the vicinity of this joint.  A histological nodule was 
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also seen overlying the MCPJ in 2 further cases where the relationship was specifically 
sought.  The close proximity of myofibroblast rich nodules with joints in the hand may be 
explained by tension, which can act intermittently on Dupuytren's tissue as movement at 
the PIPJ offers resistance against the thickened, contracted palmar fascia.  Increased tension 
through the joint, the presence of cytokines and ED-A fibronectin induce myofibroblast 
differentiation, which in turn would lead to greater force generation. A nodule, densely 
packed with myofibroblasts, could then theoretically generate and maintain greater 
contractile force, as myofibroblasts have been shown to have the ability to sustain co-
ordinated micro-contractions over a long period of time (Castella et al., 2010; Follonier et 
al., 2008).  Continuous contraction, combined with remodelling of the surrounding ECM by 
MMPs (Johnston et al., 2007; Johnston et al., 2008; Tarlton et al., 1998; Ulrich et al., 2003), 
will result in shortening of the affected fascia and over time lead to digital contracture. With 
advanced disease and the development of fixed flexion deformity, associated loss of 
movement at the joint is likely to result in “stress shielding”, with subsequent loss of tension 
and myofibroblast apoptosis. Myofibroblast apoptosis following stress-shielding and loss of 
tension was seen after re-epithelialisation (Desmouliere et al., 1995) and following release 
of tension in splinted wounds in a rat model (Carlson et al., 2003). It is, therefore, 
conceivable that with advanced digital contractures, reduced tension through limited active 
joint extension may similarly lead to myofibroblast apoptosis and resolution of the nodule. 
This may explain the progression from nodular to non-nodular cords, and why I found that 
patients with non-nodular cords from advanced disease had significantly more severe 
flexion deformities. In contrast, nodules containing highly contractile myofibroblasts were 
present in patients with less digital flexion contractures and active disease.  
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Many studies have used animal models to examine myofibroblast recruitment, contractility 
and apoptosis. However, whilst these models emulate the activity of myofibroblasts in 
wound healing, there is no animal model for the study of Dupuytren’s disease. Therefore, to 
examine Dupuytren’s myofibroblasts in vitro, I first compared 3D models of contractility 
using stress-released FPCLs to measure isotonic contraction and restrained FPCLs to 
measure uniaxial isometric force contraction using the culture force monitor (CFM). These 
models have previously been used to examine the contractility of Dupuytren’s nodule-
derived cells compared with non-matched carpal ligament control fibroblasts (Bisson, 
Tomasek). Using matched sets of Dupuytren’s nodule-derived cells and control non-palmar 
and palmar skin fibroblasts from patients, I examined cell contractility in both systems and 
also correlated contractility with α-SMA. These comparisons established that Dupuytren’s 
myofibroblasts are best examined under isometric conditions using the CFM. Stress -
released FPCLs demonstrated no significant difference between matched cells in terms of 
isotonic force contraction. However, using the CFM control dermal fibroblasts reached a 
plateau, unlike Dupuytren’s nodule-derived cells that generated continually increasing 
isometric force. Variability was reduced by comparing the three types of cells from the same 
patient and inter-patient variability was accounted for by selecting nodular samples, with 
proportionally more α-SMA as determined by immunohistochemistry.  
Whilst establishing this model I also had to address certain methodological issues. The first 
concern was Dupuytren’s tissue heterogeneity.  Initial attempts at isolating myofibroblasts 
from Dupuytren’s tissue yielded low percentages of cells with α-SMA positive stress fibres. 
In order to source Dupuytren’s nodule-derived cells with proportionally more 
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myofibroblasts for use in cell culture, I set up collaboration with Dr. Tanaka (University of 
Osaka, Japan), who has reported 4 Dupuytren’s nodule cell lines comprising a homogenous 
population of myofibroblasts (Tanaka et al., 2007). However, when examined for α-SMA 
stress fibres these cells were not a homogenous population of myofibroblasts and a similar 
proportion of cells with α-SMA positive stress fibres were also seen with nodule-derived 
cells from patient samples. Therefore, I established new methodology using patient samples 
to reliably ensure I selected samples with proportionally more myofibroblasts. This was 
done by bisecting each cord sample and processing one half for histology and the other for 
cell isolation. For cell isolation, bisected cord samples were further sub-divided with tissue 
marked for the PIPJ processed separately. This enabled me to use cells from samples with α-
SMA positive nodules proven by histology, thereby providing a reliable source of 
Dupuytren’s nodule-derived cells expressing α-SMA. Next, using the matched cells in the 
CFM, I also determined that the myofibroblast contractile phenotype was only maintained 
in early cell passage (passage 1 or 2), beyond which nodule-derived cells start to show a 
decrease in contractility and in the proportion of cells with α-SMA stress fibres. In contrast, I 
found that dermal fibroblasts develop a more contractile phenotype. These changes may 
reflect contractile adjustments by these cells as a consequence of the identical in vitro 
culture conditions. 
By using genetically matched sets of Dupuytren’s nodule-derived cells and control non-
palmar and palmar fibroblasts from patients, I also correlated cell contractility with α-SMA 
distribution, as well as α-SMA mRNA and protein levels. I found that in dermal fibroblasts, α-
SMA was typically distributed in a ‘halo’ within the peri-nucleur cytoplasm, whereas in 
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nodule-derived cells, α-SMA was frequently localised in stress fibres throughout the cell 
processes up to cell-matrix attachment sites. The presence of α-SMA in fibroblasts is not 
seen in vivo, although when fibroblasts are cultured on a rigid plastic substrate in the 
presence of foetal bovine serum they acquire proto-myofibroblast features with de novo 
expression of cytosolic α-SMA (Hinz, 2006; Tomasek et al., 2002). Upon reaching a certain 
threshold of stress in the ECM, α-SMA is incorporated in to stress fibres and this defines a 
differentiated myofibroblast (Goffin et al., 2006; Hinz, 2007). I found that higher contractility 
of Dupuytren’s myofibroblasts was reflected by increased α-SMA protein levels with 
recruitment of α-SMA to stress fibres, whilst no differences in α-SMA mRNA levels were 
seen. These findings suggest that post-transcriptional changes in α-SMA lead to the 
development of the Dupuytren’s myofibroblast phenotype (Verjee et al., 2010). Previous 
studies have only reported only differences in α-SMA protein expression and localization 
between nodule- and cord-derived Dupuytren’s cells compared to non-matched control 
carpal ligament cells. The relative levels of α-SMA mRNA in these cell types were not 
assessed (Benzonana et al., 1988; Dave et al., 2001). Here I simultaneously examined α-SMA 
protein levels, protein localization and mRNA levels in cells isolated from the same patient. 
Recent studies on cellular mechanisms of local protein synthesis have also suggested that 
not only is mRNA subject to translation, but that cells can instruct the cytoskeleton and 
translation apparatus where to transport and when to translate the intended protein 
(Rodriguez et al., 2008). Therefore, post-transcriptional changes in α-SMA expression may 
include mRNA stability, mRNA localisation, translation, cytoskeletal localisation and stress 
fibre formation. Further studies using Dupuytren’s matched cells are required to investigate 
the relative contribution of each of these. 
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Based on the surgical observation that recurrence is significantly reduced following 
dermofasciectomy, I then tested the hypothesis that non-palmar dermal fibroblasts down-
regulate the contractility of Dupuytren’s nodule derived cells. In these experiments, either 
palmar or non-palmar dermal fibroblasts were co-cultured with Dupuytren’s nodule-derived 
cells. However, no difference in contractility by Dupuytren’s nodule-derived cells was 
observed, despite controlling for different co-culture cell ratios and with longer term co-
cultures. Furthermore, no significant difference in contractility was observed between FPCLs 
set up with different aspect ratios to generate high and low strain gradients, implying that 
Dupuytren’s myofibroblasts are inherently contractile under isometric conditions (Verjee et 
al., 2010). These co-culture data suggests that contractility of Dupuytren’s cells is not 
influenced by dermal fibroblasts and that reduced recurrence rate following 
dermofasciectomy may be due a more complete excision of affected tissue, combined with 
the possibility of reduced tension following application of full -thickness skin grafts.  
Furthermore, the clinical data I collected along with patient samples suggested that 
recurrence was seen following previous fasciotomy, fasciectomy and firebreak 
dermosfasciectomy, but not following radical dermofasciectomy. The histological data from 
these patient samples also showed that nodules occurred with equal frequency in primary 
and recurrent disease samples. Taken together with my co-culture data, these data suggest 
that following less radical surgery, residual unexcised Dupuytren’s tissue may serve as a 
nidus for recurrence. The increased motion achieved following initial surgery may facilitate 
further myofibroblast differentiation and persistence. This may also explain why radical 
dermofasciectomy has a lower rate of recurrence (1-8%) (Brotherston et al., 1994; Hall et 
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al., 1997; Tonkin et al., 1984) than ‘firebreak’ dermofasciectomy (12%) (Ullah et al., 2009) or 
fasciectomy (40-50%) (Foucher et al., 1992; Hueston, 1961; Tonkin et al., 1984). 
The stimulus for myofibroblast recruitment in Dupuytren’s disease remains unclear, 
although inflammation might play a role in the pathogenesis of Dupuytren’s disease. This 
hypothesis has been proposed based on observations of inflammatory cells in nodules 
(Andrew et al., 1991; Qureshi et al., 2001; Schubert et al., 2006) and at the interface 
between nodules and palmar skin (VandeBerg et al., 1982). My histological data support 
these findings and further provide systematic analysis of inflammatory cells throughout 
excised Dupuytren’s tissue. CD3 positiveT-lymphocytes were observed in nodules as well as 
large numbers of mast cells and macrophages, which can produce pro-inflammatory 
cytokines, including TNF-α. In contrast, almost no inflammatory cells were seen in non-
nodular cord tissue.  
High levels of TNF- have previously been reported in Dupuytren’s cord tissue compared to 
control tissue from normal and frozen shoulders (Bunker et al., 2000). In the inflammatory 
phase of wound healing TNF-α is expressed by inflammatory cells and, both inhibits ECM 
synthesis and activates MMPs (Singer and Clark, 1999). In rat lung fibroblasts TNF-α has 
been shown to suppress α-SMA expression (Mariani et al., 1999) and decreased α-SMA 
mRNA expression with TNF-α has also been demonstrated in myofibroblasts from hip joint 
tissue (Mattyasovszky et al., 2010). Previous authors have measured isotonic contraction 
using human non-palmar fibroblasts and also demonstrated decreased contractility and 
reduced α-SMA mRNA and protein expression with TNF-α (Goldberg et al., 2007). In 
contrast, my data showed that under isometric conditions, TNF-α promotes a 2-fold 
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increase in palmar fibroblast contractility over 24 hours, although not to the same order of 
magnitude as with TGF-β1 which generated a 5-fold increase in contractility. Therefore, the 
precise effect of TNF-α may be variable, depending on the model system used and the cell 
type examined. It is also worth noting that TNF-α stimulation can lead to increased 
proliferation and viability of myofibroblasts from joint capsule tissue {Mattyasovszky, 2010 
#302) and human dermal microvascular endothelial cells (HUVEC) (Chaudhuri et al., 2007). A 
dose response for TNF-α will also show if this cytokine has the same effect at supra-
physiological levels, as previously demonstrated with TGF-β1 (Bisson et al., 2009; Wong and 
Mudera, 2006). Investigation of the effect of TNF-α on non-palmar skin fibroblasts under 
isometric conditions is required to determine if these effects are specific to palmar 
fibroblasts.  Furthermore, it has also been shown that TNF-α suppressed TGF-β1 induced 
myofibrobalst phenotypic changes in normal dermal fibrobalsts (Goldberg et al., 2007).  
Similarly, TNF-α has also been shown to anatagonise TGF-β1-induced upregulation of type I 
and III collagen in fibroblasts through a JNK-dependent regulatory mechanism in mouse 
fibroblasts (Verrecchia et al., 2002). The anatgonsitic relationship between TGF-β1 and TNF-
α also needs further investigation and may play an important role in maintaining tissue 
homeostasis and ECM turn-over. The combined stimulation of palmar skin fibroblasts with 
TNF-α and TGF-β1 in the CFM may result in synergistic or inhibitory effects on contractility 
and remains to be examined.  
AGE interaction with RAGE has been shown to induce a TGF-β1 dependent epithelial-
myofibroblast transdifferentiation in a proximal renal tubule cell line as observed by 
morphology, de novo expression of α-SMA mRNA and protein (Li et al., 2004; Oldfield et al., 
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2001). AGEs have been shown to accumulate in ageing tissues and in patients with diabetes, 
where they are also linked to their diet (Makita et al., 1991). I hypothesised that AGEs in the 
tissues of genetically susceptible individuals could directly stimulate the conversion of 
fibroblasts in the palmar fascia to myofibroblasts. RAGE expression in Dupuytren’s tissue has 
not been examined previously and my data showed RAGE expression co-localised with α-
SMA in nodules as well as significant differences in RAGE expression in palmar and non-
palmar skin fibroblasts. However, stimulation of palmar skin fibroblasts for 24 hours or after 
5 days with AGEs did not increase their contractility. Furthermore, my data showed that pre-
stimulation of palmar fibroblasts with AGEs may also suppress the contractile stimulus seen 
by then adding TNF-α. An explanation for this may be that RAGE is a multi-ligand receptor 
that also responds to other pro-inflammatory proteins, such as high mobility group protein 
B1 (HMGB-1) and S100 proteins (van Beijnum et al., 2008). Therefore, different 
permutations of these ligands in combination with AGEs warrant further investigation and 
will involve futre work planned beyond this thesis. 
Other areas of future work include, examining in more detail the post-transcriptional 
changes in α-SMA that occur in genetically matched cells to mediate the Dupuytren’s 
myofibroblast cell phenotype. These post-transcriptional changes in α-SMA expression may 
include mRNA stability, mRNA localisation, translation, cytoskeletal localisation and stress 
fibre formation. Further studies using Dupuytren’s matched cells are required to investigate 
each of these possibilities in turn.  
Finally, work will be carried out to analyse the ability of TNF- to induce palmar skin 
fibroblasts to develop into a more contractile phenotype will be carried out. The dose 
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response to TNF-α on palmar skin fibroblasts will determine if higher doses induce or 
suppress contractility of palmar skin fibroblasts. These experiments will also be done in 
combination with TGF-β1 to determine if the combined effects are synergistic or inhibitory 
on palmar skin fibroblast contractility and on α-SMA expression in stress fibres, mRNA and 
protein levels. The optimal concentration of TNF-α from these experiments will then be 
used to examine contractility in control matched non-palmar skin fibroblasts, and to 
determine if the increased contractility observed so far is only specific to palmar skin 
fibroblasts. 
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6.2  Conclusion 
In conclusion, I have examined in detail the distribution of α-SMA positive cells and the 
cellularity throughout excised Dupuytren’s cord. I confirmed that myofibroblasts are mainly 
found in histological nodules. These nodules were often hypercellular and comprised a focal 
condensation of cells. Myofibroblasts were also found in variable numbers outside nodules 
and in amongst collagen bundles of Dupuytren’s cord. Histological nodules were found in 
the vicinity of the PIPJ of the hand and α-SMA rich nodules were associated with lesser 
digital contracture, whereas cords without α-SMA rich nodules from advanced disease 
correlated significantly with greater fixed flexion deformity. This implies that α-SMA 
expression may be transient through Dupuytren’s disease. Reduced movement at the joint 
in advanced disease may result in a form of stress-shielding with loss of tension and 
subsequent myofibroblast apoptosis that leaves behind residual stage non-nodular cords. 
Using cells derived from α-SMA rich nodules, and genetically matched non-palmar skin and 
palmar skin I have shown that nodule-derived cells generate higher levels of isometric force 
that continue to increased over 24h, unlike dermal fibroblasts which generate less force and 
characteristically plateau. Most significantly, I have demonstrated that myofibroblast 
differentiation in Dupuytren’s nodule-derived cells is characterised by recruitment of α-SMA 
to stress fibres and reflected by increased α-SMA protein levels, but not α-SMA mRNA 
levels. Whilst contractility of Dupuytren’s nodule-derived cells was not influenced by dermal 
fibroblasts, I found in palmar fibroblasts a two-fold increase in isometric force contraction 
with TNF-α and a significant five-fold increase with TGF-β1. In Dupuytren’s disease, TNF-α 
may have a role to play in modulating the myofibroblast phenotype.
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